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Abstract 
There have been many published papers exploring women‟s the use of hormone 
replacement therapy (HRT), but most of these studies have not examined surgically 
menopausal women exclusively. This particular group of women may differ in their 
HRT needs from the general HRT - using population, in that they require an 
oestrogen-only preparation and often have a premature menopause. For surgically 
menopausal women, therapy can be considered as a true replacement treatment as it 
compensates for often abrupt and premature oestrogen loss. The purpose of this study 
is to describe HRT use in a sample of surgically menopausal women and determine if 
these women undergoing hysterectomy with bilateral oophorectomy have different 
patterns of HRT use when compared to HRT users in general. 
 
This study examines HRT use in women who had a hysterectomy with bilateral 
oophorectomy before the age of 51 years; in the period 1992-2001.All the women 
were treated in a region of Central Scotland, in one of two district hospitals 
administered by the same NHS Trust. The clinical indication for their surgery was 
heavy menstrual bleeding (menorrhagia), a benign and common condition. The study 
is retrospective, and women were asked to complete a postal questionnaire. The 
questionnaire was designed to elucidate the prevalence and duration of HRT use in 
these women, and the reasons they give for stopping treatment. Certain factors 
associated with adherence to medication in general, and with HRT use in particular, 
are considered. These variables include the age of the patient and her socio-economic 
status, the location of her treatment, and the individual consultant gynaecologist in 
charge of her care. Associations between post-operative HRT use and physician-
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gender are explored, together with the reasons these women give for the 
discontinuance of treatment. 
 
This study found that one hospital performed more operations than the other, which is 
probably explained by in-patient bed capacity. One of the consultants performed over 
a quarter of the total number of operations, probably reflecting the differing clinical 
roles held by different consultants in the department, or perhaps indicating individual 
practice. Some further evidence of differences in practice between individual 
consultants is demonstrated by the fact that two consultants jointly operate on 
significantly younger women when compared to their colleagues. 
 
There is an association found in the target sample (n = 306) between socio-economic 
group and the age at which women undergo hysterectomy, with women from less 
deprived backgrounds being significantly older. This difference, however is not 
significant in the achieved sample (n = 190), and is possibly due to the small sample 
size. Socio-economic status is not associated with whether or not HRT is prescribed in 
hospital, but women from less deprived backgrounds take HRT for longer. There are 
some differences, between women from different socio-economic backgrounds, in 
how important the possible cardiovascular protection afforded by HRT is rated. The 
Women‟s Health Initiative dispelled the claim that HRT was valuable in preventing 
cardiovascular events in 2002.  
    
When discussions about the benefits of taking HRT are considered, it appears that the 
women treated in one hospital recall such discussions in greater number than those 
treated in the other hospital do. Discussions about the risks of treatment are not 
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remembered by 65.2% of women, and there is no statistical difference according to 
where they were treated. The problem associated with the accuracy of data reliant on 
subject memory is discussed. Most women cite the doctor as the main source of 
information about HRT, but over a third of those who start HRT say they did not have 
enough information (the problem associated with the accuracy of data reliant on 
subject memory is discussed). Whatever the level of information is given, these 
women start HRT in almost exactly the same high number regardless of where they 
were treated. 
 
When comparing the findings from these surgically menopausal women with those 
from previously published studies on HRT users in general, it is apparent that there 
are some subtle differences in that use. These women are more likely to take HRT, 
and take it for longer, than the peri-menopausal and naturally menopausal women, 
who are grouped together as HRT users in general. They stop using HRT for many of 
the reasons given by the wider HRT-using population, but are more likely to consult 
their doctor before doing so. These surgically menopausal women, compared to HRT 
users in general, cite side-effects of treatment less frequently, but the side-effects they 
do complain of are the same, with the exception of bleeding problems (from which 
they obviously do not suffer).  
 
The socio-economic difference associated with HRT uptake in the wider population, 
is not seen in these surgically menopausal women, but the duration of HRT use is 
associated with higher social status, as found in the general population. The women in 
this study who came from higher socio-economic groups were older than those from 
more deprived backgrounds at the time of their hysterectomy, which concurs with 
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previous research. There is acknowledgement, within the text, that since this research 
was undertaken there have been significant changes in HRT prescribing guidelines 
and indeed in the treatments available for menorrhagia. These changes have affected 
the study findings in terms of how relevant they might be today.    
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Chapter one 
A General introduction 
Hormone replacement therapy (HRT) is exactly as the name implies a replacement of 
hormones that are deficient or absent. The term is specifically associated with the 
treatment of oestrogen loss in women at the time of menopause or peri-menopause. 
The main component of the medication is oestrogen. First used in 1941 for the relief of 
menopausal symptoms, it was promoted and became increasingly popular over the 
1970s 1980s and 1990s despite some early concerns that it may increase cancer risk. 
In 1997, Premarin, one of the earliest preparations, was the first Wyeth product to 
reach one million dollars in sales, and remained in the top 50 prescribed drugs from 
1966 to 2002  (Rothenberg 2005, p31).   
 
In order to understand the principles behind hormone replacement therapy, it is 
necessary to have some background information about the menopause. It is at this time 
in a woman‟s life that she may require hormone replacement therapy to help relieve 
some of the symptoms associated with oestrogen loss. This chapter will first consider 
physiological changes of menopause and the effects of oestrogen loss; it will then 
review the known side effects of HRT. The differences in HRT treatment for women 
with surgical menopause, compared to women with natural menopause, are examined. 
There then follows a discussion of how the menopause transition is understood from a 
sociological or feminist perspective, and how menopause has become “medicalised” 
as an oestrogen deficient disease, rather than a natural process. Recent changes in 
prescribing recommendations, together with what is already known about adherence 
with treatment and reasons for discontinuance, will be introduced subsequently. As 
there have been significant changes in both the treatment of menorrhagia, and HRT 
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prescribing, since the inception of this study, an updated review of the literature is 
appended at 1.9. To conclude the aims of the study are outlined.   
    
1.1 Physiological changes of the menopause 
Female reproductive function declines with age over a period of time known as the 
climacteric, leading eventually to the menopause, which can be defined as the 
cessation of menstruation due to ovarian follicular failure. The term “menopause” 
originates from the Greek words “menos” (a month) and “pausos” (an ending), and 
means the final menstrual bleed (Rees, Purdie and Hope 2003). It is diagnosed 
retrospectively, and can be said to have occurred once menstrual bleeding has been 
absent for 12 months.  This occurs at a mean age of 51 years, (Glasier and Gebbie 
2000). This change of life rarely happens abruptly in nature, and most women 
experience a transitional period of menstrual irregularity which may last for two or 
three years (Glasier and Gebbie 2000), or even longer at around four years (Rees 
1999). 
 
The natural menopause transition occurs as oestrogen levels gradually decline as the 
ovaries fail to respond to stimulation by gonadotrophins. These gonadotrophins are 
hormones, called follicle-stimulating hormone (FSH) and Leutenising hormone (LH), 
which together control the ovarian cycle and are produced in the pituitary gland. They 
are in turn controlled by another hormone, GnRH (gonadotrophin releasing hormone), 
produced by the hypothalamus in the brain. FSH and LH act on the ovaries, which 
produce the female hormones oestrogen and progesterone, and these hormones are 
responsible for ovulation. As a woman grows older, her ovaries become less 
responsive to FSH and LH and produce less oestrogen; they also fail to produce 
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Inhibin, which controls GnRH production. FSH and LH levels rise, as the normal cut-
off mechanism on GnRH is lost, leading to anovular menstrual cycles – that is, 
menstrual cycles in which no ovum is released. Eventually, consistently low 
circulating oestrogen levels result in an absence of menstrual bleeding known as 
„amenorrhoea‟.  
 
For most women, the menopause is a natural and gradual transition, whereby hormone 
levels fluctuate and decline over a period of years. There are a number of symptoms 
which women associate with the menopause and these can affect their lives to a 
greater or lesser extent, depending on their severity. These symptoms are linked to 
oestrogen loss. Women who experience a natural menopause, or have a hysterectomy 
before they are naturally menopausal (surgical menopause), are likely to experience 
some of the effects of oestrogen loss, both short and long term. 
  
1.1.1 Short-term effects of oestrogen loss   
The short-term effects are the most familiar to women, and include the vasomotor 
symptoms, hot flushes and night sweats. These can in turn lead to disturbed sleep 
patterns and consequent psychosocial effects such as irritability and depression. Some 
70% of women are troubled by hot flushes and night sweats (Rees, et al 2003).   
Urinary and vaginal symptoms result from the loss of oestrogenic influence on the 
vaginal mucosa, and urethral epithelium can cause urinary frequency, dysuria and 
vaginal dryness. Losses of sexual desire and/or sexual problems are also reported.  
These are the symptoms from which some women seek relief, and may take them to 
their General Practitioner (GP) for advice on hormone replacement therapy (HRT). 
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Psychological effects, such as depression, may be coincidental rather than hormone-
loss-related, especially as the menopause occurs at the same time as other life changes 
for many women. Middle age is also associated with children leaving home and 
increasing responsibility for ageing parents, amongst other social factors that could 
alone produce irritability and depression.  
 
 As the symptoms of the menopause are a result of oestrogen deficiency, hormone 
replacement therapy is designed to replace that deficiency by restoring circulating 
oestrogen levels. The most commonly used oral preparations are conjugated equine 
oestrogens, but there are many differing formulations and methods of delivery.  
 
1.1.2 Long term Effects of oestrogen loss. 
In the longer term, the loss of oestrogen has been linked with a number of conditions, 
all of which women would be keen to avoid if possible. The most widely recognised 
effect of oestrogen loss is osteoporosis, but oestrogen has also been thought to affect 
both the nervous and cardio-vascular system.  
1.1.2.1 Osteoporosis 
The most well known long-term effect of the menopause is osteoporosis. This is a 
progressive disease in which bone mass is reduced and the structure of bone is 
weakened, thereby increasing fragility and liability to fracture. Bone mass is said to be 
greatest at around 30 years of age, and after this there is progressive loss. This loss is 
accelerated after the menopause, and one woman in every four will develop 
osteoporosis (Lee 1998). The main determinant of peak bone density is agreed to be 
genetic (Smith et al 1973 cited in Swiers 1996 p35). According to Abdallah et al in 
1984 (cited in Sweirs 1996, p35), the rate of bone loss after the menopause is 5% per 
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year for 5 to 10 years, with women who have had bilateral oophorectomy experiencing 
higher rates of loss. When women undergo a bilateral oophorectomy before the time of 
natural menopause, they are losing their natural oestrogen early and therefore can be 
said to be at a higher risk of developing osteoporosis in the future. 
 
Osteoporotic fracture occurs in about 40% of postmenopausal women, and one in 
every six will suffer a hip fracture (Lee 1998). The role of oestrogen in maintaining 
bone density was recognised as early as 1941 (Albright et al 1941), and there have 
been many studies since then exploring this effect (Lindsay et al 1976, Bjarnson et al 
1996). It is thought that oestrogen may have some effect via Calcitonin and have an 
anti-resorptive effect on bone by suppressing osteoclast activity and reducing bone 
turnover (Glasier and Gebbie 2000). 
 
Results from large studies have shown that women taking oestrogen therapy did have 
a reduced risk of hip and other fractures, (Randell et al 2002, Torgerson and Bell-Syer 
2001). The thinking now is that HRT does work as a treatment for osteoporosis but 
that there a number of non-hormonal treatments that work just as well. The additional 
risks now identified with HRT have altered the risk/benefit ratio, and it is now 
recommended that it should not be used as the first line of treatment unless 
menopausal symptoms are a problem (Lynch 2004). 
 
1.1.2.2 Cognitive function 
Oestrogen is possibly implicated also in the functioning of a healthy nervous system 
by promoting cell differentiation and the formation of synapses. There was, in the 
1990s some evidence emerging that Alzheimer‟s disease, which affects women 
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usually after the age of 65, may be reduced in women replacing oestrogen loss with 
HRT (Henderson 1997). This view has now been largely dispelled by the Women‟s 
Health Initiative Memory study (WHIMS) 2004, a sub-study of the larger and now 
famous Women‟s Health Initiative hormone study (WHI) 2002.The WHI study will be 
considered in more detail later in this chapter. WHIMS examined the effect that 
oestrogen has on cognitive function. It concluded that “ oestrogen alone does not 
protect women against the normal declines in cognitive function when compared with 
placebo”, and that using oestrogen may actually increase the risk of developing mild 
cognitive impairment (WHI 2006 participant website/ findings/cognitive function). 
These results only apply to women of 65 years or older, and it is not known if the 
same applies to women of a younger age. Shumaker et al (2004) do not recommend 
the use of hormone therapy to prevent dementia or cognitive decline in women of 65 
years of age or older. There seems to be no advice available to younger women, such 
as those in this study, as to what effect taking oestrogen will have on their future 
cognitive function; but the WHI researchers advise that oestrogen should not be used 
to prevent chronic diseases.   
 
1.1.2.3 Possible Cardiovascular effects 
Another long-term effect of oestrogen deficiency was thought to possibly affect the 
cardiovascular system. Pre-menopausal women are less likely to suffer coronary 
events than men of similar age; however, coronary heart disease rates increase with 
age for both men and women. Women after the menopause have an increased risk of 
atherosclerosis  (Schwartz Freeman and Frishman 1995). Oestrogen is thought to alter 
vascular tone and influence lipid profile, and this protective effect is lost at the 
menopause (Tunstall-Pedoe 1998). Although more research was required in this area, 
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there were some indicators in the 1990s that oestrogen replacement may have had the 
potential to reduce CHD rates in women.  The WHI study of women taking oestrogen 
only HRT after hysterectomy concluded that unopposed oestrogen provided no 
protection against myocardial infarction or the coronary death of women over 60 years 
old (WHI Participant website/ findings/heart disease). It did suggest that there might 
be a lower coronary heart disease risk for the younger women, aged between 50 and 
59 years old (Hsia et al 2006), but the evidence is not conclusive statistically. Once 
again these results are difficult to interpret for women under the age of 50 years who 
are thinking about taking HRT.     
 
Doctors base their advice to patients on current guidelines and the most recent 
research. As large-scale studies researching long-term risk benefit ratios of any 
medication take time to complete, these guidelines are altered in light of the findings 
of such studies as time progresses. The Steering Committee of the Women‟s Health 
Initiative (2004) concluded that oestrogen increases the risk of stroke in post- 
menopausal women (WHI Participant website/findings/stroke). Therefore, the 
prevention of cardiovascular disease is now not used as a reason to prescribe HRT. 
So the benefits of taking HRT would be to control vasomotor effects, improve general 
well being and prevent osteoporosis in the future. Given the advice current at the time 
of this study the participants may also have been expecting cardiovascular protection 
and preservation of cognitive function. Additionally, however, there are some side-
effects associated with HRT, and these need consideration. 
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1.2 Side–effects of Hormone Replacement Therapy   
The opening paragraph of the U.S. Department of Health and Human Services‟ “Facts 
about Menopausal Hormone Therapy”(2005) states that HRT “once seemed the 
answer for many of the conditions women face as they age. It was thought that 
hormone therapy could ward off heart disease, osteoporosis and cancer, whilst 
improving women‟s quality of life.” This view has been largely dispelled in the light 
of continued research over a number of years. The pharmaceutical industry has also 
been criticised for medicalising the menopause, and for influencing the interpretation 
of scientific research findings that may damage their own financial interests, (Clark 
2003).  
 
The most powerful data on the side-effects of HRT has emerged from the major large 
scale studies, including the Heart and Estrogen/Progestin Replacement Study (HERS) 
published in 1998, the Million Women Study of 2003 and, as previously indicated, the 
Women‟s Health Initiative in 2002 and 2004.In order to illustrate the timing of these 
publications in relation to this study a time-line is provided. 
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The HERS data showed that daily oestrogens and progestin did not prevent coronary 
events in women with known heart disease; indeed, it found an increase in coronary 
heart disease (CHD) rates in the first year of use (Hulley et al 1998). In 1991 the 
Women‟s Health Initiative (WHI) was launched as a large US- based study looking at 
the effects of HRT on heart disease, osteoporotic fracture and breast cancer risk. There 
were two parts to the study, one involving postmenopausal women with intact uteri 
who took either a placebo or oestrogen and progesterone, and the other involving 
women who had undergone hysterectomy and therefore took placebo or oestrogen 
only. These trials were designed to run until 2005, but were stopped early. The 
combined therapy trial was stopped in 2002, three years before completion, and the 
oestrogen only trial ceased in February 2004. The early cessation of these trials was 
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prompted by safety considerations, as the risks were found to outweigh the benefits. 
Both arms of the WHI study found a decrease in bone fracture rates in women taking 
HRT. However, increased coronary events, stokes, breast cancers and DVT‟s were 
found in women taking combined HRT, so confirming the findings of the earlier 
HERS. The oestrogen-only trial also found increased strokes and DVTs but fewer 
cases of breast cancer and coronary events. The Million Women Study, published in 
2003, also found increased incidents of breast cancer associated with combined HRT 
in British women aged 50-64.  Ross et al (2000) conclude that the addition of a 
progestin increases the risk of breast cancer when compared to oestrogen use alone. 
According to Hulley and Grady (2004, p.1770) “numerous lines of evidence support 
an increase in breast cancer with oestrogen use” but they suggests that, for the 
meantime, given the lack of statistical significance, this finding should be interpreted 
as having occurred by chance.  
 
So we accept that HRT does increase breast cancer risk, that the Committee on Safety 
of Medicines (CSM) advises that the risk is related to the duration of HRT use, and 
that the risk disappears within about 5 years of stopping. The CSM stated in 2006 
“that for those using oestrogen only HRT for 5 years breast cancer is diagnosed in 
about 1.5 extra cases in 1000 ”(BNF 2006, p 391). Women in general cite an increased 
risk of cancer as one of their major worries about taking HRT (Griffiths and Convery 
1995, Hope and Rees 1995, Newton et al 1997). 
 
The findings from these American studies were reported in worldwide national 
newspapers, and presumably produced anxiety in women taking HRT at the time. 
When considering the findings of any research, it is important to know the 
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characteristics of the study population. It should be remembered that WHI was an 
American study, using women over the age of 50 years as their study subjects. 45% of 
participants were between 60 and 69 years of age, and 45% were classified as obese by 
body mass index (U.S. Department of Health and Human Services 2005 p7). These 
facts are likely to have some bearing on the increased rates of CVA and DVT. 
 
 Although it is thought that HRT alters the blood clotting processes, and thereby 
makes the blood more susceptible to clot formation, thromboembolism is multi–
factorial in aetiology. Thromboembolism is not related to oestrogen alone and 
increasing age also plays a significant role, as do obesity, varicose veins and diabetes. 
These considerations make decisions about HRT prescription difficult for some 
women. 
 
Jick et al (1996) found a three-fold increase in risk of venous thromboembolism 
(VTE) in women using oestrogen replacement, after controlling for predisposing 
conditions, and this increase was seen to be higher in women taking higher doses of 
oestrogen. Daly et al (1996) confirmed these findings in a British study, and found that 
the increased risk might be concentrated in new users. Rates of pulmonary embolism 
in women taking HRT were similarly found to be increased by Grodstein et al in 1996. 
Both HERS and the two arms of the WHI trials found increased rates of coronary 
events and venous thromboembolism associated with oestrogen therapy, confirming 
these results.  
  
 According to the Royal College of Obstetricians and Gynaecologist‟s Clinical 
Guideline no 19, Hormone Replacement Therapy and Venous Thromboembolism 
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2004, all women commencing or continuing HRT should be counselled about the risk 
of VTE, be aware of the signs and symptoms, and know to access medical help if they 
should suspect that they have developed the condition. It does, however, recognise that 
the risk is small and should be considered in perspective when assessing the overall 
benefits of therapy. The BNF (2006) states that women who take oestrogen-only HRT 
are at increased risk of DVT and pulmonary embolism especially in the first year of 
use. 
 
For women troubled by short-term menopausal symptoms, the benefits of HRT would 
appear to be convincing. In terms of alleviation of symptoms, such as hot flushes and 
night sweats, HRT is effective. Rodstrom et al (2002) reported that between 70% and 
87% of their Swedish study population considered HRT an effective form of 
treatment, whereas fewer than 50% of women treated with non-oestrogen therapy 
reported efficacy. In 2005, an independent panel convened by the US National 
Institutes of Health still supported the use of HRT for the relief of moderate to severe 
menopausal symptoms. 
 
1.3 Differences in HRT treatment for women with hysterectomy and bilateral 
oophorectomy compared to those with natural menopause  
There is a group of women who do not experience the menopause as a gradual 
process. Women undergoing elective hysterectomy with bilateral salpingo-
oophorectomy (BSO) – that is, the surgical removal of the uterus, fallopian tubes and 
both ovaries – do not experience a gradual transition into menopause, and can be 
described as surgically menopausal. Their ovarian loss produces a post-menopausal 
hormone profile quickly after surgery. Depending on the age of the woman at the time 
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of surgery, the hormonal drop after oophorectomy can be abrupt and produce more 
severe symptoms (Utian 1980, cited in Logothetis 1991, p.461). 
 
There are a number of reasons why a woman would have a hysterectomy; these 
include excessive menstrual bleeding, endometriosis and malignancy. The ovaries are 
often removed at the same time as the uterus, as they are often approaching atrophy 
and can be considered a possible source of future malignancy. For the women selected 
for inclusion in this study, the reason for their surgery was documented as 
menorrhagia - that is excessive menstrual bleeding- and all women had been treated 
surgically with a total hysterectomy with bilateral oophorectomy.   
 
These women lose their natural source of oestrogen suddenly, and often earlier than 
would be expected in nature, and are therefore different to those women undergoing a 
gradual natural menopause.  Women who have had a hysterectomy need only take the 
hormone oestrogen as replacement therapy. They do not need a combined oestrogen 
and progesterone preparation, as women who have not had a hysterectomy do. This is 
because they no longer have a uterus. Progesterone is necessary to prevent 
proliferation of endometrial tissue within the uterus, which would occur if oestrogen 
were taken unopposed by progesterone in women with an intact uterus. Combination 
HRT- that is with oestrogen and progesterone- has side effects related to progesterone 
dosage, such as breakthrough uterine bleeding; therefore, women undergoing natural 
menopause may have additional unacceptable side- effects, and indeed many women 
taking combined HRT complain of erratic or heavy bleeding, and cite this as a reason 
to stop therapy (Hope and Rees 1995). These side effects, and the potential for the 
development of endometrial cancer, are absent in hysterectomised women who take 
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oestrogen replacement only. So women who have had a hysterectomy and take just 
one hormone as HRT may therefore have different patterns of use to those women 
taking combination therapy. Little published research is available which examines 
hysterectomised women in particular. Most papers discuss findings from women in 
general, without distinguishing them by hysterectomy status.   
 
The women in this study took oestrogen-only HRT, but the study will not examine 
which specific preparations were used or how they were administered; it will only 
determine whether HRT was taken. There are many different HRT preparations, 
marketed by different pharmaceutical companies, and they differ in dosage and mode 
of delivery. There are oral tablets, dermal patches and vaginal rings, but the aim is the 
same: to replace lost hormones. In this study, it was not necessary to investigate which 
actual preparations the study population used; the focus was instead on the duration of 
use, and the reasons given to cease treatment.  
 
On balance, it is not difficult to see why, during the decade 1992-2001, oestrogens 
were used to alleviate short-term menopausal symptoms. They were also thought, at 
that time, to possibly protect women in their later years against debilitating and 
expensive disease in terms of health care costs. Nor is it surprising that therapy 
remains somewhat controversial for many women, given the known side effects, the 
extent of which has only comparatively recently become evident. Prescribing 
guidelines have been changed in accordance with recent research findings. 
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1.4 The medicalisation of the menopause 
Before considering the changes in HRT prescribing, it is necessary to consider the way 
in which the menopause transition is perceived as either a “medical” or “natural” 
event. The perspective in which menopause is viewed may affect the way it is 
managed.  
 
So far the description of menopause has been based on a mainly medical perspective 
because the women in this study have been treated for menorrhagia by surgical 
intervention, in all cases before the average age of natural menopause. This study 
would however not be complete without examining the feminist perspective of 
menopause and the criticism that the  “medicalisation” of this time in women‟s lives 
is unnecessary and seeks to control women. 
 
Peter Conrad defines “medicalisation” as seeing “a problem in medical terms, using 
medical language to describe a problem, adopting a medical framework to understand 
a problem, or using a medical intervention to treat it. This is a sociocultural process 
that may or may not involve the medical profession, lead to medical social control or 
medical treatment, or be the result of intentional expansion by the medical 
profession.” (Conrad 1992, p 211). Many conditions, not really “diseases” in a true 
sense but rather natural human diversity, have been medicalised and treated; for 
example many types of cosmetic surgery are used to “improve” on nature. 
Interventions have been made by medicine into “natural” life events such as childbirth 
and fertility with the use of elective caesarean section and introduction of the 
contraceptive pill. If, as Grady (1999 p 5) suggests, medicalisation seizes “upon aches 
and pains that people used to live with and declare them dysfunctions that must be 
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treated”, and where in the past it was “acceptable to leave certain conditions alone, 
doing so now might be considered cruel neglect”, then it is not surprising that 
medicalisation is usually interpreted as negative. The criticism is that medicalisation 
transforms social problems into medical ones, and interferes unnecessarily in 
“natural” processes, and that in both cases it subjects them to the control of the 
medical profession. 
 
According to some feminist writers, this is what has happened with the menopause: a 
natural, life-cycle process has been transformed into a medical problem requiring 
unnecessary intervention. It is this perspective that will now be explored. 
  
If menopause is not regarded as a natural or normal stage of life and one that all 
women experience, but rather a medical condition caused by oestrogen deficiency, 
then women are turned into patients. This in turn creates “new markets for special 
clinics, diagnostic tests, pills and self help books.” (Grady 1999 p1). Burrell (2009 p 
212) says, “the course of nature in ageing women has been re-categorised as 
unnatural.” As menopause is thought of as a deficiency disease, HRT is marketed as 
the answer in terms of replacement. She says, “although therapeutic in a few cases, 
hormone preparations are in fact potentially dangerous lifestyle drugs”. There is 
discussion in her paper about whether or not the findings of the WHI in terms of risk 
were overstated. She points out that government health advisories have not been 
altered in the light of criticisms of the methodology used in the WHI studies, and that 
conservative approaches to treatment are still recommended. The WHI findings will 
remain as the gold standard of evidence unless future research discredits their 
conclusions (Cirigliano 2007 cited Burrell 2009 p216). 
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To understand how the menopause has become a medical problem, Burrell (2009) 
uses the work of French philosopher Michel Foucault to provide an insight into the 
effect of power and knowledge on the medical construct of menopause.  
 
Foucault would suggest that the reason that menopause is thought of as a disease is 
because of the values held within medical science. Medicine likes to classify the 
“normal” and the “abnormal”, it looks to identify disease and categorise symptoms to 
aid that identification.  Deviation from the norm becomes a reason for medical 
intervention. In The Birth of the Clinic (1963/1973), Foucault describes what he calls 
the medical gaze where “the patient is only relevant in that what they reveal in 
history, symptoms and measurements permitting identification of disease”(Burrell 
2009 p 213). He also suggests that through various power relations “medicine derives 
social authority, influencing social orthodoxies thus normalising the subject via 
discursive constructs” (Burrell 2009 p 213). Foucault‟s theory of genealogy focuses 
on how one is turned into a subject by this process of normalisation in which the 
concept of the “normal” is formed, as a product of history, culture and professional 
discourse all shaping the accepted idea of what for instance is the normal female 
body.  
 
 The normal female body is one, which is potentially fertile. Feminists in the 1980s 
and 1990s criticised the dominant medical construction of menopause on the basis 
that it represented “women as biologically weak and vulnerable and emphasised 
popular ideals about beauty and youth.” (Murtagh & Hepworth 2003, p 1643).  
Burrell (2009) concludes that a “ Foucauldian lens has revealed importantly that the 
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construct of post menopause as a defective condition has led to the administration of 
substances that are unnatural for the time of life concerned, as treatment is based on 
some standardised ideal of the healthy fecund woman” (Burrell 2009 p 219).  
 
If the popular ideals of beauty and youth are the basis on which women are valued, 
then the process of ageing becomes less acceptable, and older women are not 
regarded as highly as their younger sisters are. The promise then of a treatment that 
preserves youthfulness and attractiveness becomes valuable to women. HRT has been 
promoted along these lines, with claims of improved skin texture; more lustrous hair 
and improved libido, all linked to the replacing of lost oestrogen. Frances McCrea, 
writing in 1983, showed how the two opposing definitions of menopause evolved, 
and how feminists argued against medicalisation. She uses some rather extreme 
examples of how menopausal women were described by influential writers in the mid 
1960s. There are according to McCrea (1983), four “negative themes common to 
medical definitions of menopause”. She lists them as follows; 
 
1. Women‟s potential and function are biologically destined. 
2. Fecundity and attractiveness determine women‟s worth. 
3. Rejection of the feminine role will bring physical and emotional havoc. 
4. Ageing women are useless and repulsive. 
 
She finds evidence for such claims in literature of the time, including the famous 
book Feminine Forever (1966) by eminent gynaecologist Robert Wilson, and in 
David Reuben‟s (1969) best seller Everything you wanted to know about sex but were 
afraid to ask.  In these publications, the menopausal woman is portrayed, not only as 
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suffering a deficiency disease, but also causing social chaos. Hormone replacement is 
strongly advocated as the solution to hot flushes, sagging breasts, irritability, frigidity 
and depression. Wilson (1966) says, “oestrogen makes women adaptable, even 
tempered, and generally easy to live with” (Wilson 1966 p 64).  Reuben‟s (1969) 
book goes even further, saying that “as oestrogen is shut off, a woman comes as close 
as she can to being a man. Increased facial hair, deepened voice, obesity, and decline 
of breasts and female genitalia all contribute to a masculine appearance. Not really a 
man but no longer a functional woman, these individuals live in a world of intersex. 
Having outlived their ovaries, they have outlived their usefulness as human beings.” 
(Reuben 1969 p287). 
 
It is hardly surprising that these views were challenged by feminist writers at the 
time, and continue to be of concern today. 
 
There is evidence that similar, but perhaps less extreme, themes exist also in the 
available published literature on menopause and HRT use. In 2002, Coupland and 
Williams examined the content of three different sources of information for women, 
and found this same negative construct of menopause evident in two of them. The 
three “discourses” examined are based on printed texts on the menopause from the 
pharmaceutical, the alternative therapy, and the emancipatory feminist perspective. 
Information leaflets published by or in association with, pharmaceutical companies 
use “metaphors of deficiency, decline and depletion” and imply that HRT can solve 
the problem. Such leaflets, because they are provided by the doctor or are available in 
the surgery, are likely to attract “conferred expertise” status (Fairclough 1989, cited 
Coupland and Williams 20002, p 422). Although newspaper and magazine articles 
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proposing “alternative therapies” to HRT reject the need for medical intervention and 
advocate “natural remedies”, they still view the menopause in a negative way. The 
same basis of replacing lost hormones applies, but it differs in what is used for such 
replacement. Manufactured HRT preparations are seen as a cleverly marketed 
solution, while naturally occurring herbal remedies are preferred. Both the 
pharmaceutical and the alternative therapy perspective are ageist in their approach, 
with their focus on the preservation of youthful femininity. 
 
However, books and articles from a feminist stance however reject both the medical 
and the alternative therapy positions. They argue that menopausal women should not 
be viewed as patients in need of prescription medicines, or as needing “natural” 
remedies, on the basis that no remedy is required. They reject the so -called natural 
alternatives to HRT on the basis that there are no natural substitutes, and advise 
caution in the use of non-prescription preparations, claiming to act like HRT, which 
are not endorsed by the Medicine Control Agency (Coupland and Williams 2003, p 
436). Feminist writer Germaine Greer, in her book The Change (1991), expressed the 
fear that, by trying to cancel the menopause by the use of HRT, women were being 
prevented from accepting a rite of passage leading to fresh challenges (Greer 1991, 
cited Coupland & Williams 2003, p437). She also questioned some of the scientific 
claims made for HRT, suggesting (for example) that younger looking skin is 
“magical” and “unsubstantiated”. She also criticises women using HRT as being 
manipulated by the pharmaceutical industry (Greer 1999, p187, cited Coupland and 
Williams 2003, p437)  
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There is little doubt that pharmaceutical companies have profited greatly from the 
HRT market, a fact often noted by those who believe that women have been, in 
effect, manipulated by a pharmaceutical conspiracy. 
 
Feminists criticise the medical construct of menopause for assuming that, as all 
women eventually become menopausal, and because a decrease in circulating 
hormones is the causal mechanism of menopause, symptoms are the same for all 
women. Because the menopause is universal, the effects of menopause are also 
universal. McCrea (1983) illustrates this thinking, and quotes an article in the New 
York Times by Brody in 1975, which included the following statement by an 
American gynaecologist: “I think of the menopause as a deficiency disease like 
diabetes. Most women develop some symptoms whether they are aware of them of 
not, so I prescribe oestrogens for virtually all menopausal women for an indefinite 
period” (Brody 1975, cited McCrea 1983, p116). So even if women did not suffer 
from symptoms, HRT was viewed as a necessity by the gynaecologists of the past. 
Feminist authors have disputed the „universality of symptoms‟, finding evidence that 
there are differences in the experience associated with culture, social class and 
ethnicity, as shown in work by Lock (1998) and Gifford (1994). There is also a 
counter-argument from the medical perspective: viewing the menopause as a 
transition requiring no medical help can lead to severe menopausal symptoms felt by 
some women being ignored (Murtagh and Hepworth 2003 p 1644).   
 
It can be argued that there remains a medical rational for HRT prescription, even 
leaving symptom control behind. If menopause is constructed as a long-term health 
risk, then there is still a medical reason to promote the use of HRT to prevent 
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osteoporosis in later life. Prior to the findings of the WHI studies, HRT was also 
thought to prevent heart disease and preserve cognitive function. So even if women 
reject HRT as a method of preserving their femininity, their doctors may persuade 
them to take it on a risk management basis to prevent osteoporosis in the future. This 
may be viewed as an unnecessary control from a feminist perspective, or a health 
promotion strategy from the perspective of the medical profession and the 
pharmaceutical industry.  
 
If the “preventative” approach is used, women have a choice whether or not to take 
HRT as part of their responsibility for their own health. Such decisions are supposed 
to be made by well-informed, autonomous women. Autonomy is one of the principles 
of medical ethics, and is the right to freedom of choice and consent; but limitations on 
autonomy come with the competence of the individual  (Murtagh and Hepworth 2003, 
p1645). Sherwin (1998) states that: „Autonomy is conventionally understood as a 
recognition of the authority of the patient to make choices about their health care‟ 
(cited Murtagh and Hepworth 2003, p 1646). However the truly autonomous patient is 
probably a rarity, as social interaction and experience influence autonomy, and it is 
restricted by the „role‟ of the individual in society. Murtagh and Hepworth (2003, p 
1643) suggest that the „ethic of autonomy‟ and an „offer of choice‟ actually are not 
emancipatory for women making HRT decisions, because they intensify the power 
relations between women and their physicians. They say that doctors, while claiming 
to empower women and support their choices, actually do the opposite by limiting 
their choice through „constructing menopause solely within biomedicine‟ (p1646). 
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Murtagh and Hepworth (2003) use another of Foucault‟s concepts, namely 
“governmentality”, as a useful way to criticise the biomedical view of menopause. 
Foucault proposes that all social relationships are essentially relationships of power, 
and he coined the term “ biopower” to refer to the management of people in relation 
to practices in public health. It is well recognised that the power dynamic between 
doctor and patient in the consulting room is rarely equal. The doctor is viewed as the 
expert with the knowledge and authority to advise the patient. 
 
According to Foucault, “The doctor‟s gaze is not faithful to truth, nor subject to it, 
without asserting, at the same time, a supreme mastery: the gaze that sees is a gaze 
that dominates”  (Foucault 1963, p39 cited Downing 2008, p 34). Women are thus 
produced as “the subjects of medical and self scrutiny that act as a mechanism of 
control”. Whether or not they decide to take HRT is required to be a choice, but with 
“precisely the practice of freedom acting as a mechanism of governmentality” 
(Murtagh and Hepworth 2003, p1646). Foucault does not accept that authentic 
freedom is a genuine possibility, due to the many external and internal influences on 
the individual. He argues that patient-centred practice “does not necessarily lessen the 
power relation between the doctor‟s gaze/touch and the medicalised body – indeed it 
may bring it all the more sharply into focus. Or may create it ex nihilo.” (Dowling 
2008, p37) So real choices for patients are not possible; the individualising of the 
patient is only the effect of the operation of power, according to Foucault (Downing 
2008, p37). 
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The medicalisation of the menopause, and the criticisms levelled at this, have been 
explored. We now turn to the feminist view of the menopause as a natural life event 
perspective, to examine this in more detail. 
 
Instead of the negative construct of menopause leading to medicalisation there is, 
from a feminist perspective, an acceptance of menopause as part of the natural ageing 
process for women; but this is regarded as a positive, normal and emancipatory time 
in women‟s lives. Gannon (1996) says that at menopause “ovarian serenity is 
restored”, that levels of oestrogen become stable once more as menstruation ceases, 
and that women are thus released from the reproductive pressures which dominate 
their younger years (Gannon 1996 p 243, cited Coupland and Williams 2002, pp 439- 
440). It has to be said that Gannon almost implies, in this particular statement, that it 
is the reproductive years that are abnormal. Freedom from worries about 
menstruation and pregnancy, it is claimed, allow women to concentrate more fully on 
their careers and social activities. Rather than the „medical‟ picture of the menopausal 
woman as „mad or bad‟, this construction of menopause sees women re-evaluating 
their lives, and being able to make choices previously impossible due to family 
responsibilities.  
 
This rather rosy picture of menopause has been questioned on a number of levels. It 
has been criticised as ignoring the fact that, for some women, the symptoms of 
menopause are severe (Daly 1995, cited Murtagh and Hepworth 2003, p 1644) and 
can be relieved by the use of HRT (Rodstrom et al 2002). McCrea (1983) adds that 
feminists have overlooked the women who do suffer menopausal symptoms, and that 
the feminist view is too ideological. She suggests that “in their efforts to fight off the 
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stigma of menopause, some feminists have inadvertently contributed to ageism”, and 
that they have extrapolated their analysis of the medicalisation of childbirth to that of 
menopause “without adequate appreciation of the problems of ageing women” 
(McCrea 1983, p 120).  
 
According to Laura Purdy, “defining states of affairs as “natural” or “normal” implies 
nothing about how to deal with them”. She gives examples of instances where 
medical intervention in „normal „ life events like childbirth has been essential to save 
lives.  She also says “ „the natural‟ still exerts substantial power over us”, and that we 
should resist it, as it makes us accept health trends that could be avoided, such as 
obesity (Purdy 2001, p254-255). So does the thinking that menopause is universal, 
“natural” and “normal” to women imply that nature, by design, does not need any 
outside intervention, that “natural” is best and needs no improvement?  
 
It is interesting to note that menopause is not a normal or natural part of life for the 
females of any mammalian species, other than humans and toothed whales (Johnstone 
and Cant 2010). From an evolutionary angle, menopause seems to be an anomaly. 
Natural selection demands that all species maximise their reproductive potential, thus 
ensuring the continuation of their genome. The best way for this to occur is to 
reproduce until death. Most animals die before they lose the capacity for 
reproduction, and this occurs because they succumb to extrinsic threats. Human 
beings have, unusually, learned to control extrinsic pressures, and hence have 
extended their lifespan. It is our extended post-reproductive lifespan that makes us 
different from other primates, not the fact that we cease to reproduce at an earlier age.  
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There are two main theories of how menopause emerged: one argues that it is an 
adaptation, the other argues that it is an epiphenomenon (Peccei 2001). The adaptive 
theory is that females have better reproductive success by investing in fewer new 
offspring in favour of extending their protection to existing offspring and their young. 
That is to say, their genes are better propagated down the bloodline, rather than in the 
production of multiple children (Johnstone and Cant 2010). The theory of menopause 
as an epiphenomenon believes that it is a result of some other evolutionary 
development, in this case extended lifespan. Menopause occurs because the female 
has lived long enough to exhaust her reproductive capabilities (Wood et al 2001). 
Evidence from female macaques supports the epiphenomenon theory (Pavelka and 
Fedigan 1999, cited Citzendium 2011). If this theory is preferred, menopause 
occurring in human females can be thought of as an evolutionary design fault. Since 
it can produce unpleasant symptoms for some women it is something which we might 
wish to correct.  
         
Purdy (2001) argues that, rather than reject medical intervention on the basis that it is 
against nature and unnecessary, we should use the power of medicine to advance the 
welfare of women. She clearly does not think that feminism and women‟s medicine 
cannot work together. She does, however, argue that the feminist claim that 
medicalisation is used to control women is too simplistic. Menstruation, fertility, 
pregnancy, childbirth and menopause are all areas of women‟s lives subjected to 
medical scrutiny, yet are all natural processes. She points out that medical advances 
have indeed liberated women from some reproductive processes, giving them 
increased control over their own bodies. The most obvious examples of this are the 
introduction of the contraceptive pill and the legalisation of abortion, where women 
 45 
have used medicalisation for genuine empowerment. So “the answer is not to „suffer 
our fate‟” by rejecting treatment which may help us, but rather to  “use medical means 
for our own ends, whether to reduce pain or shape our own lives” (Purdy 2001 p257). 
The problem, according to Purdy (2001), is therefore not so much medicalisation but 
rather the culture of medicine itself. The goal of medicine is to treat disease and is 
government funded accordingly. So conditions that are not really diseases are either 
medicalised or non-funded. Purdy advocates a need to recognise that it can be 
appropriate to use medical means to prevent suffering, even if the source of the 
problem is not a disease. “The biomedical model also focuses on individuals separate 
from their social context, prefers action rather to watchful waiting, cure rather than 
prevention, heroic technical fixes and individual solutions to political or social 
problems” (Purdy 2001, p260).   
 
Women today have a far greater life expectancy than women of the past, and will 
consequently have many years of life of post-menopause. These years should be 
supported by health care which understands the needs of such women, and sees them 
“as persons in their own right, persons whose needs, desires and interests areas 
intrinsically important as those of men” (Purdy 2001, p259). The recommendations 
made by Purdy – changes in medical training, so as to include the humanities and 
social science, longer consultation times, and access to nurse practitioners – would 
perhaps lead to a greater understanding how women‟s health is affected by their 
social role.  
 
To return to the subjects of this study, it is important to recognise that, for all of these 
women, their menopause was not “natural”. Medicine had intervened with their 
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agreement to rid them of a condition they found debilitating and unacceptable. It was 
common, at the time of the study, for ovaries to be removed at the time of 
hysterectomy for menorrhagia, rendering the woman “surgically menopausal”. HRT 
was then prescribed as a true replacement treatment for the premature loss of 
circulating oestrogen. So the feminist argument of “interfering in nature” does not 
really apply to the HRT prescription for these women, as medicine had already 
„interfered‟ to cure a biological problem. If we were not to interfere with nature, then 
these same women would have been subject to heavy menstrual bleeding, a common, 
well recognised complaint, but one, which they themselves found difficult to manage. 
Left untreated, these women may have suffered a negative impact on their quality of 
life for a protracted length of time, the relief from such a situation, is the rationale for 
medical intervention in the first place.  
 
There is perhaps a point of interest, from a feminist perspective, in the removal of the 
ovaries at the time of hysterectomy for no other reason that these organs may cause 
problems in the future. From a medical stance, removal was thought to be reasonable 
on the basis that the risk of future ovarian cancer was negated, and that the ovaries 
were nearing their functional demise anyway. When women are told that they can 
avoid a cancer risk in the future by removal of the potential source, at the same time 
as an operation they are having anyway, most agree to it. Perhaps this is manipulative 
and controlling of women; yet most would opt to avoid the possibility of malignancy 
in the future if given that option. It has to be said that since the women in this study 
were treated, hysterectomy is used far less often as a treatment for menorrhagia. 
Prophylactic oophorectomy, to prevent ovarian carcinoma, in low risk women is not 
supported by some studies (Parker et al 2009). Now more conservative alternatives 
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are preferred, with hysterectomy being the last resort when other methods fail. As 
discussed in chapter four, there has been a steady reduction in the rate of benign 
hysterectomy in the United Kingdom since 1995-1996 (Reid and Mukri 2005). 
Burrell (2009) notes that the medical terminology used to describe exogenous 
hormones has changed in the course of the last ten years. Authors now use HT rather 
than HRT, as hormones are now used to treat symptoms rather than simply replace 
lost hormones. This distinction could be useful when comparing naturally 
menopausal women and women with surgically induced menopause. For the 
treatment of symptomatic naturally menopausal women HT is acceptable, as the term 
does not imply that hormones should be present. For women with premature 
oestrogen loss due to surgery, HRT is a more useful term as it is a true replacement.  
 
Either way, it is still medicalisation; but the timing is different. Symptomatic 
naturally menopausal women can use medicine to improve their quality of life. For 
surgically menopausal women, the medicalisation has already happened by way of 
surgical intervention in the first place. HRT prescription is a subsequent part of a 
process already started. Women treated for menorrhagia now will be more likely not 
to have a hysterectomy with bilateral oophorectomy, and will thus avoid the need for 
further medical intervention in their menopausal years. 
 
Returning now to the current study, an explanation of the time frame over which the 
data was collected, together with changes in HRT prescribing which have occurred 
since the study was conducted, follows.  
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1.5 Changes in prescribing guidelines during the time-scale of the study. 
The timing of this study has a major impact on the findings made and their relevance 
today. So it is important to be clear when the study was conducted, and when the data 
was analysed, so that the reader may understand how the extended time frame impacts 
upon the results. 
  
The study was commenced as part of an academic qualification in 2002, and selected 
patients treated in the preceding 10-year period (1990-2001), to allow a retrospective 
study of the recent past. There was no other reason to select this particular decade.  
The questionnaires were sent to participants in 2003, at a time when HRT treatment 
was beginning to be covered in the national press as the results of WHI 2002 became 
known. The impact of these studies cannot be ignored as a potential influence on the 
opinions of the study subjects.  
 
Not only did these studies potentially affect the responses given by women in the 
study; they have affected the relevance of the study findings to HRT decisions made 
today. To understand the study, it is necessary to understand the premises at the time. 
Before the WHI findings were published, HRT was used widely by women and their 
doctors as a treatment for the relief of menopausal symptoms. It was also promoted as 
a treatment to prevent osteoporosis, preserve cognitive function and protect against 
cardiovascular disease. As previously discussed, these benefits have now been 
somewhat discredited, and side effects such as increased rates of breast cancer and 
venous thromboembolism become evident.  
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The questions asked of the study participants were relevant to the area of study at the 
time, and women who had undergone hysterectomy and bilateral oophorectomy had 
not been considered as a separate group in published papers. The study was therefore, 
designed on what was known at the time. Due to the extended time taken to present 
its‟ findings, and the results of large scale research now apparent, there are 
fundamental differences today in how HRT treatment is viewed, by the medical 
profession and women alike.  
The current recommendations for the treatment of menorrhagia, the career of HRT to 
date, and the changes in the attitudes to its‟ use, will be further reviewed at the end of 
this chapter. 
 
Women who are pre-menopausal prior to surgery need to be aware that their hormone 
status will change subsequent to surgery, and that they will have lost their source of 
natural oestrogen prematurely. 
 
 In 2001, according to the British National Formulary (BNF, March 2001), long term 
HRT was indicated for women with early or surgical menopause (before age 45). 
These women are at high risk of osteoporosis, and long-term use was considered 
favourable in risk-benefit terms for menopausal women without a uterus. It was 
recommended that therapy should continue for 5-10 years, in order to be of benefit in 
preventing osteoporosis. By 2006 the advice given in the BNF had changed 
somewhat. It stated that HRT may be used in women with early menopause, either 
surgical or natural, up to the age of 50, but that alternatives should be considered if 
osteoporosis is the main concern. It states “that for the treatment of menopausal 
symptoms, the benefits of short term HRT outweigh the risks for the majority of 
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women, especially in those aged under 60 years (p 375). These changes to the 
prescribing guidelines came as a direct result of the research findings of the Women‟s 
Health Initiative hormone study.  
 
The women in this Scottish study had their operations between the years 1992 and 
2001, and therefore the advice given to them regarding HRT will have been different 
to that now given to women in terms of length of treatment. As all the study subjects 
had elective hysterectomy with bilateral oophorectomy before the age of 51 years, the 
reasons for taking HRT will have been much the same as they are today- that is, the 
relief of menopausal symptoms. It is likely, however, that these study participants 
were led to expect more from HRT in terms of osteoporosis prevention and possible 
cardioprotection, and they may have thought that it should be taken for a longer time. 
The impact of the publication of the WHI findings in the national press in 2002, 
which was approximately nine months prior to the women in this study being 
surveyed, will be discussed later in chapter 5.  
 
The advice given today to women after hysterectomy and bilateral oophorectomy is 
that they should take HRT until around the time of the average natural menopause at 
51 years. They should take it primarily to relieve the short-term menopausal 
symptoms, such as night sweats, and they are told that it will protect their bones. Once 
they reach the age of natural menopause, and symptoms are not a problem, there are 
other effective preparations to use to protect bone density should this be necessary. As 
indicated earlier, the research on which these recommendations are based is reviewed 
separately at the end of this chapter. 
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The information women receive about a medication, and what they might reasonably 
expect from it in terms of short and long-term risks and benefits, may be considered to 
affect their decision to commence and/or continue to take it. With this in mind, we 
now consider the issues around compliance with, or adherence to, HRT prescription.   
  
1.6 General Compliance/ adherence issues 
HRT is considered a long- term medication designed to be taken for a number of years 
to prevent the symptoms of the menopause. In order for it to be effective, it should be 
taken as prescribed. Before examining what is known about adherence to HRT 
prescription in particular, some consideration will be made of the subject in general. 
  
The term “compliance” is generally accepted to mean adherence, co-operation or  
acquiescence, the yielding to the wishes or advice of others. In medicine it means 
that, for example, the patient adheres to the prescribed treatment plan. On the surface, 
it might be expected that the issue of compliance would be simple in that, once a 
patient has sought medical advice, they would comply with the prescribed treatment. 
This, however, does not occur, and it is estimated that between 30-60 % of patients do 
not fully comply (Richman 2002 p 99). Patients are more likely to comply with 
treatment if they are suffering physical ill health, but the severity of the illness, its 
duration and the degree of debilitation have little or no association with compliance 
(Smith and Birrell 1990). Compliance is now a rather outdated term with its 
implication of a passive part played by the patient, and health- related literature now 
uses “adherence” or “concordance” as preferred terms. These terms better reflect a 
recognition of the patients‟ own beliefs in the making of their decisions, and, with the 
advent of nurse prescribing, this different perspective is of importance to nurses. 
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The term “ concordance” was first introduced in 1997 by the Royal Pharmaceutical 
Society of Great Britain, and is defined as “a new approach to prescribing and taking 
medicines, based on partnership” (Courtenay and Griffiths 2004 p122). This idea 
moves away from the traditional dictatorial role of the prescriber, and is designed to 
produce a more consultative approach, where the patient‟s wishes are valued and 
decisions are reached by informed discussion and interaction between patient and 
prescriber. Bond and Bywaters (1999, p 855) suggest “Compliance is neither an 
adequate nor appropriate concept to use in relation to women‟s decision making about 
HRT”. They suggests that it implies a “too narrow a model of consultation” and 
ignores other sources of information women may access. However, most of the studies 
conducted so far do use the term “compliance” to describe the continuance of HRT 
therapy. 
 
Whichever term is used, the reason patients either continue or cease using prescribed 
medication is a complicated issue. For the purpose of this study the author has chosen 
to use the term “adherence” as this implies a patient- centred approach, even though 
the study subjects were treated at a time when “compliance” was the accepted term. 
   
For years researchers have been trying to explain how people make decisions about 
their health-related behaviours, and adherence to a prescribed treatment is such a 
decision. Many theoretical models have been developed in an attempt to identify the 
factors which impact upon such decisions, and which might therefore be useful in 
predicting behaviour. Three such models -The Health Belief Model, (Becker et al. 
1977), Protection Motivation Theory, (Prentice-Dunn and Rodgers 1986) and 
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Leventhal‟s Common Sense Model of Self Regulation, (Leventhal, Brissette and 
Leventhal 2003) - will be discussed here.    
 
It is accepted that a number of factors may influence a person‟s decision to take 
medication, and the “Health Belief Model”, (HBM) developed in the 1950s, by 
Becker, and used widely, attempts to explain this. The model illustrates the 
complicated interaction of many different influences that may determine compliance 
by modifying the individual perception of personal susceptibility to a disease and the 
seriousness of that disease (Becker et al. 1977). According to this model, factors such 
as age, sex, social class and peer pressure determine the likelihood of action based on 
the balance of “what is to be gained by following a treatment” (perceived benefits) 
versus “what cost to me, i.e. effort, financial” (perceived barriers), together with the 
perceived likelihood of suffering from the health threat and the perceived severity of 
that threat. The validity of The Health Belief Model to predict health related 
behaviour has been questioned by Harrison et al (1992), and similar but more 
comprehensive models have now replaced it. 
 
Protection Motivation Theory (Prentice-Dunn and Rodgers 1986) is very similar to 
the Health Belief Model in that the individual evaluates the health threat in terms of 
probability of occurrence, severity and the effectiveness of treatment. When 
considering the costs of behaviour change, however it differs from the Health Belief 
Model. Where the HBM classes all costs - time, effort, money inconvenience - as one 
variable, the Protection Motivation Theory separates out the costs. It takes into 
account the individual‟s own belief in their ability to adhere to treatment (self-
efficacy), and the loss of current internal rewards and extrinsic rewards of change, as 
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separate variables rather than grouping them together (Weinstein 1993 p 325). 
Additionally, the model includes an emotional input- that is, how the patient feels 
about the potential health threat. So it takes into account both the severity of the threat 
and the susceptibility to the threat, but also how these are dealt with emotionally. Both 
these theories would predict that a woman who was worried about osteoporosis, and 
who believed HRT would prevent, it would be more likely to accept and adhere to her 
prescription, in spite of known risks, than a woman who viewed HRT as ineffective, 
unnatural or unnecessary.    
 
Leventhal‟s common-sense Model of self-regulation of health and illness, or CSM, is 
perhaps the most useful model when considering HRT choices. The very name 
implies a less medical and more patient- focussed approach. This model is based on 
problem solving, and acknowledges that fear of a health threat is important; but it 
recognises that fear alone does not explain patients‟ decisions.  It has a parallel-
response framework, representing the ways in which the health threat is represented, 
coped with and evaluated. Hale et al (2007, p 904) say “the key construct within the 
CSM is the idea of illness representations or lay beliefs about illness”.  According to 
Leventhal et al (2003, p 50) there are five domains of illness representation, which are 
perceptual in nature and are as follows: 
 
1. Identity or label e.g. symptoms and what they mean. 
2. Timeline or duration e.g. perceived time of onset and duration. 
3. Consequences or expected outcome e.g. disability or pain. 
4. Cause e.g. genetic inheritance, lack of sleep, and contact with sick individual. 
5. Control of illness e.g. is treatment effective? Can it be prevented? 
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All of these domains can be complicated by various social influences, such as the 
opinions and experiences of other patients, family and friends, and the media. Each 
patient will have an individual illness representation based on his or her perceptual 
information. This in turn informs their coping procedures and action plan, and may 
change over time. 
 
Leventhal et al (1992) suggest that this model is useful when trying to understand 
adherence, as it combines many of the variables used individually in previous models. 
To take a simple example, the patient most likely to take the prescribed medication, 
would believe the following: that he would get bad symptoms; it will happen soon and 
last; it will be painful or dangerous; medication will take that risk away. The patient 
for whom any medication is prescribed is likely to question any long-term treatment 
that has associated side- effects, such as those seen with HRT, and the potential 
benefit of decreased risk of future illness may be outweighed by shorter-term side-
effects. Towey et al (2006), in their review of psychological and social interventions 
in the menopause, consider Leventhal et al‟s model a useful tool in consultations 
about HRT prescription, as it specifically considers the identity, the consequences and 
the control for the individual. In other words, it allows for the influence of the 
individual‟s perception of the meaning of symptoms and their severity, - that is, what 
will the menopause be like for them. This may well vary greatly between individuals. 
The possible consequences of not taking the medication in terms of susceptibility to 
symptoms such as hot flushes and osteoporosis, will vary between different women. 
Likewise the perception of the risks of treatment will also vary on an individual basis. 
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Most importantly the individual's belief in the success of treatment, is accounted for 
in Leventhal‟s model. 
 
 All these models are based on what information the person has to process in order to 
reach their decisions, so clearly that information is vital. The information about how 
HRT works, and about the risks and benefits of treatment, are central to the evaluation 
women make when making their decision, so the source of the information (and how 
well it is delivered is) important.  
    
The nature of the relationship between patient and prescriber, in terms of 
communication, will affect adherence, and Latter (2004) suggests that non-adherence 
may relate to the quality of information given (p125). This has been confirmed by 
much earlier studies (Svarstad, 1976 cited in Leventhal et al, 1992, p145). Finley et al 
(2001) cite the influence of the health care provider as a major influence in HRT use.  
 
Consultation styles have been strongly implicated in patient adherence. Consultation 
styles may vary among different doctors and their patients, and it is recognised that a 
participatory style (Korsch 1969, cited Richman 2002, p97) produces a higher level of 
adherence. The participatory style allows the doctor and their patient to become 
partners in any decision regarding treatment, by open discussion. It is this particular 
style of consultation that is central to the principle of concordance, since it has room 
for the patient‟s views, and values their personal beliefs about medications in general. 
Communication between medical advisor and patient is important when women are 
making HRT decisions (Mansfield and Voda 1994).  
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 Martin Robb (2004) states that gender is a factor affecting communication in 
healthcare services and, if communication between a doctor and their patient is 
affected, then this may negatively affect the quality of the consultation. This in turn 
may influence the outcome of such consultations in terms of adherence to therapy. 
There is some debate here when adherence to HRT is considered. The gender of the 
doctor is not a significant determinant of adherence with HRT therapy, according to 
Maclaren and Woods (2001): but Hope et al (1998) found that 52% of their 393 
patients, would prefer to see a female doctor, while 65% felt more would be done if 
men experienced the menopause.  
 
We now consider what is known about rates of adherence of HRT treatment in 
particular. 
 
1.7 Rates of adherence to HRT prescription 
It is interesting to note that many studies of the uptake of HRT, and adherence 
thereafter, have found the rate of long-term compliance to be poor (Hope and Rees 
1995, Maclaren and Woods 2001). The literature is extensive on reasons for 
discontinuance, but most is generalised in terms of sample characteristics. 
 
Many studies group peri-menopausal and menopausal women together, and do not 
consider those women who have undergone hysterectomy with BSO separately 
(Maclaren and Woods 2001, Den-Tonkelaar and Oddens 2000, Hope and Rees 1995).    
This makes the interpretation of data more difficult when considering only those 
women who have had hysterectomy with bilateral oophorectomy. It could be argued 
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that women who have had a surgical menopause are different from women 
experiencing natural menopause, in terms of age and severity of menopausal 
symptoms, and that they might therefore may have different reasons for continuing or 
discontinuing HRT. It is also important to recognise that hysterectomies are performed 
for different reasons, and that post-operative HRT is not appropriate in all cases. The 
reason for surgery is not documented in most published studies. There are, however, 
publications which have shown adherence rates with HRT users in general which 
include women with hysterectomy; some of these studies give separate adherence rates 
for these surgically menopausal women. 
 
Hope and Rees (1995) investigated 525 HRT users aged between 45 –54 years, 
divided equally between current and lapsed users. A third (33%) of the sample had 
undergone hysterectomy, and half of these had also had an oophorectomy. It is not 
completely clear what criteria were used to classify the lapsed user, but in this group 
51% of women had stopped HRT within 1 year and 74% within 3 years. Women with 
hysterectomy and BSO are not studied separately. There is no presented data on the 
effect of age on HRT use, so it is not clear if the older women were the ones who 
stopped early. 
 
A study by Den-Tonkelaar and Oddens in 2000, of 4 general practices in the UK, 
questioned 615 past or present HRT users. These women were selected on the basis 
that they had used HRT during the previous three years. They found that women who 
had had a hysterectomy or oophorectomy were significantly more likely to be long-
term users of HRT (over 6 years). Of the 611 women who reported the duration of 
HRT use, 4.6% had used it for more than 10 years, 19.6% for between 6-10 years, and 
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28.5% for between 1-2 years. These figures are from a broad population of women, 
with no figures specific to hysterectomy with BSO, so it is difficult to know how these 
findings relate directly to this particular group. 
 
Finley et al. (2001) used a mailed survey to assess associations with the prevalence of 
HRT use in American women. They found that a past history of hysterectomy was 
associated with a threefold increase in odds ratio of HRT use. Oophorectomy was 
associated with a twofold higher odds ratio, but there are no details of age as related to 
type of surgery, or the reasons why it was performed. This study surveyed women of 
between 50 and 70 years of age primarily to investigate socio-economic trends, and 
therefore did not explore duration of therapy or reasons for discontinuance. 
 
Maclaren‟s American study of 884 women, aged between 40 and 65 years (Maclaren 
and Woods 2001) used an odds ratio to predict HRT use. They showed that 
hysterectomy is a significant predictor of HRT use, which would be expected, but the 
oophorectomy status of their subjects was not detailed. The overall duration of use, 
with no distinction between those who had undergone hysterectomy with BSO and 
those who had not, was found to be 12% for between 1-18 months, and 86% for one or 
more years. The wide age range of their study subjects is reflected in these results, as 
older women would be expected to take HRT for a shorter time.  The median duration 
was 5 years, and 25% of the women in the study took therapy for more than 10 years. 
The 25% who took HRT for longer than 10 years are not described in terms of natural 
or surgical menopause, so once again women who have had a hysterectomy with 
bilateral oophorectomy are not investigated separately. 
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The Gallup survey sponsored by the North American Menopause Society (NAMS)  
(Utian and Schiff 1994) showed that 53% of hysterectomised women (oophorectomy 
status not specified) were current users of HRT, but that 35% had never used it. It has 
to be said that current user status does not necessarily mean long-term adherence. It is 
estimated in the U.S.A. that 20%-30% of women who receive prescriptions for HRT 
do not fill them, and that 70% are non-compliant in the long term (Rowles, 1990 cited 
Coope and Marsh 1992, p157). 
 
Studies specifically concerned with women who have a hysterectomy and BSO have 
found higher rates of compliance with HRT. An American study found that 71% of 
women used HRT after BSO, and that these women were 1.9 times more likely to 
continue therapy for at least 5 years than were women with a natural menopause (Brett 
and Maddens 1997). 
 
Likewise, a British study by Griffiths and Convery (1995), using patients from one GP 
practise in Stockton –on –Tees, Cleveland, UK, found that 71% of women who were 
under 52 years old when they had a hysterectomy with BSO were taking HRT. 8.4% 
had taken HRT in the past, but had stopped, and 20.6% had never taken it. Of the 
women who had started therapy and then stopped, there was no reason for 
discontinuance recorded for 13 of the 20 women in this group, which also included 
those women who had had a hysterectomy without removal of ovaries. 
 
Khastgir and Studd  (2000) followed 194 patients undergoing hysterectomy +/- BSO 
for non-malignant reason, and found a therapy continuation rate of 97.4% at 2 years. 
However, this study used HRT in the form of subcutaneous implants placed in situ at 
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the time of surgery, and replaced at 6-month intervals with advice to continue the 
therapy, which may explain their higher rate of compliance. 
 
In one Danish study a calculated compliance rate of 89% at 1-3 years was found in 
hysterectomised women with BSO (Hee 1999). This study, however, presents its data 
in ambiguous fashion, and it is not clear when and in what number women discontinue 
therapy over the 1-3 years. 
 
In contrast to these findings, a Spanish study evaluating the effects of long-term 
oestrogen on bone density in surgically menopausal women claims only one third of 
patients were continuing therapy at 5 years (Castelo-Branco et al 1999). There are 
some problems with the data presentation in this study, as it appears that some of the 
numbers do not add up, a problem which has been raised by another authors  (Ettinger  
2000).  
 
It is clear from this (pre- WHI) literature that women undergoing hysterectomy +/- 
BSO are more likely to take HRT, and to take it for longer, than women experiencing 
a natural menopause. It is not so clear, however, what the long-term compliance rate 
is, or, for those who discontinue therapy, exactly when they stop and for what reasons. 
Cultural influences may also play a part, thus perhaps explaining the differing findings 
between studies. We now consider the reasons women give for stopping HRT. 
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1.8 Reasons given for discontinuance and socio-economic considerations 
 
Many authors have studied the reasons behind women‟s decisions to stop, or indeed 
never start, HRT. Hope and Rees (1995) found that 38% of lapsed users stopped HRT 
without medical consultation, and that these women were unaware that there may be 
other preparations that could have suited them better. In this study, only 33% of the 
sample had undergone hysterectomy, and half of these had also had an oophorectomy; 
so once again this data comes from a generalised group of women. Newton et al. 
(1997) found that 53% of past users stopped therapy on their own, the women in her 
study being classified by current or past use of HRT rather than by hysterectomy 
status. Clearly, there must be some powerful reasons behind these actions, and there is 
consensus in the literature as to what those reasons are. 
 
The main concerns of women would appear to be both current and potential in nature. 
Side-effects of HRT are a major factor. Oestrogenic effects, such as breast tenderness, 
headache and sickness, and a dislike of taking hormones, are commonly cited reasons 
for discontinuation in studies (Draper and Roland 1990, Wren and Brown 1991, Lewis 
et al 2000, Den-Tonkelaar and Oddens 2000,). Weight gain is also often mentioned as 
a side-effect important to women and is cited as a reason to ceasing to take HRT 
(Hope Wager and Rees 1998). 
 
Bond and Bywaters (1999), in a small study of 16 women, make some interesting 
observations on the lack of information available to women from their doctors, and the 
somewhat confusing and conflicting opinions they receive- both of which contribute to 
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discontinuance. Many women view the menopause as a natural event, not requiring 
medicalisation (Newton et al 1997). 
 
Anxiety about the increased risk of breast cancer is a major concern (Utian and Schiff 
1994). Breakthrough bleeding, or the continuation of menses, is only applicable to 
women with an intact uterus, so will not be discussed here. 
  
The literature cites these aspects of HRT as reasons given for discontinuation, but 
there does not appear to be a study which examines how long these effects are 
tolerated before discontinuation occurs, or whether the reasons for stopping therapy 
change with time. Nor have there been many studies specific to British women having 
elective hysterectomy with bilateral oophorectomy. If women are discontinuing HRT 
early after hysterectomy with bilateral oophorectomy, it could be argued that they are 
putting their future health at risk. 
 
HRT may have long-term benefits for women in their later years in terms of 
osteoporosis protection, so it is a subject, which can be explored from a health 
promotion angle. Since the Black Report, published in 1980, it has been recognised 
that there are inequalities in health status between the social classes, and that 
behavioural and cultural differences, together with material and life circumstances, 
combine to affect a person‟s health. The White paper “Towards a Healthier Scotland” 
(1999) recognised Scotland‟s poor health record, and health issues for women are part 
of this. The Scottish Executive Health Departments‟ (2004) publication, Health in 
Scotland, acknowledges a “Scottish effect” in their opening chapter, stating that for 
some reason those living in Scotland are still less healthy than in other countries. As in 
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so many areas of health promotion, those women more likely to use HRT are white, 
middle class with some higher-level education (Maclaren and Woods 2001, Finley et 
al 2001, Lewis et al 2000, Brett and Maddens 1997). Younger age is also a correlate of 
HRT use (Newton et al 1997). Education, life experience, the influence of family and 
lay beliefs all inform the individual‟s life expectations and subsequently their health 
choices. The problem lies in ensuring that that all women regardless of their social 
background receive appropriate consultation and access to preventative medicine.  
 
1.9 Changes in treatment for menorrhagia, and the career of HRT 
Since the original literature review for this study was performed there has been further 
research published in connection with HRT use, the findings of this research impact 
heavily upon the relevancy of the study today. In order to avoid confusion as to what 
was thought at the time and what is known now, the recent literature is discussed 
separately rather than as part of the main text.  
 
 In 2010, women presenting to their doctors complaining of menorrhagia will be 
offered a number of treatments before hysterectomy is decided upon. These 
treatments were in their infancy in the 1990‟s and it was estimated that at least 60% of 
women with menorrhagia ultimately had a hysterectomy, often without any other 
treatment being offered (NICE clinical guideline 44 2007 p4). With the efficacy of 
more conservative treatments, the inherent dangers of major surgery, and the cost 
implications to the health service, a different approach is now recommended. 
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The National Institute for Health and Clinical Excellence (NICE) recommend an 
approach that is individual to the patient and that  “Whether menstrual blood loss is a 
problem should be determined not by measuring blood loss but by the woman 
herself”(NICE clinical guideline 44 2007 p9). It advocates trying pharmaceutical 
treatments such as levonorgestrel releasing intrauterine system (LNG-IUS, i.e.Mirena 
coil), daily norethisterone tablets, or long acting progestogens first. If these fail to 
control symptoms then non-hysterectomy surgical interventions such as endometrial 
ablation should be considered. Only when these treatments are contraindicated, fail, or 
are not wanted by the woman, then hysterectomy is considered. The removal of 
healthy ovaries at the time of hysterectomy is not recommended and “should only be 
undertaken with the express wish and consent of the woman” (NICE clinical guideline 
44 2007 p20). The resulting impact of oophorectomy must be discussed with the 
patient. The reasoning behind these recommendations is that these treatments have 
been shown to be effective in reducing menstrual bleeding. Lethaby, Cooke and Rees 
(2009), have shown in their systematic review that LNG IUS is more effective than 
oral norethisterone, and that despite some short term side effects women were willing 
to continue treatment. LNG IUS is not as effective as endometrial ablation at reducing 
blood loss but this does not affect patient satisfaction. LNG IUS is however associated 
with progestogenic side effects not found with endometrial ablation. One trial 
assessing quality of life in women eligible for hysterectomy found that those women 
treated with LNG IUS cancelled their surgery in greater numbers than those treated 
with other medical treatments (Hurskainen et al 2001). This same study reports 
reduced treatment costs of LNG IUS compared to hysterectomy at one and five years 
follow up. 
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Not only the treatment pathway for menorrhagia has changed since the women in this 
study were surveyed. The expectations of HRT treatment and the recommendations 
for its use are also altered, and this will now be considered, in historical context.  
 
As long ago as 1981, McKinlay described some types of medical mistakes by 
outlining the typical career of a medical innovation. By “medical innovation” he 
means a new drug, a new surgical intervention, the use of new equipment, or a change 
in clinical management. His paper describes how such medical innovations become 
part of medical practice, and what types of evidence are employed to support them. A 
description of an alternative approach, based on randomised controlled trials, then 
follows. This is a very interesting paper, which notes criticism of obstetrics and 
gynaecology, as a speciality, for not randomising certain procedures such as induction 
of labour and foetal monitoring before widespread use (p 376). He describes seven 
stages of development and this provides a very useful framework to examine the 
career of HRT, as shown in a paper by Wright in 2005. 
 
The first of McKinlay‟s stages is that of promising report, which he observes, often 
has no methodological criteria. An exciting therapy is piloted on patients often with 
no control, and if results are good then a randomised controlled trial (RCT) is 
recommended but often is delayed for ethical reasons. It may be years later before 
other clinicians do a controlled trial (McKinlay 1981 p380). During the stage of 
professional and organisational adoption, more widespread and influential support 
is mobilised and “physicians and their associates believe that they are being more 
effective, humane scientific, or whatever, and secondarily derive financial 
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benefit”(McKinlay 1981 p381-382). Public acceptance and state (third party) 
endorsement comes next, “partly because of exposure to promising reports but 
mainly as a result of professional and organisational adoption, a general approval 
(acceptance) of the innovation emerges among the public”(McKinlay 1981 p385). 
This leads to public demand.  
 
Once generally accepted, the innovation becomes established and respected, and this 
McKinlay calls the stage of standard procedure and observational reports. It is at 
this point that observational studies are initiated, often by those who were involved at 
the beginning of the innovation, for example, the pharmaceutical industry. McKinlay 
notes that “ for every controlled trial that provides evidence against an innovations‟ 
effectiveness, there are sometimes hundreds of observational studies that produce 
support for it”(McKinlay 1981 p390). Stage five from McKinlay is the stage of the 
randomised controlled trial, and it is this type of research that “remain the most 
valuable method of evaluating the efficacy of therapies”(p393). It is acknowledged 
that they are difficult to do due to ethical and legal reasons, and their results can cause 
difficulties for the medical profession and elicit defensive responses. The results from 
the large scale RCTs, (the WHI studies) has been discussed earlier, and it is the data 
from these, and other studies which have led to altered HRT prescription.  
 
Stage six of McKinley‟s stages is the stage of professional denunciation. The 
medical profession is accused of responding defensively when research findings 
question what has become a standard procedure. “Much of it is a hostile response 
from a group self interestingly protecting a domain of activity” according to 
 68 
McKinlay (1981 p395). In the light of research findings, claims are modified and not 
as universally applicable as first thought, in the stage of erosion and discreditation. 
This can take a long period of time, often more than a decade, and gradually the 
support for the innovation is eroded. Sometimes the innovation can be replaced by a 
new one, but McKinlay says, “discreditation or discard usually occurs only when a 
replacement becomes available” (p399).  
    
McKinlay (1981) suggests that potential harm could be avoided if medical 
innovations were evaluated earlier. He advocates that there must be demonstrated 
benefit over and above any placebo effect, and that side effects and added risk must 
be part of the outcome measures. He maintains that “with few exceptions, acceptable 
evidence of effectiveness can be established only through comparative experiments, 
that are as free as possible from sources of bias”(p 405). 
 
These seven stages, can well describe the career of HRT as an innovation, as shown 
by Wright in 2005, and will now be examined. The early claims made for HRT, have 
been discussed in the preceding text, and include the idea that all menopausal women 
could benefit from treatment, and remain forever feminine (Wilson 1966). By the 
1990‟s, HRT  was also recommended as a preventative medicine, against osteoporosis 
and heart disease. Based on observational studies, it was recommended for five years 
after menopause to prevent osteoporosis (Barzel 1988, Lindsay 1987 and Stott 1991 
cited Wright 2005 p1091). It was reported in the press that it may reduce coronary 
related death in women by up to 50% (Clark 1994, cited Wright 2005 p1091). These 
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are powerful claims, but as McKinlay points out they were not based on sound 
methodological criteria.  
 
Due to the increasing claims of HRT and its endorsement by Menopause societies, 
celebrities and eminent doctors, the rate of prescriptions for HRT more than doubled 
to 32 million in 1989, and by 1990 doctors were finding it difficult “to maintain a 
conservative approach to prescribing HRT”  (Wright 2005 p1091-1092). As the public 
believed that HRT was an effective and desirable treatment, so the demand for 
prescriptions grew. McKinlay believes that this demand is created by a combination 
of powerful marketing by the pharmaceutical industry, together with doctors 
endorsing an innovative treatment for a new condition, and in this case, a population 
who wants a panacea for the menopause.       
 
There is certainly a vast literature on the risks and benefits of HRT, generated 
throughout the 1990‟s, but still no completed RCT. Prescription became a “standard 
procedure”, despite evidence that the claim of reduced heart disease in HRT users was 
flawed (Vandenbroucke 1991). McKinney et al (1998) maintained that continued use 
of long-term HRT was necessary to reap the benefits of treatment. So the women in 
this study were treated at a time when although the risks were known; the benefits of 
treatment were thought to outweigh the risks. Then came the results of the randomised 
controlled trials, some thirty years after the introduction of HRT as a treatment for the 
menopause and associated symptoms.  
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The efficacy of hormone therapy for the relief of menopausal hot flushes has been 
well documented in a number of RCTs, which were reviewed by MacLennan, Lester 
and Moore in 2004. It is thought that a better than 75% reduction in hot flushes can be 
attributed to treatment (Currie and Cochrane 2010, MacLennan, Lester and Moore 
2004). Oral oestrogens relieve vaginal atrophy in menopausal women but local 
preparations in the form of pessaries, creams or vaginal rings are also effective 
(Suckling, Lethaby and Kennedy 2006). 
 
The Cochrane review of long term hormone therapy for perimenopausal and 
postmenopausal women was updated in 2009, in an attempt to provide an overview of 
all relevant clinical outcomes, to aid clinicians and patients in their HRT decisions 
(Farquhar et al 2009).  This review selected a total of nineteen randomised double-
blind trials of treatment versus placebo, including HERS and WHI 1998. Classifying 
surgically menopausal women together with naturally menopausal women, as the 
postmenopause group, the review focuses on both combined and oestrogen only 
therapy. The WISDOM 2007 trial (Vickers et al 2007) and some smaller trials 
(Haines 2003, Munard 2000), included in the review examined oestrogen-only 
treatment, in hysterectomised women, and these, together with the oestrogen-only arm 
of the WHI trial, provide the basis of current recommendations for oestrogen only 
therapy. The conclusion of this Cochrane review is that HRT should not be used for 
chronic disease management. Long term oestrogen-only treatment increases the risk 
of VTE, stroke and gallbladder disease. Breast cancer rates with oestrogen only 
treatment were seen to decrease (although not to a statistically significant degree) in 
the WHI study. A recent review of breast biopsies taken from the participants, shows 
an increase of benign breast disease, which requires longer follow up, to clarify if 
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indeed this translates into an increase in malignancies (Rohan 2008 cited Farquhar 
2009 p23). The authors acknowledge that more research is needed to provide 
evidence on the safety of HRT in younger women, especially as their review is 
dominated by the WHI findings, which did not include women under the age of 50 
years. For women in their fifties “ the absolute risk of a life-threatening event is 
low”(Farquhar et al 2009 p25). However, in a review of therapies in 2009, 
MacLennan concludes that breast cancer risk increases after several years of 
combined HRT, but there is no such increase associated with oestrogen only HRT. A 
review of hormone therapy for endometriosis and surgical menopause was also 
published in 2009 by Al Kadri et al, but is not relevant to this study, as it examines 
women taking HRT who were treated surgically for endometriosis, and measures pain 
and recurrent disease outcomes. 
 
There has been previous comment about the relevance of the findings made in the 
large American trials to the women in this study, earlier in this chapter. It is 
interesting to see that certainly HRT use was defended from some powerful quarters, 
such as the menopause society and articles in the medical press in 2004 (Wright 2005 
p1095). 
 
It can be argued that the benefits attributed to HRT treatment may have been eroded, 
but it has not been completely discredited. It has been shown to be effective at 
relieving menopausal symptoms, but many so–called benefits have been disproved, 
and the risks of treatment now have some quantification.   
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There are a number of alternative therapies of a herbal nature, that have claimed 
success in treating menopausal symptoms, together with lifestyle changes in diet and 
exercise, but as discussed earlier these often have no support from The Medicines and 
Healthcare products Regulatory Agency (MHRA). The efficacy of such herbal, or 
homeopathic remedies have been refuted by MacLennan (2009), who concludes that 
phytoestrogens, black cohosh, and other complementary therapies have no greater 
effect than placebo in quality RCT‟s, and that their long term safety has not been 
evidenced.  The claims made by bisphosphonates to treat osteoporosis made it popular 
for a while, but long term safety is now questioned (Watson, Wise and Green 2007). 
  
The prescribing of HRT to women, in the UK, aged 40 years and older has fallen by 
about 50% since 2002 (Watson Wise and Green 2007). Menon et al (2007), in their 
study of post menopausal women aged 50- 70 years, attribute the decline in its use to 
the early closure and subsequent publicity of the WHI trials.  Attitudes to menopause 
and HRT have been studied in the light of these major studies. Lindh-Astrand et al 
(2007) concluded that Swedish woman, had a mainly biological view of menopause, a 
perspective unchanged between 1999 and 2003. However in 2003, fewer women 
thought that HRT should be used for menopausal symptom relief, a change they 
attribute to women‟s and their health care provider‟s appraisal of the risk/benefit ratio. 
In a study of Icelandic women aged 47-53 years old by Sveinsdottir and Olafsson in 
2006, more positive attitudes to HRT treatment were associated with higher age, 
current HRT use, and discussing treatment with their physicians. This same paper 
recommends the strengthening of the advisory nature of the nurse‟s role. There is still 
little published on adherence rates for women taking oestrogen only HRT. The WHI 
oestrogen only arm found 53.8% of women were non-adherent with treatment at 6.8 
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years (Farquhar et al 2009). A study of British women conducted between 1992 and 
1998, found that 53.8% of women, aged 45-64 years, with hysterectomy 
(oophorectomy status not known), used HRT for at least 3 years (Bromley, de Vries 
and Farmer 2004). The reasons given for discontinuance are still the fears of side 
effects, especially breast cancer as shown in a study of Spanish women aged between 
40 and 65 years (Castelo-Branco et al 2007). This same study found that few (9.4%) 
current users were worried about treatment and that their main reason for continuance 
was the efficacy of treatment for menopausal symptoms. There still seems to be no 
data on the reasons for discontinuance given by surgically menopausal as a separate 
group.   
 
Wright (2005) concludes her paper by saying that the historical pathway of HRT is an 
example of how the Medical and Nursing professions continue to accept innovation 
uncritically. In the interests of patient safety she urges doctors and nurses to attain 
best practice by adopting evidence based care. For the women in the present study, 
treated in the time frame 1992-2001, before they had reached the average age of 
natural menopause, it is difficult to determine, (in view of the extended duration of 
treatment as recommended at the time), whether or not their treatment was, to their 
overall benefit. However, if we consider what the recommendations for HRT use are 
for women in 2010, and apply them to the study participants, treated in the past, then 
it is possible to defend the use of HRT in these women.  
 
Oophorectomy before natural menopause, results in a sudden drop in circulating 
oestrogen, which in turn may produce severe menopausal symptoms. HRT is still 
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recommended as the most effective therapy to relieve hot flushes, night sweats 
vaginal dryness and dyspareunia (McLennan 2009,Pinkerton and Dale 2010, Currie 
2010). It is also improves joint pains and protects against fractures (McLennan 2009, 
Currie 2010, Pinkerton and Dale 2010). For women, without thrombotic risk factors, 
HRT taken around the age of menopause is associated with only a small increase in 
VTE (McLennan 2009, Currie 2010). The Nurses‟ Health study observed long-term 
health outcomes in women who had hysterectomy at age 30-55 years, for benign 
disease. It commenced in 1976 and follow up finished in 2004. The results of this 
observational study found, that bilateral oophorectomy at the time of hysterectomy, 
was associated with an increased risk of coronary heart disease, and the authors 
suggest that oestrogen only therapy may reduce this increased risk (Parker et al 2009).   
Women in the oestrogen only arm of the WHI trial showed no increased risk of 
coronary heart disease (Currie 2010), suggesting that, if oophorectomy does indeed 
increase CHD risk, then HRT be of benefit. The increased risk of breast cancer is only 
apparent after 5 years of oestrogen-only HRT use, and is only small (Currie 2010), or 
is not apparent at all (McLennan 2009). There is still debate about the effect of 
oestrogen on cognitive function. Evidence from short term RCT‟s in women with 
surgical menopause suggested that HRT might be of benefit, and there is some 
thought that there might be a “critical window” when treatment is of benefit. It is 
proposed, but not proven, that HRT commenced around the time of menopause be of 
benefit, while starting later may be detrimental  (Pinkerton and Dale 2010, Henderson 
and Sherwin 2007).  
      
So, for the women in this current study, after their hysterectomy with bilateral 
oophorectomy for benign disease, HRT prescription can be justified. The treatment 
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would primarily relieve menopausal symptoms, and it would also protect their bone 
density. There may even be some positive effects on cognitive function and reduced 
CHD after all, however these effects are not proven. There is a slight increase in the 
risk of VTE in the first year, and a small risk of breast cancer after five years of use. 
A much shorter duration of treatment is now recommended, with regular review to 
assess the risk/ benefit ratio.  
 
1.9.1 Conclusion 
In conclusion, it would appear that compliance with HRT had been well covered in the 
literature available at the time the study subjects were surveyed. However, there had 
been few studies concerned only with women who had undergone hysterectomy with 
BSO, a group of women most at risk from the effects of early oestrogen loss. Since the 
WHI findings were published, there has been much more data available on women 
taking oestrogen-only HRT, but studies specific to younger, surgically menopausal 
women are still lacking.  
 
Compliance rates are uncertain, the reasons for discontinuance, although well 
specified, have not been examined in relation to the age of the patient. The timing of 
discontinuance has not been linked to the reasons given for stopping. It may be 
expected that the reasons for discontinuance differ between those women who stop 
HRT early and women who take it for a longer time. 
 
Socio-economic parameters are influential on patterns of healthcare access in general, 
and will therefore affect HRT use. Most of the current literature is based on either 
American women or those in the south of England (Draper and Roland 1990,Hope and 
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Rees 1995, Rees 1997, Tanna and Pitkin 1997, Hope et al 1998, Khastgir and Studd 
2000). The social backgrounds and cultural beliefs of these study subjects may be 
different to women in central Scotland. As lay beliefs are now more widely recognised 
as of importance in health decisions, Leventhal‟s model may be useful in 
understanding the adherence to or discontinuation of HRT.  
 
There have been “rapid changes in the attitudes of HRT use in the past 20 years” 
(Newton et al 1997), and indeed attitudes to preventative medicine in general. The 
general public now demands a more consultative approach from their health care 
providers, rather than the dictatorial one of the past. 
 
Most of the published data appeared in the 1990s and there was a 10% rise in the 
number of female GPs, and a 6% increase in female consultants, in the 10 year period 
in which this study was carried out (Statistics for General Medical Practitioners 1990-
2000). This may well affect prescribing patterns for HRT. Although not statistically 
significant, Maclaren and Woods (2001) found that women consulting male 
gynaecologists were more likely to use HRT. 
 
The publication of the Women‟s Health Initiative, occurring towards the very end of 
this study‟s time-scale, has altered somewhat the advice that women now receive 
about HRT. For women experiencing surgical menopause, HRT is prescribed post-
operatively with the advice to continue therapy until the timing of natural menopause, 
when re-evaluation can occur.   
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Women having hysterectomy and bilateral oophorectomy before the age of natural 
menopause are at increased risk of suffering menopausal symptoms and developing 
osteoporosis. Given that most published data does not study these women as a separate 
entity within the general population of HRT users, it is appropriate to revisit this field.  
 In every gynaecology unit, women are admitted for elective hysterectomy, and many 
are advised to take hormone replacement therapy after surgery. There has been a vast 
amount of literature published, both in medical journals and in the general press, 
concerned with the risks and benefits of such therapy. This in turn has led to somewhat 
confusing advice for women trying to decide whether or not to take such therapy after 
surgery, and how long to take it for. This study will examine the patterns of HRT use 
specifically in women undergoing elective hysterectomy with BSO for menorrhagia 
within a region of Scotland, between the years 1992- 2001. 
 
1.9.2 The aim of this study was to answer the following questions 
 How many women in the study area, who have undergone elective hysterectomy   
with bilateral oophorectomy for menorrhagia, take hormone replacement? 
 When do they commence therapy? 
 When do they stop therapy? 
 Why do they stop? 
 Are the reasons for early discontinuance different from those for late 
discontinuance? 
 What factors affect HRT use? 
 
With respect to all these questions, the aim is to be able to see if the patterns of HRT 
use in these hysterectomised women differ to those of HRT users in general. 
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The next chapter will examine the variables thought to exert an effect on women‟s 
HRT decisions, variables which therefore need to be taken into account when 
considering these questions. 
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Chapter Two 
Variables that may influence the use of HRT 
 
The purpose of this chapter is to review the variables that might effect HRT decisions. 
Much of the information on rates of adherence and the factors believed to contribute 
to the decisions women make has been gleaned from women experiencing a natural 
menopause – that is one that has not been surgically induced. As previously indicated, 
the HRT decisions of women following hysterectomy with bilateral oophorectomy, as 
a sub-section of the general HRT - using population, are not well documented. There 
are reasons to suppose that, following hysterectomy with bilateral oophorectomy 
before the age of 51 years for benign reasons, the risk/ benefit balance is weighted in 
favour of treatment. These women have lost their oestrogen abruptly, and because 
they have no remaining uterus, do not suffer the problems with erratic uterine 
bleeding that some women with intact uteri might experience. So do these women 
differ in any way from those whose menopause was a natural event? 
 
In this chapter, the variables which might influence HRT decisions (for any woman) 
will be examined. Each variable will first be discussed in terms of its known general 
influence on health care, and subsequently in terms of its effect, if known, on HRT 
use in particular. In the conclusion, reasons why these particular variables may affect 
HRT use in hysterectomised women will be suggested.        
 
2. 1 Factors that may affect HRT use 
What affects women‟s decisions to take HRT in general? Probably the same 
influences that shape decisions about health care and medication in other situations. It 
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is known that a number of variables, such as socio-economic group, media-influences 
and health promotion strategies, can influence these health decisions. What is not so 
clear is whether or not women undergoing surgical menopause follow the same 
patterns of HRT use as their natural menopause counterparts, and whether they are 
influenced by the same variables. All the women in this study had their 
hysterectomies performed for the same clinical indication, but they are not in any 
other sense identical, given that they were treated by different consultant 
gynaecologists, in two different hospitals and cared for by two different nursing 
teams. The women themselves differ in their age at the time of operation, and in their 
social background.   
 
There are therefore a number of independent variables that may directly affect the 
individual woman‟s decisions to take HRT, and how long she takes it for. The 
variables listed below, which may determine patterns of HRT use, will be considered. 
 
 The socio-economic group to which the study participants belong, as defined by 
Scottish Index of Multiple Deprivation (SIMD). 
 
 The ability of the patient to pay prescription charges. 
 
 The geographic location of the hospital in which the women were treated 
 
 The individual consultant in charge of care. 
 
 The gender of the consultant in charge of care. 
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 The information given by health professionals to their patients about the risks and 
benefits of taking HRT. 
 
 The age of the woman at the time of surgery. 
 
 Media effects on HRT taking. 
 
 
The rationales for the examination of these variables are as follows. 
 
2.1.1 Socio-economic group to which the patient belongs 
It has long been recognised that social class influences health. The poorer an 
individual, in terms of income, environment and education the poorer their health is 
likely to be. Sir Douglas Black‟s landmark report, Inequalities in Health 1980 found 
that, in Britain, there were “large differentials in mortality and morbidity that 
favoured the higher social classes,” (Smith et al 1990, p 373). The Black Report 
concentrates on mortality and morbidity, and found that it tends to rise inversely with 
falling occupational rank or status for both sexes and at all ages. Social class is used 
as the principle indicator of social inequality, since it is correlated closely with 
various other measures of inequality such as morbidity and sickness absence rates. 
  
This report used the Registrar General‟s classification of social class, in which 
individuals are classed by occupation. Professional people are classed as group 1, 
intermediate (for example managers or teachers) as group 2, skilled workers non- 
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manual and manual, as group 3, partly skilled manual workers as group 4, and 
unskilled manual workers as group 5. The report found that even with the National 
Health Service available to all, the rates of chronic illness rose with falling socio-
economic status, and tended to be twice as high in unskilled manual males as in the 
professional classes. 
 
In trying to explain these differences the report looked at health service usage and 
geographic differences in service availability. In 1968, Titmus had argued that, 
although the NHS was designed to give free access to all regardless of their status or 
means, higher income groups knew how to make better use of the service. When 
Black examined GP consultations and preventative services, it was found that the 
middle class patient generally had longer consultations with their GP, and made better 
use of health promotion services than those in lower classes. Class gradients were 
found in antenatal attendance and cervical screening. 
 
It had also been argued, by Tudor Hart (1971) that the “Inverse Care Law” could 
explain differences in the availability of health care found between “wealthy” and 
“poor” geographical areas. The suggestion is that the health services in the areas of 
most sickness, are overworked in terms if case load, lack of equipment and 
recruitment problems; consequently, good medical care varies inversely with the 
needs of the population it serves. The Black report confirmed differences in health 
service usage by social class and differences in health care provision by geographic 
location.  
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The Black report proposed four explanations for the continuing influence of social 
class on health.  
 
1. The first is an artefact, due to a reduction in the number of the lowest classes as a 
percentage of the whole population. The oldest, less healthy people are left in the 
bottom group, and the younger, fitter people get better jobs and have better health 
compared to those left behind. 
 
2.  The second is a natural and social selection explanation, where health actually 
dictates social resources, and therefore class, where young fit people climb the 
social ladder. The fittest people moving to those areas in which opportunities for 
employment are better, leaving the sick behind in the poorer areas, could explain 
geographic differences. 
 
3. The third explanation is based on social structural considerations, and suggests 
that impoverished early years in childhood affect cognitive ability, education and 
therefore opportunity. Middle class children were believed to be more likely to 
leave school with a greater ability to control their social and economic 
environment. 
 
4. The final explanation is culturally and behaviour – related, given that higher 
income families tend to have a healthier diet and lifestyle. Some would attribute 
this to better education and more financial resource, while others would say that a 
“culture of poverty” exists and that deprivation is transmitted. Lack of education 
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may be responsible for unhealthy practices, or people may feel unable to alter 
their life course via health promotion exercises. 
 
The conclusions of the Black report were that further research was necessary, but that 
the focus should be on reducing inequalities in childhood. Apart from recommending 
greater surveillance of child health, it also suggested a preventive and educational 
approach to improving the health of a larger proportion of the population as a whole.  
 
Since the publication of the Black Report there has been a vast literature published on 
socio-economic inequality in relation to health. Smith, et al (1990) find that even ten 
years after the Black Report, the social class differences in mortality are actually 
widening, and that alternative measures of socio-economic position have exhibited 
greater inequalities. Wilkinson (1997) agrees that the divide is widening, and that 
health remains very sensitive to socio-economic status. He stresses that the 
differences in mortality are linked more closely to relative income and social 
inclusion, rather than just income alone. The Independent Inquiry into Inequalities in 
Health, chaired by Sir Donald Acheson was published in 1998. It found an overall 
downward trend in mortality between 1970 and 1990, but confirmed persistent 
differentials between the social classes. In particular, differences in income and in 
mortality rates per social class had increased, so providing evidence of a continued 
and increasing divide. Further evidence of the importance of both individual income 
and income inequality is provided by Kahn (2000). His study of American women 
found that poorer women suffered self- reported poor health and depressive symptoms 
in greater numbers than richer women. In those states where there was greater income 
inequality, greater numbers of low-income women suffered poor health when 
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compared to low-income women living in states with less income inequality. So 
health is affected both by personal income, and by how that income compares with 
that of others living in the community you live in. Evidence that richer people are 
getting healthier more quickly and that they continue to live longer in the UK is found 
in The House of Commons Health Committee‟s Health Inequalities 2009. This report 
demonstrates the divide vividly when it says that, “in 2006 a girl born in Kensington 
and Chelsea has a life expectancy of more than ten years higher than Glasgow City, 
the area in the UK with the lowest figure” (p9). This same report found that the health 
inequalities between social classes have widened more for women, than they have for 
men. The gap has increased by 11% for women and 4% for men, so demonstrating 
clear gender differences in health inequalities (p 15). The report concludes that 
inequalities are not only apparent between socio-economic groups and by gender, but 
they also exist between different ethnic groups and that the elderly and those suffering 
mental health problems have worse health than the rest of the population (p 26).      
 
Deprivation indices, including housing, education, car ownership and unemployment 
levels are now thought to be more accurate classifications of socio-economic status 
than the old professional classification of the Registrar General‟s, (which was 
replaced by NS-SEC in 2001). Using such indices, Smith, Bartley and Blane (1990) 
suggest that Black‟s artefact and social selection explanations for inequalities in 
health do not account for differences in mortality, but that his materialistic and 
behavioural explanations are more useful. Likewise Pincus et al (1998, p 407), in 
summarising the literature on the importance of access to medical care suggest: “poor 
health in socio-economically disadvantaged populations results more from 
unfavourable social conditions and ineffective self management than from limitations 
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in access to care”. Access to healthcare is also acknowledged as having a less 
significant role than other determinants in the House of Commons Health 
Committee‟s Health Inequalities report 2009. 
 
It remains difficult to ascertain which parameters that make up socio-economic 
categories are most influential on health. Education, income, occupation, 
environmental and behavioural factors all contribute and together affect health 
outcomes (Link and Phelan 2005, p 72, Health Inequalities 2009 ). 
 
HRT use has been shown to be associated with women of higher socio-economic 
status, with poorer women less likely to use it (Finley et al 2001). In order to classify 
the study participants in this research project in terms of socio-economic background, 
the Scottish Index of Multiple Deprivation (SIMD) was used. This index is a tool used 
by local authorities, the Scottish Government and the NHS for effective targeting of 
resources. First published in 2004, this index divides Scotland into 6505 data zones, 
and uses seven domains of social indicators - namely income, employment, crime, 
education, health, housing and access to services - to “ score” and rank each data 
zone. These ranks are then used to calculate a SIMD rank for each data zone.  The 
lower the score, the more deprived the area is classified to be. It is possible to obtain a 
SIMD for each postcode, so that a given study population can be classified according 
to the area in which they live. This index however cannot be used to determine the 
individual characteristics of people. It is not possible to say that an individual living in 
a SIMD1 area is economically or educationally disadvantaged when compared with 
someone from a SIMD 9 area, only that they live in very different areas, as classified 
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by deprivation measures. On the basis that health decisions are determined by many 
different factors, it is an appropriate tool to use in order to classify the participants. 
Like other census information the SIMD is updated and SIMD 2006 has been used, as 
this was the index in use at the time the data was analysed.  
 
2.1.2 The ability of the patient to pay prescription charges 
 
Income, although closely linked to socio-economic group, has been shown by Ettner  
(1996) to positively affect health when other factors are controlled for. She suggests 
that reductions in disposable income could potentially affect morbidity. 
  
“In 1979 a prescription cost 20 pence”(Moore 2005), but now the charges have risen 
considerably. There is evidence that many people “do not get the medicines they 
require because they cannot afford them” (Moore 2005). There is pressure to abolish 
prescription charges across the UK and, in early 2007, this was achieved in Wales. 
However, in Scotland and in England charges still apply and produce considerable 
revenue to the sum of about £300 million annually (Campbell 2002). 
 
It may be supposed that, if a woman was under financial pressure and having to pay 
for her HRT, then she may not fill her prescription. This decision may be influenced 
by her perception of the benefits of taking the medication against the financial cost of 
continued adherence.  
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For the time that the participants of this study were taking HRT they would have been 
charged the appropriate fee, unless they were exempt due to chronic disease or in 
receipt of income benefits. 
   
2.1.3 The unit in which treatment took place 
“The random countrywide variations in the provision and quality of public services 
have been referred to as „ the postcode lottery of care‟, that is where you live dictates 
where you are treated, which in turn dictates how you are treated, and this affects 
whether you survive”(Munro 2001, cited Bungay 2005, p37). It has been argued by 
central government that these regional differences are due to a lack of national 
standards, and decisions being made at a local level as to what services to provide, 
(Bungay 2005 p37). GP fund holding allowed faster access to treatment for the 
patients of budget- holding GP practices, resulting in a two-tier postcode lottery 
(Butler 2000).  
 
 Sarah Bosely and Sarah Hall, writing in The Guardian in 2006, say that provision of 
treatment differs widely between primary care trusts, and that not all the differences 
can be attributed to the age and needs of individual patient populations. Although the 
focus of such reports are the management and treatment of serious illness such as 
cancer and coronary heart disease, geographic differences are recognised in the access 
to all types of service in practice (Bungay, 2005, p 37). Waiting times, availability of 
certain drugs and access to cancer screening services are all affected. 
 
If we accept that there may be differences between treatments in one unit when 
compared to another, then the possible reasons for this need to be explored. Eddy 
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(1984, p 86) suggests that regional differences in medical practice are seen because 
individual doctors tend to “follow the pack” and concur with the practice of their 
peers in their locality. This, he suggests, provides “safety in numbers”, with the 
practice “defended by the concurrence of colleagues”.  
     
It may be supposed that, if differences occur in all aspects of service provision, as is 
suggested by Bungay (2005), then there may be geographic differences in the use of 
hysterectomy for the treatment of menorrhagia and subsequent HRT prescription.  
There are, according to Gupta and Manyonda  (2006), wide variations in the rates of 
hysterectomy, not only between developed countries but also between regions of the 
same country and between consultants at the same hospitals. If rates differ depending 
on which consultant is seen, then it is conceivable that, overall, one unit differs from 
the other in terms of treatment option. Allowing for the “concurrence of colleagues” 
theory, consultants in one unit may collectively differ from those in the other unit. 
 
2.1.4 The individual consultant in charge of care  
Individual doctors may have different ideas about best therapy for their patients. They 
may also have different consultation styles, and reach clinical decisions in different 
ways. David Eddy (1984) states: “nothing more underscores the reality that medical 
care represents a melding of art and science than the wide variation in the use and cost 
of that care” (p 74). He believes that variations in practice occur partly owing to the 
“uncertainty in the minds of doctors about how to approach a particular medical 
problem” (p 74). As a doctor and also a mathematician, he describes the role of 
uncertainty in clinical decision-making. He gives many examples of situations where 
physicians have come to very different conclusions when faced with the same clinical 
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details. He recognises that “uncertainty, biases, errors, and differences of opinions, 
motives, and values”(p 75) can affect treatment selection. He describes how complex 
clinical decision-making is, and how poorly it is understood. He focuses on the 
uncertainty which surrounding the outcome of any procedure, and how this will affect 
the advice given by the physician. It may be this uncertainty in the outcomes of 
treatment that makes doctors concur with their colleagues when making clinical 
decisions.  
  
Strategies to reduce the uncertainty in clinical decision making in general have 
included policy development and the construction of clinical guidelines. The Royal 
College of Obstetrics and Gynaecology (RCOG) have published many such 
guidelines, and one exists for the management of menorrhagia, specific to secondary 
care in hospital (RCOG 1999 Guideline no 5). Developed using clinical research 
findings, the aim is to produce standardised, cost-effective practice known as 
evidence- based practice (EBP). Much has been written about evidence-based practice 
or evidence- based medicine. Sackett (1996, p 71) says that “evidence based medicine 
is the conscientious, explicit, and judicious use of current best evidence in making 
decisions about the care of individual patients”. He argues that “good doctors use both 
individual clinical expertise and the best available external evidence, and neither 
alone is enough.” He suggests that “external clinical evidence can inform, but can 
never replace, individual clinical expertise, and it is this expertise that decides 
whether the external evidence applies to the individual patient at all and, if so, how it 
should be integrated into a clinical decision.” 
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EPB has been criticised by some for putting constraints on clinical freedom, and being 
designed to cut costs. One general practitioner said that the environment of medicine 
was becoming “like that of a Stalinist state” and that, if he chose through experience 
to deviate from a protocol when treating his patients, then he “must expect to be 
brought to task”(Sherifi 2004, p 4). Sackett (1996, p 72) counters this opinion by 
saying that evidence based medicine is not  “ cookbook” medicine and that, because it 
combines best clinical evidence and the expertise of the doctor, together with patient 
choice, it cannot result in dictated outcomes; instead, it will provide better but perhaps 
more expensive care. 
 
So, even allowing for guidelines and protocols, it is still possible that there might be 
some differences in the way different doctors assess and manage their patients, and 
likewise the way that those individual patients then choose to be treated. This may 
explain the differences in hysterectomy rates between consultants seen by Gupta and 
Manyonda (2006). Individual clinicians may vary in the way they assess symptoms 
and some may favour trying less invasive treatments more exhaustively than others 
before recommending hysterectomy. If we consider the consultation a woman has 
with her hospital doctor regarding treatment for menorrhagia then the doctor, as in 
consultations for many other conditions, bases his opinion on the symptoms told to 
him by the patient, and relies on the patient‟s description of the extent of her bleeding, 
and resultant debilitation. 
 
Menorrhagia is defined as excessive menstrual bleeding but, in practice, it is difficult 
to specify what counts as “excessive bleeding” because what is acceptable to one 
woman may be unacceptable to another. It is difficult, as Eddy (1984, p 75) says, to 
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determine the dividing line between normal and abnormal. Part of the RCOG 1999 
guideline for the management of menorrhagia is that an objective or semi-objective 
assessment of menstrual blood loss should be carried out before surgical treatment. 
Ali et al (2007) found that this particular assessment was not performed for women 
being treated in (for example) Blackpool. 
 
Anecdotally, it is of interest that only a few women admitted to the units in this 
Scottish study, for hysterectomy for menorrhagia, had at any time pre-operatively, an 
abnormally low haemoglobin level. This would indicate that the blood loss is not 
seriously excessive, but may of course still be debilitating to the patient. Exact figures 
were unfortunately not collected as part of the study. In order to diagnose 
menorrhagia, the doctor necessarily relies on the patient‟s description of blood loss 
and associated symptoms such as fatigue. According to Eddy (1984, p 77), doctors 
vary in their ability to ask about symptoms, observe signs; interpret test results and 
record answers; and women may perceive their menstrual loss as heavier than it 
actually is (Ali et al 2007 p172). 
 
 Hysterectomy is the most effective, but also the most invasive, treatment option for 
menorrhagia and carries the risks associated with major surgery. Consent advice for 
doctors provided by The Royal College of Obstetricians and Gynaecologists (Consent 
Advice 4 2004) states clearly that alternative, less invasive treatments - including no 
treatment at all - must be discussed with the patient prior to deciding on hysterectomy. 
Many women when offered more conservative treatments refuse them in favour of 
hysterectomy (Ali et al 2007). 
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So the symptoms of menorrhagia are difficult to assess objectively, and there are 
treatment options other than hysterectomy; which means that the result of each 
individual consultation may be different. The timing of hysterectomy may be delayed 
in favour of initial conservative management, which in turn would make the patient 
older at the time of surgery. The age of the patient at the time of hysterectomy affects 
the duration of recommended HRT use, with older women needing it for a shorter 
time.  
 
During the consultation, when hysterectomy with bilateral oophorectomy is decided 
upon, the resulting early menopause and the possibility of subsequent use of HRT 
should be discussed (Royal College of Obstetricians and Gynaecologists, Consent 
Advice 4 2004). This, however may be a secondary issue with the bulk of consultation 
time being devoted to focusing on the operative procedure itself, the recovery, time 
spent in hospital, and the need for convalescence and time off work. 
 
Subsequent post-operative discussion regarding HRT choices are conducted on the 
ward, when consultants are busy and patients are perhaps reluctant to ask too many 
questions. The patient may therefore base her choice on the recommendation given to 
her at the longer, more private, pre-operative consultation. Conversely some patients 
may insist on an in-depth discussion with the consultant, prior to making a decision, 
before they leave hospital; or they may wait to discuss issues with their GP once at 
home. Whatever the timing of these discussions, the quality of the communication 
between doctor and patient is important. 
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In general, after hysterectomy with bilateral oophorectomy, most women commence 
therapy soon after surgery.  It would not be surprising if some women were better 
informed than others were, as a result of more detailed discussions with their 
individual consultants. These more detailed discussions may result in earlier 
commencement of therapy and better adherence rates for HRT use. The age of the 
patient at the time of surgery does affect the advised duration of that use (a topic 
which will be discussed later).   
 
2.1.5 Gender of consultant in charge of care 
Because menopause, whether natural or surgical, is a time of change in both physical 
functioning and psychological adjustment, consultations regarding these changes are 
important in terms of the patient‟s perception of sensitivity and understanding by the 
doctor. The perceived quality of these consultations may well affect the patient‟s 
adherence to medication prescribed. There have been studies conducted in the past to 
explore whether or not the gender of the physician affects the physician-patient 
relationship and patient satisfaction. 
 
“Gender” refers to the meanings, associations and identities associated with basic 
sexual differences. The term denotes more than just the biological and physiological 
differences between men and women (Robb 2004).   Differences in communication 
with patients have been demonstrated between physicians of different genders, with 
female doctors taking a more “emotionally focussed” approach than their male 
colleagues. The patients of female doctors, whether they are male or female, tend to 
express more “biomedical and psychosocial information” during consultations than do 
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patients of male doctors.  Female doctors also build partnerships with their patients to 
a greater degree than do male doctors  (Hall et al 1994, Roter et al 1991, cited Roter et 
al 1999, p 635). 
 
Roter, et al (1999) acknowledge previous research concluding that patients prefer 
same-gender physicians when seeking help for intimate health problems including 
gynaecologic and obstetric care. The extent of this preference is not perhaps as great 
as one might expect, and Schmittdiel et al (1999) in their large mailed survey found 
that only just over half (52%) of women prefer a female provider for basic 
gynaecological care.  
 
Roter et al, (1999) studied women making their first antenatal visit and attempted to 
describe the communication between doctor and patient. The findings in this study 
were that, although male doctors engaged in longer consultations and made more 
checks to determine whether the patient had understood them properly than did their 
female counterparts, women were still more satisfied with a female physician. Roter 
et al (1999) also cite Hall, Roter and Katz (1988), who found that patient satisfaction, 
recall of information, and adherence to medical recommendations was associated with 
female physicians (p 636). Lurie and Slater et al (1993) found that patients of female 
primary care doctors are more likely to undergo cervical screening and 
mammography. It would appear then that most women prefer to see women when 
faced with gynaecological or intimate problems, but it is not clear that female 
gynaecologists provide better information and advice than their male colleagues do. 
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2.1.6 The information given by health professionals to their patients about the 
risks and benefits of taking HRT 
The information about a medicine that a patient receives is central to their 
understanding of its method of action, its expected benefits, and possible side-effects. 
Information allows patients to make informed choices. Rosalyn Anderson, a 
pharmacist, writes about the responsibilities of prescribing, and the provision of 
adequate patient information. She specifies that the patient should be told the reason 
for, and the purpose of, the prescription, the duration of treatment to be expected, and 
possible side effects (Anderson 2002, p 78). Verbal information is important but often 
difficult to remember in its entirety, whereas it is believed that written information 
may be referred to repeatedly to clarify understanding. Leaflets, both generic and 
product-specific are available and used by some health care professionals to reinforce 
or expand the discussions they have had with their patients. 
 
Waller et al (2005, p 123) points out: “ most people know that medicines may have 
side effects but, unless clearly told otherwise, they expect these to be minor and 
reversible or to be so rare that it won‟t happen to them”. It is important, then, that 
women are advised, on an individual basis, as to what they may expect in terms of 
personal risk and benefit. 
 
Apart from discussions with the doctor about the risks and benefits of HRT, there are 
other information sources. Nurses are a source of such information, and should be 
able to give relevant information to patients. Do nurses give adequate information to 
women about HRT? Women making HRT decisions are known to use written 
information (Newton et al 1998), but general educational materials are “limited in 
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helping women judge personal benefits and risks of HRT” according to O‟Connor et 
al (1998, p 268). O‟Connor et al (1998) found that using a decision aid was of value 
in women deciding about HRT. Working in Canada, they devised an audiotape and 
illustrated booklet for women to use at home before returning for a follow-up visit 
with the doctor for further discussion. The booklet contained general HRT 
information and a personal worksheet which identified the patient‟s individual risks 
and benefits of taking HRT, together with her own assessment of the importance of 
the risk/benefit ratio. Any questions the patient might have were also listed. The 
completed worksheet then provided the basis for the next consultation. The use of this 
tool did not radically alter the women‟s decision, but they felt more confident about 
those decisions. In Forth Valley, such a tool is not used, and women rely on 
information given verbally or in written form. We do not know who or what they 
consider to be their primary source of information, or how good is that information 
deemed to be. 
 
2.1.7 The age of the patient at the time of surgery 
The Health Survey for England (1998) found that, for both men and women, the use 
of all types of health services increases with age, with those considering themselves to 
be in poor health using GP consultations and hospital outpatient departments more 
frequently. Likewise, the use of prescribed medication rises steeply from the age of 45 
years, with considerably more women than men under the age of 65 years taking 
prescribed medication (Bajekal 1998 p10). Most users of HRT (62%) in the Health 
survey sample had commenced therapy between the ages of 45-54 (Bajekal 1998 
p13).  
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Twenty percent of women in the United Kingdom will have had a hysterectomy by 
the time they reach the age of 60 years (Gupta and Manyonda 2006). These operations 
will be performed for a number of reasons, of which menorrhagia is only one. The 
timing of hysterectomy, in terms of the age of the patient, for non-malignant reasons 
is left up to the individual gynaecologist and their patient.  
  
In a descriptive study of hysterectomy patients with benign disease in England, Wales 
and Northern Ireland in 1994 and 1995, the median age at operation was 45 years, and 
43% of women had no ovaries conserved (Maresh et al 2002). This is similar to 
American findings of Jacobson et al (2006), who found that the hysterectomy rate 
over a 10-year period ending in 2003 was highest in women aged between 40 and 49 
years.  The women in the Jacobson study were analysed by 5- year age groups, with 
the youngest being 20-24 years old and the eldest 55 years or over. Although the 
study was to ascertain hysterectomy rates for benign disease, it did not look 
specifically at menhorragia as a clinical indication; nor did it specify whether 
oophorectomy was also performed.  
 
The age of a woman at time of hysterectomy with bilateral oophorectomy will affect 
what is the recommended duration of treatment with HRT. A woman having a 
hysterectomy with bilateral oophorectomy in her early 40s will need HRT for a longer 
time than a woman of 48 years at the time of operation. This is because the younger 
woman will have “lost” more years of natural oestrogen. Reference to the changes in 
prescribing guidelines during the data collection timing of the study has been made in 
chapter one, however the broad principles regarding the duration of HRT treatment 
with regard to age still apply. Younger women, who may experience more severe 
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menopausal symptoms, would be required to take medication for a longer time. Older, 
peri-menopausal women approaching the time of average natural menopause, who 
may have already suffered some menopausal symptoms, and who may even 
commenced HRT prior to their operation, may need a shorter duration of therapy 
post- operatively. 
The advice given to patients will take into account their specific requirements, and 
because of this it is expected that the duration of use will vary across the age range. 
 
2.1.8 Media influences on HRT taking 
The Media has a powerful effect on thinking and behaviour in general. Most people 
can be influenced by what they read in newspapers or watch on television, and the 
quality of these reports can vary. Margot James, chief executive of a public relations 
company employed by several pharmaceutical companies, acknowledges that the 
quality press gives the best information when it comes to public health. She also states 
that “people from lower socio-economic groups get their information from television 
and the tabloids” and are more likely to read sensationalist material than to receive 
useful information (Ferriman 1999, p 1208). Walley and Williams  (2004, p 71) point 
out that “ the media portrays sensation and tends to see medicines either as „wonder 
drugs‟ or „killer drugs‟: the notion that what is a wonder drug in one situation can also 
be a killer in another is a subtlety that banner headlines cannot deal with”. 
 
Scare stories sell newspapers and in general cause public concern. This is especially 
true of stories about prescription drugs. Waller et al (2006) is an interesting paper on 
drug safety, and the media, pointing out that journalists and television presenters have 
total control over how they present medical material and may tend to use the more 
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controversial aspects, rather than the more mundane but fairer representative angles, 
and that this can lead to a too simplistic interpretation of data. They further question 
the lay public‟s ability to interpret data in terms of risks and benefits, without a proper 
understanding of how the data was acquired. They state that “media coverage of drug 
safety issues rarely reflects uncertainty”(p 124), and highlight how the media has in 
the past possibly damaged patients by “scares” surrounding drug safety. One obvious 
example of this is the MMR story, where the press made uncritical use of 
unsubstantiated research reports concerning the possible side-effects of the vaccine, 
leading to a fall in immunisation rates (Anderson 1999). However, Waller et al, 
(2006) also point out that the media represent a useful communication tool if used 
responsibly. 
 
 A report in The Scotsman newspaper on Tuesday 4
th
 March 2003 (p 7) was headed  
“Late HRT treatment for women may do more harm than good.” This article was 
concerned with the findings of the American Women‟s‟ Health Initiative, and the 
early cessation of the trial when increased risks of breast cancer, stroke and heart 
attack became apparent in older post menopausal women taking combined oestrogen 
and progesterone HRT. An earlier article in The Herald, July 17
th
 2002 (p 3), 
concerned with oestrogen-only HRT, was entitled: “HRT linked to cancer twice in 
one week”. Even the front page of The Times announced on 10th July 2002: “HRT is 
linked to breast cancer”, and “Patients suffer 41% increase in stroke risk”.  
 
Articles such as these, and other more sensational reports in the tabloid press, could 
certainly alarm women taking HRT, despite government ministers advising calm, and 
confirming that there was no need for women to rush to their GP and stop treatment. 
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The reported findings from the American study were difficult enough for medics to 
interpret. The women participating in the trial were aged between 50 and 79 years old, 
and they used slightly different HRT formulas than are prescribed in the UK. In terms 
of the relevance to British women who were taking HRT after hysterectomy, being 
younger and taking oestrogen-only preparations, the risks might be less applicable.  
For the lay public, however, it would have been more difficult to interpret the 
findings, and women may have been worried by the reported facts, which were not 
necessarily completely applicable to their individual case. 
 
Joe Collier, Editor of the Drug and Therapeutics Bulletin thinks, “more information 
for patients is good”, but that “in many ways biased information is worse than no 
information at all because it thoroughly confuses people” (Ferriman 1999 p1208). 
Certainly, the complex nature of the data emerging from the Women‟s Health 
Initiative made it difficult for women to interpret what was relevant to them 
personally, without the benefit of specialist knowledge. Some of these women may 
have sought advice from their GP, but others may have been frightened enough to 
have discontinued therapy without the benefit of such a consultation. 
 
(In the present study there are no questions in the questionnaire exploring, 
specifically, the possible affect of the media on HRT decisions. In hindsight this is a 
pity because such questions may have yielded some interesting data. The reason for 
this omission is the timing of the press releases in relation to the formulation of the 
questionnaire. The questionnaire was compiled, and ethical approval gained, before 
the press carried the big headline reports from the WHI trials. To change, or add a 
question would have necessitated a further review from the ethics committee, a time 
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consuming process and one, which would have further delayed the mailing of the 
questionnaire. It was hoped that media influence would be revealed by the responses 
to the question about the reasons for discontinuing therapy.)   
 
2.2 How this study attempts to examine the factors affecting HRT use  
 
Having explored the reasons why certain variables might be thought to influence HRT 
use, we now describe how the study of women in Scotland might attempt to ascertain 
whether or not these variables do, in fact, affect the patterns of HRT use in this 
particular group of women. (The design of the study is described in more detail in the 
next chapter.)  
    
Previous studies have found differences in HRT use linked to social class. The women 
in this study were selected for participation based on the criteria for the study, which 
did not include any assessment of their socio-economic status or income, per se. 
However, these women obviously come from different backgrounds in terms of 
income, and social status. It is therefore supposed that some differences in their use of 
HRT, associated with these differences, may be apparent. 
 
Using the Scottish Index of Multiple Deprivation (SIMD), women were ranked 
according to their postcode to be given a score representing their deprivation decile. 
As noted earlier, this system is an alternative to the NS-SEC classification for the 
purposes of determining socio-economic group. The higher the score on a scale of 1-
10, the less deprived in terms of current income, employment, health, education, 
geographic access to services, housing and crime the respondent is deemed to be. The 
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Index of multiple deprivation has been shown to be an effective tool when trying to 
explain differences in health inequalities (Jordan et al 2004). 
  
Not only did the women included in this study differ in terms of social background, 
they also were of different ages at the time of their operation. A woman having a 
hysterectomy with bilateral oophorectomy at the age of 50 years will have different 
HRT needs from a patient aged 30 years. The effect of patient age at time of operation 
on subsequent use of HRT was examined over the age range of study participants. All 
the women in this study were up to 51 years of age at the time of their operation, but 
their ages range from 28 years old to this upper age limit. HRT will have been offered 
to all these women, but the advice on duration of therapy will have differed according 
to their age, as previously discussed. 
 
 In order to determine if there were differences in terms of geographical location or 
postcode variations in HRT use, patients were recruited from two hospitals.   
Study participants were treated in two different general hospitals in a region of 
Scotland. These two hospitals, although administered by the same NHS trust, operated 
as two distinct units during the time of this study. Each had its own gynaecology 
outpatient clinics and inpatient ward. Different consultant gynaecologists and 
gynaecology nurses ran the services. 
  
It might be supposed that, given the individual nature of the two units that were in 
existence at the time of the study, there might be some procedural differences in 
patient care. For instance, some consultants may wish to delay hysterectomy in favour 
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of less invasive treatments. The timing of hysterectomy, in terms of patient age, 
together with differences in the sources of information about subsequent HRT use and 
the quality of such advice, could all affect HRT decisions. Did the consultants and 
nurses in one unit collectively differ from those in the other unit in their treatment of 
women? 
 
The women in this study were seen, and had their surgery performed, by different 
consultants, so it may be supposed that they did not all receive exactly the same 
information. Consultants and healthcare professionals are supposed to give patients 
up-to date, accurate and individually tailored advice regarding treatment and 
medication options. The individual consultants whose patients are sampled in this 
study vary in age and by gender. They may have different consultation styles, and 
therefore different ways of relaying the same information. 
 
There were both male and female gynaecologists working in both units, so not only 
individual, but also gender, differences could be examined. Are women 
gynaecologists more likely to give better levels of advice to women about HRT than 
their male counterparts? All gynaecologists work to clinical guidelines, and there 
should be concurrence in their advice; but is it possible that female gynaecologists are 
perceived by their patients to give better information?  Do patients of female 
consultants, as Hall Roter and Katz (1988) suggest, adhere better to HRT treatment 
than those cared for by male consultants? Perhaps women doctors have a deeper 
understanding or increased interest in the relief of menopausal symptoms when 
compared to men. Female gynaecologists may, however, be influenced by their own 
view of menopause, which could affect the advice they give. Equally, male 
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gynaecologists will never personally experience the menopause and, as a result, may 
be more sympathetic to a condition that they have no personal experience of. 
Alternatively, the reverse may be true. 
  
Different sources of the same information may lead to different levels of 
understanding and affect HRT use. This study examines which source of information 
the subjects rate as the primary source, and whether or not the patients‟ information 
requirements are met. Do nurses provide good quality information for women in 
hospital? Are leaflets useful, and are they used to reinforce verbal information? 
Which professional source of information is judged to be most effective by the 
women who receive it? 
 
Information gleaned from other sources also affects decisions, and media influences 
are known to be strong. Although the press reports on the long-term effects of HRT 
came late into the timing of this study, they may still have had an effect on the study 
participants HRT decisions. The women in the study had their hysterectomies 
between 1992 and 2001, but were not approached to answer the study questionnaire 
until 2004-2005. It is therefore reasonable to question whether or not press reports and 
magazine articles influenced decisions made by women and their doctors, especially 
those undergoing hysterectomy in the later years of the study.   
 
In order to examine whether the above mentioned variables affect women‟s HRT 
decisions following hysterectomy with bilateral oophorectomy, and the extent to 
which they influence such decisions, it was necessary to design a research study. The 
study would need to try and answer the original research questions posed at the end of 
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the preceding chapter. Accordingly, in the next chapter the study design and methods 
are described.    
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Chapter 3  
Design and methods 
This study is a retrospective cross-sectional survey of women‟s use of hormone 
replacement therapy following hysterectomy and bilateral salpingo-oophorectomy. It 
will examine the patterns of HRT use specifically in hysterectomised women. 
Although there has been a quantity of research literature published in the past, 
concerned with adherence with HRT, most studies have focussed on women with 
natural menopause, or have not separated the HRT users by hysterectomy status. The 
main aim of this study was to determine whether patterns of HRT use in 
hysterectomised women differ from those of HRT users in general. In order to explore 
this, the study will assess the number of women taking HRT following hysterectomy 
and the patterns of that use. The research questions posed in chapter one were as 
follows: 
 
 How many women in this region of Scotland who have undergone elective 
hysterectomy with bilateral salpingo-oophorectomy for menorrhagia take HRT? 
 When do they commence therapy? 
 When do they stop therapy? 
 Why do they stop? 
 Are the reasons for early discontinuance different from those for late 
discontinuance? 
 What factors affect HRT use? These have been discussed in chapter two and the 
study will determine if and indeed how they affect women with hysterectomy and 
bilateral oophorectomy. 
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Once the answers to these questions have been obtained, they will (in turn) help to 
elucidate the answer to the question: 
 Do patterns of HRT use in women with hysterectomy and bilateral oophorectomy 
differ from those in HRT users in general? 
 
In this chapter, the design and methods of the study will be detailed. The chapter is 
divided into three broad sections. After a short description of the local background to 
the study, the first section describes how the study was designed, in terms of data 
collection and analysis.  The second section describes how the design was 
implemented, outlining the procedures used to identify and recruit the study subjects, 
and detailing how the study was conducted. Finally section three will consider the 
necessary legal and ethical requirements. 
  
This study was conducted in a region of central Scotland. The study population 
consisted of women who had their operations carried out at either hospital A or 
hospital B, between 1/1/1992 and 31/12/2001. These two hospitals serve the local 
population and are together managed by the same NHS Trust. Although gynaecology 
services are now centralised in hospital A, at the time of this study patients were cared 
for in two distinct and separate units, each with their own medical and nursing staff. 
These two gynaecology units were run individually, with no cross-cover from nursing 
staff and the consultant gynaecologists worked cross-site only for occasional weekend 
on-call. The Department of Medical Records provided details of women suitable for 
inclusion in the study from both hospital sites. 
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3.1 Study design, data collection and analysis 
3.1.1 Study design 
This study was designed to examine HRT use in a group of women selected because 
they had undergone a specific operative procedure (in the same NHS Trust) for a 
specific complaint, before the average age of natural menopause at 51 years. It is 
otherwise non-biased in terms of participant characteristics as the women on the study 
were selected on these criteria alone with no account taken of their social background, 
financial income or who treated them. 
 
According to Robson, (2001 p 49), surveys are designed to gather information in a 
standardised form from groups of people, often of a specific population, so producing 
a “snap shot” of that population in terms of generalised characteristics. In this case, 
the study population were the women in the region who underwent hysterectomy with 
bilateral oophorectomy, as patients of either hospital A or hospital B, between 1992 
and 2001. This time-frame was chosen as the 10-year period prior to the 
commencement of the study to allow a retrospective examination of HRT use over the 
past 10 years. These women were elective admissions, and the specific reason for 
surgery was menorrhagia, that is heavy menstrual bleeding, a benign and common 
condition. So all study participants had undergone the same operation, for the same 
reason, within the specified time frame.  
   
The study is cross-sectional as it samples women representative of those undergoing a 
particular operation for a specific reason. It is also retrospective, in that it examines 
decisions made in the past, and the factors which may have affected these decisions. 
The retrospective nature of the study is significant; and how the findings may be 
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influenced by the accuracy of recollection, and changes of opinion over time, will be 
considered in more detail in Chapter Five. 
 
The research questions in this study are designed to ascertain who takes HRT 
following surgery, how long they take it for, and what influences their decisions to 
continue or cease therapy. Surveys are “well suited to descriptive studies” (Robson, 
2001,p 49, as they can indicate common trends or opinions in a population, and 
usually employ a questionnaire as the method of collecting data. This study involved 
women being asked to complete a postal questionnaire (Appendix 3.1).  Participants 
were asked what decisions they made, and what their experiences were in relation to 
their use of HRT. These responses were examined with the intention of revealing 
what factors may be associated with the use or non-use of HRT therapy, the duration 
of use, and the timing of discontinuance.      
 
Given that the women in the study were no longer inpatients in hospital, a postal 
questionnaire was the best way in which to elicit their responses to these questions. 
The main advantages of using a postal questionnaire are that it is a relatively 
inexpensive method of data collection, in terms of both finance and time, and it offers 
the participants‟ greater anonymity (Kumar 1999, p 114). The first two factors were 
of importance to the researcher whose time and finance is limited. There are some 
logistic difficulties in contacting patients, some of whom had been treated many years 
previously, to request their participation in research studies. The voluntary nature of 
participation and the anonymity afforded by a questionnaire was an effective method 
of eliciting responses from this study population. A postal questionnaire allows a 
large number of subjects to be sampled quickly and, being relatively quick to 
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complete without face-to-face contact, may be more likely to elicit a response from 
subjects not willing to participate in more time-consuming studies. It also protects 
patient anonymity to an extent, in that demographic and health details may be known 
to the researcher, but the respondent need not actually meet the researcher in order to 
give her responses. 
        
The study population was defined according to the following criteria:  
 female. 
 age 51 years or younger at the time of surgery 
 elective total hysterectomy performed either abdominally or vaginally, with 
bilateral oophorectomy. 
 surgery carried out in the study location between 1/01/1992 and 31/12/2001 
 
 The age limit was set as the researcher was interested in the experiences of those 
women becoming menopausal due to surgery rather than the more gradual transition 
to natural menopause. Fifty-one years is considered to be the average age of natural 
menopause, so women having surgery after this age are likely to have already 
experienced the menopausal transition. 
  
The route used to perform the surgery has no relevance to the resulting hormonal 
profile, and by including both abdominal and vaginal hysterectomies, the number of 
women eligible for the study was increased.   
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The time-frame defines this particular population and, in view of the changes in HRT 
guidelines, care will be needed generalising the findings to women having 
hysterectomy with bilateral oophorectomy today. 
 
The target sample for this study was the whole population, that is 100% of those 
women identified for inclusion. This represents a total of 362 women, which was 
fewer than expected, and probably related to coding issues (which will be addressed 
later in this chapter). 
 
Women who had elective hysterectomy for malignant disease, or who had a prior 
medical history of breast cancer, were excluded. The reason for exclusion was that 
HRT use with either of these conditions would be contraindicated. Death, severe 
psychiatric illness, breast cancer diagnosed after surgery, and not now being resident 
in Scotland were the other reasons to exclude.  
   
3.1.2 Data collection 
The questionnaire is a popular method of data collection and, as previously 
mentioned, efficient in terms of finance and researcher time. However the 
construction of a good questionnaire is more difficult than it may appear to be. 
Robson (2001, pp 247-249) makes some suggestions, derived from research literature, 
as to how an efficient questionnaire can be constructed. He states that specific 
questions are better than general ones, that closed questions are better than open ones 
and that, although there are no particular rules on how to place the order of questions 
one should start with general questions and follow with specific. The order of 
questions is particularly important, as it is well recognised that the interpretation of 
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any given question can be influenced by the preceding question (Robson 2001, p 
249). Robson also recognises that data collected via questionnaire may not be 
completely honest, and its accuracy is often subject to memory (p128). In this 
particular study, responses are also based on recollection of past events, which may be 
subject to less than accurate recall. Accuracy will depend on how long ago the event 
happened, and the saliency of that event. Bowling (2002 p305) suggests that asking 
about events occurring more than six months ago should be avoided, unless they are 
highly salient. It could be argued that hysterectomy, as major surgery, is a highly 
salient event but the subsequent HRT prescription is conceivably not.     
 
The questionnaire is divided into four sections (Appendix 3.1). Each section is 
introduced to the respondent as to the context of the questions. The format of the 
questions was simple, with a choice of responses to be answered by ticking an 
appropriate response. The first section is concerned with the hysterectomy, and with 
the information given before and after surgery. The questions were designed to 
ascertain whether the patient was told of the risks and benefits of taking HRT, which 
particular factors were discussed, the source of the information, and whether or not 
the patient felt that they were sufficiently informed. Simple „yes‟ or „no‟ answers 
applied to most of the questions. In five of the questions, a choice of alternative 
responses was offered, with clear instruction as to the number of responses allowed. 
 
The second section asked questions about taking HRT, both before and after surgery, 
the duration of use and the reasons for stopping. Again „yes‟ or „no‟ responses, or a 
choice between specific alternatives, were requested.  The third section was more 
opinion-based, considered the patient‟s perception of risks versus benefits, and asked 
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if prescription charges influenced use. The fourth section requested simple 
demographic details, and asked whether the respondent had ever suffered a condition, 
which would prevent the use of HRT. 
 
Finally, the respondent was asked if they would consider participating in an interview. 
A small number of women did agree to an interview but this part of the research was 
not ultimately undertaken. Originally, it was planned to interview those women who 
agreed to meet with the researcher in order to explore in further detail their responses, 
so providing a deeper understanding of their choices. The primary reason that this was 
not carried out was because a period of two years elapsed between the return of the 
questionnaires and the completion of the data analysis. This delay was caused by 
events personal to the researcher; and to approach these women again, after such a 
significant lapse of time, was considered unethical.  
 
In order to identify any difficulties in the interpretation of questions asked in the 
questionnaire, a pilot study was necessary. Robson (2001, p 301) suggests that a 
“dummy run” should be carried out before gathering any sort of data, to identify flaws 
in the design. Initially, it was planned to pilot the study in another hospital, outwith 
Forth Valley, but this idea was rejected when it became apparent that separate ethical 
approval from the relevant NHS Trust would be necessary, so delaying the start of the 
study.     
The questionnaire therefore was piloted on women undergoing hysterectomy in the 
gynaecology  ward  of hospital B, the then place of work for the researcher. This pilot 
revealed few problems with the questions asked. Some minor alteration to the format 
was made by the addition of clearer statements to indicate in what context/ stage of 
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treatment the questions should be answered, prior to the commencement of the main 
study. On reflection, a pilot undertaken elsewhere would have identified problems 
more effectively. Respondents unknown to the researcher may have identified any 
difficulties more openly than those who were approached by the researcher whilst 
they were patients in the ward. Another consideration would have to be that these 
women completed the pilot at the time of their hysterectomy, whereas the study 
subjects were asked to remember events from the past. 
  
Some of the women completing the questionnaire had undergone surgery some years 
before, and the responses were all based on their recollection of events at the time. It 
is entirely possible that their responses are influenced by more recent information or 
that they were unable to recall clearly the events or opinions of the past. 
 
Despite clear instructions and attempts to prevent ambiguity in the questions, it 
became apparent, once the responses were returned, that some of the questions had 
been ambiguous. The closed questions, to be answered by either „yes‟ or „no‟, did not 
produce any problems, but those with more than two choices sometimes elicited more 
than one response, even though the instruction to the respondent was to tick one 
response only.  
 
One question that proved difficult was one in which the respondent was asked to rank 
their answers in order of importance. Robson (2001 p 248) suggests that the middle 
alternative should be avoided if intensity of an opinion is to be measured as people 
may use “ medium” as a non-committal response. The researcher wished to identify 
the order of importance respondents chose for the benefits of taking HRT but a 
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number of women were assumed to consider the options as equally important as they 
gave the same rank to more than one answer. 
  
3.1.3 Statistical Analysis of Data 
SPSS was used to generate some descriptive statistics pertaining to the   
characteristics of the target study population as a whole (n=306) and of the returned 
sample (n=190). The purpose initially was to examine the target population as a 
whole, and to check if the demography of the returned sample, in comparison with 
target sample, was representative in terms of age, date of operation, socio-economic 
group and consultant in charge of care. In this way, provided that those subjects 
returning their questionnaires did not differ significantly from those subjects who did 
not, the information gleaned from the returned questionnaires could be treated as 
representative of the population in general. 
 
Simple statistical tests were then used in the analysis of the data, in order to examine 
the association of independent variables and the HRT decisions women make. 
Independent variables in this study include the age of the patient, the individual 
consultant, and the SIMD classification of the patient. Other examples are: the unit in 
which treatment took place, who gave HRT information, and whether or nor HRT had 
been taken prior to surgery. It is possible that any, or all, of these might have some 
association with the decision to take HRT. The dependent variables in the study 
include whether or not to take HRT in the first place; how long to take it for; when to 
stop, and why. 
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The t-test is used to analyse the difference between two sub-groups in the sample, 
defined by one independent variable, and determines whether there is a significant 
difference between the means of these two groups on a dependent variable (when the 
latter is a ratio or interval variable). In a normally distributed population, the null 
hypothesis would be that there is no significant difference between the two means. So, 
for instance, according to the null hypothesis there should be no difference between 
the mean age of women treated in two different hospitals, or according to which 
consultant who treated them, or whether or not they returned their questionnaire. The 
probability of finding the t value by chance, or by sampling error (assuming the null 
hypothesis is true) is then calculated. If this probability is very low, then the 
researcher is entitled, provisionally, to reject the null hypothesis, and assume that 
there is a difference between the two groups concerned. Conventionally, the 
accept/reject threshold of probability is set at .05. 
 
Pearson‟s chi square measures the association, if any, between two categorical 
variables, such as SIMD and whether or not the questionnaire was returned, or the 
source of information and the unit where treatment was undertaken. A contingency 
table is constructed, and the test calculates the difference between observed and 
expected counts (on the assumption that the null hypothesis is true). If the difference 
between observed and expected counts is such that the probability of obtaining the 
observed values is low (with the threshold again set at .05), then the null hypothesis 
can, conventionally, be rejected. Interval and ratio variables such as age, or duration 
of treatment, can be re-coded into categorical variables, to allow chi square analysis. 
The hypothesis can be one-tailed, that predicts the direction of the association (for 
example, older women take HRT for shorter times) or two-tailed, where the direction 
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of the association is not predicted (for example, there will be a difference in length of 
HRT use associated with women‟s ages). Two-tailed tests are less likely to give false 
results, and have been used in the analysis of this data.  
 
3.2 The implementation of the study, how the study population was identified, 
accessed and subsequently recruited, and the management of returned 
questionnaires  
3.2.1 Identification of study population 
The study population was identified by hospital computer record. The Medical 
Records department provided the researcher with a list of hospital unit numbers and 
dates of birth belonging to women who, according to their records, had undergone 
hysterectomy with bilateral oophorectomy, either by an abdominal or vaginal route, 
for menorrhagia within the time frame 01/01/1992 and 31/12/2001. At the time of any 
surgical procedure, a record is made of the patient (unit number), the reason for the 
surgery (the diagnosis code), and the operation performed (the surgical procedure 
code). These details can then can be used to identify the number of any particular 
operation performed for a specific diagnosis and the patient details. Each operation 
and each main diagnosis has its own code. It is possible, therefore, to distinguish a 
woman having had a hysterectomy for endometriosis from a woman who has had a 
hysterectomy for menorrhagia.  In this way, only women who had undergone 
abdominal or vaginal hysterectomy with bilateral oophorectomy for menorrhagia 
could be recruited. There are three codes that indicate menorrhagia, one ceasing to be 
used after 1997, and they are listed below. 
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1. 6262 = excessive or frequent menstruation, menorrhagia, heavy periods, 
polymenorrhoea, menometrorrhagia. (Code 6262 used prior to 1997)  
2. N920 = excessive, frequent and irregular menstruation with regular cycle. 
3. N921 = excessive, frequent and irregular menstruation with irregular cycle. 
 
There is one surgical procedure code for abdominal hysterectomy, one for vaginal 
hysterectomy, and (for some reason) two codes used interchangeably for bilateral 
oophorectomy, and these are as follows, 
 
1. Q074 = Total abdominal hysterectomy. 
2. Q089 = Vaginal hysterectomy. 
3. Q221 or Q223= Bilateral oophorectomy. 
 
The researcher screened the list, and those subjects over the age of 51 years at the 
time of operation were excluded. 
 
Errors in coding do occur, and it was necessary for each case note to be checked prior 
to inclusion in the study. This was a very time-consuming exercise. Funding was not 
available to allow clerical staff to locate case notes for the researcher, so the 
researcher herself performed the actual retrieval of each case note. This involved 
many hours in the medical record file rooms locating case notes, a laborious task and 
not without difficulty at times owing to problems with misfiling, or lost or destroyed 
notes. It also took the researcher some time to become familiar with the method of 
case note retrieval using the terminal digit filing system used by the records 
department. In general case notes are kept until a patient is 25 years old, and 
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maternity notes are also kept for 25 years. However, notes are destroyed if the patient 
has not attended hospital for eight years. These records not used and those 
approaching eight years old are kept separately in what is known as secondary 
storage, located outwith the main records department. It was necessary for the 
researcher to visit secondary storage to view a small number of notes located there. 
Some of the identified notes were not available in file at the time the researcher was 
seeking access; other departments, such as outpatient clinics or inpatient wards, were 
using them. In these circumstances, the researcher was required to visit other 
departments in order to find and extract the necessary data. Once found each medical 
case note was examined, and the detail of each individual operation was checked 
against the recorded code. By personally examining the individual case notes, the 
researcher was sure that only relevant cases were selected. If reasons for exclusion 
were apparent, then those patients were not approached. Checks were also made to 
ensure that the selected women were all still living. From the eligible case notes, 
further details were collected and recorded on a data sheet (Appendix 3.2). These 
details included the patient‟s name and address and their registered general 
practitioner. The operation note was checked to confirm that the recorded diagnostic 
and operational procedure codes were correct, and that the patient had no medical 
history of breast cancer. The consultant gynaecologist in charge of their care was also 
noted.  
 
A number of cases were lost to the study at this point as, for one reason or another, it 
was decided that they did not fit the study criteria. Unfortunately, some of the earlier 
case notes had been destroyed, and some operations had been incorrectly coded. The 
details of those excluded at this point are as follows, 
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The computer record identified 241 hospital A cases, 31 of which were removed for 
the following reasons: 
 
Patient now deceased, n  = 1 
Case note destroyed, n  = 6 
Operation incorrectly coded, n = 4 
Case note untraceable, n = 7 
Case notes incomplete, n = 5 
Patient no longer resident in Scotland, n = 3 
Severe psychiatric history, n =3 
Diagnosis of breast cancer, n = 2 
 
Similarly the computer record identified 121 hospital B cases, and of these 19 were 
removed for the following reasons: 
 
Patient now deceased, n = 1 
Case note destroyed, n = 5 
Operation incorrectly coded, n = 7 
Case note untraceable, n = 2 
Patient no longer resident in Scotland, n = 1 
Evidence of psychiatric trauma related to Hysterectomy operation, n = 1 
Diagnosis of breast cancer, n = 2 
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Once the target population was thus identified, the patients could be approached for 
recruitment to the study. The number of women in the target sample at this point was 
312.  
 
3.2.2 Access to and recruitment of study participants 
A letter from the researcher was sent to each gynaecologist whose patients were 
identified as being possible participants in the study, asking for their permission to 
access and check the relevant case notes and approach the women for participation in 
the study (Appendix 3.3 (a) and (b)). All the gynaecologists approached were 
supportive of the study. 
 
In order to comply with Data Protection and Caldicott Guardianship, the first 
approach to any patient must be from the clinical team involved with their care. A 
letter was drafted by the researcher, with the assistance of Dr X, and signed by each 
consultant gynaecologist to introduce the study and the researcher to each individual 
patient. In this letter, it was stated quite clearly that if the individual woman did not 
wish to take part in the study then she could telephone the Gynaecology office and 
ask for her name to be removed from the list of possible participants (Appendix 3.4). 
 
A letter introducing the study and the researcher was also sent to the general 
practitioner with whom the identified potential participants were registered. This letter 
asked the general practitioner for permission to approach women in his care, and to 
identify those that he thought should not be approached. These doctors were asked to 
notify the researcher directly if they wished any of their patients to be excluded from 
the study. They were not asked to divulge the reason for wishing exclusion (Appendix 
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3.5). General practitioners referring to hospital A withdrew one patient from the 
study. Likewise General practitioners using hospital B also withdrew one patient. The 
reasons for withdrawing these two patients were not specified. 
 
Participation in the study was, as previously stated, voluntary. Three patients from the 
hospital B cohort opted to withdraw themselves from the study at the time of first 
contact by following the instruction to communicate with the Gynaecology 
Department.  One woman from the hospital A cohort also withdrew. The reasons for 
their non-participation were not explored. 
 
Provided consent had not been refused within ten days, either by the general 
practitioner or the patient, the questionnaire was sent out. Given the losses already 
mentioned, the study numbers were reduced, with questionnaires being sent to 306 
women. 208 were treated in hospital A; 98 were hospital B patients.  
 
Accompanying the questionnaire was a letter of introduction, inviting participants to 
complete the questionnaire, and asking them to return a blank copy if they did not 
wish to participate: this would then prevent further contact with the researcher. The 
letter explained how long the questionnaire would take to complete, and gave a date 
by which it would be helpful to have it returned (Appendix 3.6). A patient information 
sheet also accompanied the questionnaire, explaining how the study participants had 
been chosen, outlining the purpose of the study, and emphasising confidentiality 
(Appendix 3.7). A self-addressed, postage-paid envelope was included for the return 
of completed or non-completed questionnaires. This ensured that the participants did 
not incur any expense, and was designed to assist a successful return rate. 
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3.2.3 The management of returned questionnaires  
It is well recognised that response rates to postal questionnaires are often low, since 
many people do not return them, and those that do return them may have motivations 
differing from those who do not (Kumar1999, p 114). To minimise the effect of a 
self-selection bias in collected data, it is important to do everything possible to 
enhance the rate of return, so maximising the chance of obtaining data from the whole 
study population. 
 
Robson  (2001 pp 250) suggests that a number of factors can secure a good return 
rate. These include the use of quality stationary, stamped in preference to being 
franked, and personally addressed. All correspondence was made on good quality 
hospital-address headed paper, and sent by stamped first class postage to a named 
individual. Pre-survey letters are thought to increase return rates, but are also 
necessary to comply with data protection legislation. Clear information indicating the 
aim of the study, suggesting its importance, and assuring prospective participants of 
confidentiality also affect return rates. Robson also indicates that follow-up letters are 
the most effective way of increasing return rates from those who initially fail to return 
questionnaires. He suggests as many as three reminders may be used. In this study, 
however, only one reminder was sent, which included a further copy of the 
questionnaire and another stamped-addressed envelope (Appendix 3.8). The reminder 
was only sent to those women who had not returned their questionnaire by the date 
requested.   
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The return rate for hospital B was better than that for hospital A, with 76 completed 
questionnaires and 4 blank questionnaires returned - a rate of 81.6%. Given that only 
the completed questionnaires are of value, the useable return rate is 77.5%. 
 
Of the 208 subjects from the hospital A cohort, 120 returned their questionnaires; but 
6 of these were blank. This yields an overall return rate of 57.6%, and a useable return 
rate of only 54.8%. Kumar (1999, p114) suggests a 50% return rate is considered 
good, but Bowling (2002, p 264) suggests that over 75% is good, and points out that 
even then 25% of the sample have not responded, a proportion who may be different 
in some “ important way” from those who do respond. There is no obvious reason for 
the disparity between the rates of return between the two cohorts. 
 
Combining these figures it can be seen that, out of a total of 306 questionnaires sent 
out, 200 were returned, an overall return rate of 65.3%. However only 190 returns 
could be used, and therefore the overall useable return rate is 62.1%. 
 
Data was collected from both primary and secondary sources. The primary source was 
responses to the questions included in the questionnaire. The secondary source was 
the data gathered from the medical records of the participants, such as date of birth, 
date of operation, name of GP, and name of hospital consultant.   
 
The questionnaires were numbered to match the data sheet compiled at the time of the 
case note screening, so that when they were returned to the researcher at the 
Gynaecology office, it was possible to determine which woman had completed which 
questionnaire. It was therefore possible to match the demographic and other personal 
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details with the responses to the questionnaire. Once this had been completed the data 
was coded to anonymise the source and protect the participants‟ confidentiality, At 
this point, it was entered into the computer. 
 
There were 116 questionnaires not returned, or returned blank. There is little value in 
these except to use the demographic data, which they contain, to investigate the 
similarities and differences between the returned data and the target sample as a 
whole. The only data used from these non-returned questionnaires were details of date 
of operation, age at operation, Scottish Index of Multiple Deprivation (SIMD) scores, 
and the consultant responsible for care.  
   
When those who returned the questionnaire were compared with the target sample, it 
was found that those who returned their questionnaire were slightly older and from 
less deprived backgrounds. This is not totally unexpected. Published research has 
shown that response rates rise with increasing age, and that people from lower socio-
economic groups are less likely to respond (Cartwright 1983, cited Bowling 2002, p 
269). Cartwright, however, does not find differences in postal survey response rates 
by social class. The implications of this will further discussed in Chapter Four. 
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3.3 Ethical and legal considerations, issues of consent and necessary permissions 
sought prior to the commencement of the study 
3.3.1 Ethical considerations 
Before the study could begin, a number of permissions were required. The major 
consideration of any research study involving patients is one of ethical approval, and 
to this end an application was made to local Health Board‟s Ethics of Research 
Committee.  
 
As this study was essentially based on voluntary participation, with no obligation to 
complete the postal questionnaire, the study participants were not at high risk of being 
exposed to discomfort, distress or much inconvenience. However, it was recognised 
that some subjects might feel obliged to participate for fear of jeopardising future 
health care in the local NHS Trust. To prevent this, it was made quite clear to 
prospective participants that any future health care would not be influenced by their 
decision whether or not to take part. Before any questionnaires were sent through the 
post, all potential recipients were checked against hospital data files of recorded 
deaths, in order to avoid the possibility of a mailing to a deceased person, causing 
distress to their family members. Patients were not approached in the immediate post-
operative period, thus avoiding any potential sense of obligation to participate on their 
part. 
 
Confidentiality was emphasised at the first point of contact, in the letter of 
introduction (Appendix 3.6), and data was edited, coded and securely stored. It will be 
disposed of in accordance with the Data Protection Act. As this was a voluntary study, 
no formal consent was obtained from each participant, the returning of the 
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questionnaire being non compulsory. A patient information sheet sent with each 
questionnaire explaining the purpose of the study, and emphasising the voluntary 
nature of their participation (Appendix 3.7). Consent of those involved in the clinical 
care of the study participants - their hospital consultant and general practitioner - was 
also sought (Appendices 3.3 and 3.5).  
 
A second ethical committee was also approached for their approval of the study. As a 
student of the University of Stirling, it was necessary for the researcher to obtain 
ethical approval from the Departmental Research Ethics Committee. After some 
minor adjustments, both committees granted the study ethical approval. 
 
The ethical committees also granted their approval for participants to be interviewed 
by the researcher after the questionnaires were completed. This was to be allowed 
providing the participants had indicated that they were willing to participate and had 
completed a formal consent to interview (Appendix 3.9). It was recognised by the 
researcher that, even if a respondent had opted to participate in an interview, it might 
be possible that asking women about hysterectomy, and its aftermath, could reactivate 
some distress if their experience in hospital, or their post-operative recovery, had been 
traumatic. In anticipation of this possibility, a clinical psychologist Mr Y was 
approached, and agreed to support the researcher if the women interviewed requested 
psychological support following their description of the hysterectomy and their 
hospital experiences. However as indicated earlier this part of the study was not 
carried out.   
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It is necessary not only to obtain ethical approval for hospital based research studies, 
but also to have permission from other individual members of the Health Board. 
Indeed, it is part of the granting of ethical approval that permission is sought from the 
relevant Clinical Director and/or Chief executive of the Trusts in which the work is to 
be carried out. To this end, the Chairman of the Women and Children‟s Unit, and the 
Medical Director and Caldicott Guardian for the Acute Hospitals NHS Trust were 
both approached. The Chairman gave his support to the study whilst the Medical 
Director and Caldicott Guardian gave permission for the release of non-anonymised 
patient information without patient consent from medical records to the researcher.  
 
The study subjects were no longer under hospital gynaecological care and the study 
was retrospective, so subjects should not have felt obliged to participate for that 
reason. It was made absolutely clear to all potential participants, in the patient 
information sheet (Appendix 3.7), that any future health care would not be influenced 
by their decision to participate or not in the study.  If a request was made to remove 
an individual from the list of possible participants, this was done.  
 
The fact that the researcher was employed by the local Health Board and practising as 
a staff nurse in Gynaecology services would perhaps aid, rather than compromise, the 
study in terms of encouraging the return rate of questionnaires. Although the study 
may have involved women who had been directly under the care of the researcher at 
some time in the past, this fact should not put those women under any increased 
obligation to participate.         
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3.3.2 Legal considerations  
To aid the researcher‟s understanding of her obligations under data protection and the 
law she met with the Lead Data Protection Officer for NHS Forth Valley, prior to the 
commencement of the study, to discuss how data would be collected and protected. 
Reference was also made to the local Data Protection and Confidentiality Policy for 
Personal Information, and the NHS Code of Practice on Protecting Patient 
Confidentiality, together with the Nursing and Midwifery Council‟s Code of 
Professional conduct regarding patient confidentiality. There are a number of 
legislative documents concerned with the protection of personal data, which 
determine what information may be accessed by a researcher and govern how such 
data is used. These include:  
 
 Data Protection Act 1998. 
 Caldicott Report 1997. 
 Professional Ethics such as the NMC Code of Conduct 
 Freedom of Information (Scotland) Act 2002. 
 Human Rights Act 1998 (article 8) 
 Computer Misuse Act 1990 
 
The first three documents will be discussed in some detail, as they have the most 
practical relevance to the study. 
 
The Data Protection Act 1998 became law in March 2000, and  protects the rights of 
individuals when their data is being processed. This Act is only concerned with 
personal data - that is data, which would, alone or with the addition of other data also 
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known to the data controller, identify a living individual. There are eight main 
principles of the Data Protection Act, which ensure safe and lawful use of personal 
information. These principles are that information must be: 
 
1. Fairly and lawfully processed. 
2. Processed for one or more lawful purpose. 
3. Adequate, relevant and not excessive. 
4. Accurate and up to date. 
5. Not kept for longer than necessary. 
6. Processed in line with the data subject‟s rights. 
7. Secure. 
8. Not transferred outside the European Union, as Data Protection only applies to 
Europe. 
 
On a practical basis for this study, all these principles were adhered to. The data was 
retrieved and used lawfully. The Health Board is registered for research purposes, and 
permission was gained from the Caldicott Guardian to access non- anonymised 
information.  The only details gathered were those necessary for determining whether 
or not the subject was eligible for inclusion in the study in terms of age, diagnosis 
code and operational code. Demographic details such as name, address, postcode and 
general practitioner were collected to enable contact with prospective participants 
once their general Practitioner had granted permission. 
 
All data has been processed in accordance with the rights of the data subjects, as the 
study participants were informed clearly in writing of the purpose of the study and 
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assured that their identity would be kept confidential by anonymising their 
questionnaire responses. 
 
All identifiable data has been kept secure. At no time did the case notes leave the 
Medical Records Department file room, provided they were in file at the time of 
screening. Those case records located outside the file room were viewed at their 
location, i.e. outpatient clinic, and not removed by the researcher. Once collected, 
names, addresses and general practitioner details were removed from the data prior to 
processing and the individual subjects given a code number to protect their identity. 
 
The Caldicott Report 1997 was commissioned by the Chief Medical Officer of 
England and chaired by Dame Fiona Caldicott to address concerns about how patient 
information was being used in the NHS in England and Wales. The report is mainly 
concerned with the security of details and the impact of new technology. The NHS in 
Scotland adopted it in 1999. The Caldicott Principles are much the same as those 
contained in the Data Protection Act, and are specifically designed to protect patient 
confidentiality due to the sensitive nature of medical records. They ensure that the use 
of patient identifiable data is justified, necessary and minimal. Only those who need 
to access patient identifiable information should have access to it and such 
information must be used lawfully. The report recommends that each health 
organisation should have a senior health professional to act as a guardian responsible 
for the safeguard of confidential patient information. The researcher met with The 
Caldicott Guardian for the NHS Trust after ethical approval for the study had been 
granted, and he gave his permission to access non-anonymised patient information. 
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In addition to the two sources of guidance above, as a nurse the researcher is also 
bound by the NMC‟s Code of Professional Conduct, which states clearly that patient 
information must be protected and only used for the purpose for which it was given. 
 
The remaining three legislative Acts will only be discussed briefly for completeness. 
The Freedom of Information (Scotland) Act 2002 states that there exists a general 
entitlement of the public to know what information is held by any organisation about 
them and that, if requested, that information must be released to them. A formal 
request must be made, and must be dealt with by the organisation within 20 working 
days. 
 
The right of the individual to have respect for their private and family life is law under 
the Human Rights Act article 8. 
 
The computer Misuse Act 1990 addresses unauthorised access to computer material 
and is designed to safeguard computer held information.  It forbids unauthorised 
access, which is punishable by imprisonment. On a practical basis, all computer held 
data for this study is coded and password protected. 
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Chapter Four Results 
 
In this chapter the results of the study will be presented. After some observations 
about the extent to which the achieved sample can be taken as representative of the 
population, the variables which might be associated with HRT use (as discussed in 
chapter 2) are analysed; and, subsequently, the reasons why women stop HRT, and 
the point at which they do so, will be examined. Throughout the chapter, where 
appropriate, additional comment will be offered, although the main discussion will be 
left until chapter 5. To aid the reading of the text and tables in this chapter the 
following abbreviations have been used. 
Hospital A (HA) 
Hospital B (HB) 
Scottish Index of Multiple Deprivation (SIMD) 
  
 4.1 Is the data collected from a sample, which is representative of the population 
as a whole? 
The first objective of the statistical analysis was to determine whether the data 
collected from the questionnaires was representative of the whole target sample. The 
population as a whole consists of women undergoing hysterectomy with bilateral 
oophorectomy in the same NHS trust for menorrhagia. The target sample within this 
population was the 306 women to whom the questionnaires were sent, and the 
achieved sample was those women who returned their questionnaires. To determine if 
the data collected originated from women who are representative of the target 
population, a comparison between those who return their questionnaires and those 
who do not was made.   
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Demographic details were compared between the two groups to see if there were 
differences in patient age at the time of operation, or differences in the socio-
economic group to which the women belonged. The unit where the operation took 
place, and the consultant in charge of care were also compared. It became apparent 
that: 
 
 The mean age at operation is significantly different for the returned sample at 
43.92 years compared with 42.80 years for those who did not return their 
questionnaires, (see Table 4.1). 
 
Table 4.1 Comparison of the mean age at operation of those who returned the 
questionnaire and those who did not.  
 
 
Return       n Mean Std. Deviation  
Questionnaire 
returned 
Questionnaire 
not returned 
     190 
 
     116 
116 
     43.92 
 
     42.80 
 
42.80 
      4.483 
 
      4.933 
 
4.933 
       t-value 1.983  
       p < .05  
 
 The return rate was significantly higher among those women treated in HB, with 
77.6% returned from HB patients and 54.8% returned from HA patients. This may 
be explained by the fact that the original letter inviting participation was headed 
on HB notepaper and the patient information sheet stated that the researcher was a 
nurse in gynaecology at HB. 
 
 The patients of some consultants return their questionnaires in greater number 
than the patients of others. The poorest return rate of 48.6% is seen for the 
consultant who performed the most operations and the best for the consultant who 
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performed the least operations. This may be explained by the fact that the 
consultant performing the least operations was new to the unit and had only 
operated on women in the recent past, whereas the consultant performing the most 
operations was a senior consultant who had been in post for some considerable 
time. 
 
 There is a better return rate among those women with SIMD scores of 7-10, that is 
the less deprived. 71% of these women returned their questionnaires, compared 
with 58.2% of those in SIMD groups 1-6, as shown in Table 4.2.   
 
Table 4.2 Comparison of the Socio-economic group of those who return the 
questionnaire and those who do not.  
   
  
 Questionnaire not 
returned  
Questionnaire 
returned 
 
Total 
SIMD 1-6  
n  
% within SIMD 1-6 
 
89 
41.8% 
 
124 
58.2% 
 
213 
100.0% 
SIMD 7-10 
n 
% within SIMD7-
10 
 
27 
29.0% 
 
66 
71.0% 
 
93 
100.0% 
Total 
n 
% within SIMD 1-
10 
 
 
116 
37.9% 
 
190 
62.1% 
 
306 
100.0% 
-square 4.472 
p  < .05  
 
 
 
To summarise, the achieved sample over-represents women who were slightly older at 
the time of surgery and who have less deprived social backgrounds.  There are 
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conflicting findings from studies trying to determine who does and who does not 
respond to surveys. Bowling (2002 p 269) acknowledges the difficulties in defining 
the characteristics of non-responders and suggests that the topic of the survey is partly 
responsible for the inconsistencies found. She quotes Cartwright (1983) who found 
that response rates to surveys vary with social class, but that these differences are not 
seen when postal surveys are used. Other researchers have found that socio-economic 
group is strongly associated with response rates to questionnaires. Turrell et al (2003) 
found in their survey of food purchasing behaviour that non-responders were older 
and less educated concluding that socio-economic position is a strong predictor of 
non-participation. Similarly, findings made by Van Loon et al (2003) support the 
socio-economic link, but these authors found that younger people are less likely to 
respond. Bowling (2002, p 269) however, states that research has shown that “among 
older people, response rates increase with increasing age”. So the achieved sample in 
this study is in keeping with both Turrell and Van Loon‟s findings with regards to 
socio-economic status, but supports Bowling‟s statement on the association of 
increasing age and higher response rates. 
 
Although a larger percentage of HB patients returned their questionnaire, fewer 
women were approached in Falkirk. A higher percentage of the overall returns were 
from HA patients, with 114 completed returns compared with 78 completed by HB 
patients.  
 
The data collected from the achieved sample is now presented. Some general 
observations concerned with where, when and by whom the women were treated are 
made before an examination of which variables are associated with HRT use. 
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Number of cases per unit  
Table 4.3 shows that hospital A (HA) performed more operations than hospital B 
(HB) over the ten-year period examined in the study. HA performed 60% of the total, 
while HB was responsible for 40%. This may be explained by the fact that the unit in 
HB was slightly smaller than that in HA, with 13 Gynaecology inpatient beds 
compared with 18 in HA. 
 
Table 4.3 Number of cases by unit in the achieved sample. 
 
 
 Frequency percent 
HB 
HA 
Total 
76 
114 
190 
40 
60 
100 
 
 
When cases treated by individual consultant are analysed, it can be seen that a HA 
based consultant (H) is responsible for more than a quarter of all cases, performing 
27.4% of all procedures.  All consultant gynaecologists in each unit have slightly 
differing areas of specialist interest and clinical practice, and some have extensive 
administrative roles. This impacts on the time available to them for theatre cases. 
During the time frame of this study, one consultant retired (G), two took maternity 
leave (I and J), and one was newly recruited (C). This would obviously affect the 
number of cases each surgeon would perform. Table 4.4 details the number of cases 
treated by each consultant.  
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Table 4.4 Number of cases treated by consultant in the achieved sample. 
 
 
Consultant Frequency Percent 
A 
B 
C 
D 
E 
F 
G 
H 
I 
J 
Other 
 
  20 
  20 
    5 
  16 
  12 
    4 
  21 
  52 
  14 
  12 
  14 
 
  10.5 
  10.5 
    2.6 
    8.4 
    6.3 
    2.1 
  11.1 
  27.4 
    7.4 
    6.3 
    7.4 
 
Total 190 100.0 
 
 
Date of operation 
The distribution of returned questionnaires according to the year of operation is 
depicted in Figure 4.1.The numbers are roughly comparable for each year, with the 
exception of 1996. 
 
The year 1996 has a very low return rate, and this must be looked at in context of the 
whole target population to see if there were actually fewer operations performed in 
this year. When the whole target sample was examined in terms of number of cases 
per year, it was clear that in 1996 fewer operations with the specified diagnosis codes, 
were performed according to statistical records. It was found that, in fact, only eight 
questionnaires were sent out to women whose operations had been in 1996. So the 
low number was not related to poor return rates but to very low target numbers.  
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Figure 4.1 Frequency of operation by year in the achieved sample. 
 
 
 
 
 
 
 
This dramatic drop in numbers is difficult to explain except in terms of coding. It is 
possible that in this year the recorded diagnosis codes for these cases differed from 
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those selected for this study. If cases were coded with diagnosis codes other than 
6262,N920, or N921 (see Chapter three) then they would have been excluded. The 
recorded diagnosis for any operation is linked to clinical findings prior to the 
operation, and selected from a pre-existing list of codes. Often there may be more 
than one diagnosis for the case, for example a hysterectomy may be performed to treat 
endometriosis or dysmenorrhoea which may co-exist with menorrhagia but as 
diagnoses have separate codes. This study has used only the main diagnosis code 
recorded to select study cases. So it is possible that the reason there were apparently 
fewer hysterectomies for menorrhagia in 1996, was that the operations were 
differently coded. It could be argued however that this would be the case in any of the 
studied years. There may be another possible explanation for the reduced numbers in 
1996, again linked to coding. In 1996 two consultants joined the hospital. It may be 
that these new doctors did not perform so many total hysterectomies with bilateral 
oophorectomy for menorrhagia, preferring to follow a more conservative treatment or 
coded their operations with a different main diagnosis code, such as dysmenorrhoea.  
Munro (2007) acknowledges that it is difficult to measure the exact rate of 
hysterectomy for heavy bleeding, due to coding issues.  Hysterectomy rates in the 
United States of America remain at much the same level, despite the advent of many 
medical and minor surgical treatments for heavy menstrual bleeding according to 
Munro (2007). In England, however, there has been a steady reduction in the numbers 
since 1995-1996, thought to be associated with increased rates of endometrial ablation 
and the use of the Mirena coil (Reid and Mukri 2005). Similarly the figures quoted by 
Bridgman and Dunn (2000), show falling hysterectomy rates since 1992-1993, with a 
dip in the numbers for the financial year 1995/1996.Again this is related to the 
alternative treatment, endometrial ablation being used more frequently in these years. 
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It is likely that fewer hysterectomies were performed in the year1996 in Forth Valley 
due to these national trends but also that variations in coding from year to year, have 
also played a part in the exceptionally poor numbers of target subjects for this 
particular year. 
 
We now return to the variables considered in chapter two, in order to determine 
whether any of them are associated with the HRT decisions made by women in this 
study. 
 
4.2 Is socio-economic status associated with HRT use? 
Using the Scottish Index of Multiple Deprivation (SIMD), cases were ranked 
according to their postcode to be given a score according to their deprivation decile. 
The higher the score on a scale of 1 – 10, the less deprived in terms of current income, 
housing, health, education, skills and training, and employment the area is deemed to 
be. This system in some ways replaces the old Registrar General‟s classification for 
the purposes of determining socio-economic group, or level of deprivation. 
 
In order to determine whether the achieved sample was representative of the 
population of the local area as a whole, a comparison was made of the representation 
of each decile in both groups. There are a total of 371 data zones within the local 
geographic area, each with its own decile. Likewise the 190 women who returned 
their questionnaires each belong to a decile based on their postal code. It is possible 
then to compare the percentage of the population belonging to one SIMD decile in the 
total population of the region with the percentage found in the achieved sample (Table 
4.5).  When this comparison is made, it is clear that the sample is roughly comparable 
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to the population of the local region as a whole, in terms of socio-economic 
background.  
 
Table 4.5 and Figure 4.2 show that SIMD Group1 is particularly under-represented in 
the achieved sample and Group 5 is over-represented. Both these SIMD classes are 
grouped together as SIMD1-5, as the more deprived groups in the statistical analysis 
of the data obtained. So although there are fewer of the very poorest women in the 
sample, there are somewhat higher numbers of SIMD Group 5 women, who (for the 
purposes of this study) are still considered to be in the more deprived group.  
 
Table 4.5 SIMD classification of achieved sample compared to the region as a whole. 
 
   
SIMD       Whole Region 
Frequency (n )  Percent(%) 
Achieved study sample 
Frequency (n)  Percent (%) 
1 
 
24 6.5 1 0.5 
2 
 
31 8.4 18 9.5 
3 
 
50 13.5 28 14.7 
4 
 
40 10.7 27 14.2 
5 
 
41 11.1 37 19.5 
6 
 
28 7.5 13 6.9 
7 
 
41 11.1 15 7.9 
8 
 
39 10.5 23 12.1 
9 
 
48 12.9 16 8.4 
10 
 
29 7.8 12 6.3 
Total 
 
371 100 190 100  
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Figure 4.2 Population of the whole of the region by SIMD classification compared 
with the sample achieved in this study. 
 
 
 
 
The following five questions related to socio-economic group were addressed by the 
study: 
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4.2.1 Is socio-economic status associated with the age of the patient at the time of 
operation? 
There is an association between socio-economic group and the age at which women 
undergo hysterectomy. When the whole target sample is analysed (n=360), 
differences in the mean age by socio-economic group are seen (Table 4.6).  If the 
target sample is then divided into SIMD groups 1-5 and 6-10, there is a significant 
difference in the age at operation. For groups 1-5 the mean age is 42.92 years, while 
for the less deprived groups, 6-10 the mean age is 44.42 years (Table 4.7). 
 
Table 4.6 Target sample mean age at time of operation by SIMD score. 
 
SIMD MEAN AGE n Std. Deviation 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Total 
39.80 
42.75 
43.23 
43.14 
43.14 
44.79 
45.95 
43.56 
43.42 
44.60 
43.49 
10 
32 
47 
43 
57 
24 
22 
32 
19 
20 
306 
5.653 
3.742 
5.719 
5.012 
4.871 
3.788 
3.798 
4.181 
3.934 
3.662 
4.682 
 
 
 
Table 4.7 Target sample mean age at time of operation classified by SIMD groups1-5 
and SIMD groups 6-10. 
   
 
SIMD n MEAN 
Age at 
operation 
SIMD 1-5 
SIMD 6-10 
 
 
189 
117 
 
 
42.92 
44.42 
t- value –2.905 
p< .01 
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It may be argued that women from less deprived backgrounds with superior education 
may understand the issues surrounding early hysterectomy in terms of oestrogen loss 
more completely, and hence delay hysterectomy in favour of more conservative 
therapies. It has been shown that women from poorer backgrounds are more likely to 
have a hysterectomy before they become naturally menopausal, i.e. that they are 
younger than less deprived women (Cooper et al 2008).  
 
When the data from the returned questionnaires is analysed, however, this socio-
economic association with age at operation is not seen. The mean age at operation for 
SIMD groups 1-5 is 43.42 years, and for those classified in SIMD groups 6-10 it is 
44.61 years. The difference between which is not statistically significant (Table 4.8). 
 
Table 4.8 Achieved sample mean age at time of operation classified by SIMD groups 
1-5 and SIMD groups 6-10. 
 
 
 
SIMD age at 
operation 
n  MEAN Std.Deviation 
 
SIMD 1-5 
SIMD 6-10  
 
111 
79 
 
43.42 
44.61 
 
4.761 
3.989 
t-value –1.805 
p = 0.073 
 
 
This can probably be explained in terms of sample size. It is assumed that, had more 
subjects returned their questionnaires, then the association between socio-economic 
group and age at operation would have shown in the achieved sample also. 
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4.2.2 Is the socio-economic status of the patient associated with hospital 
prescribing of HRT? 
It might be expected that the social background to which the patient belongs has some 
effect on the level of information exchanged between doctor and patient during a 
consultation, and this in turn may affect HRT uptake. The Black report of 1980 found 
that middle class patients have consultations with their doctors of longer duration than 
those from poorer backgrounds. If the consultations are longer, is the information 
given more detailed, or different in any other way?  This was examined in relation to 
the responses to the questions 3-10 in the questionnaire, concerned with information-
giving and subsequent acceptance of HRT prescription. In this study, the socio-
economic group of the patient does not seem to be associated with any of the 
responses to questions 3-10.  
 
If the population is split at SIMD band 5, where bands 1-5 are the most deprived and 
bands 6-10 the least deprived, then there appears to be no effect of socio-economic 
status. This is true in terms of who mentioned HRT, before the operation, and whether 
or not symptoms of the menopause were discussed. SIMD has no effect on whether 
osteoporosis or heart disease protection is mentioned, or indeed on whether side-
effects such as increased cancer and DVT risk are discussed. So discussions between 
women from less deprived backgrounds and their doctors do not differ significantly 
from those between more deprived women and their doctors, in terms of information 
given regarding risks/benefits of HRT. There is also no difference in terms of unit 
attended. 
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HRT is offered in hospital to women regardless of their SIMD status. Slightly more 
women in the lower SIMD groups, which are the most deprived, accept HRT when 
offered although this is not statistically significant in this sample. SIMD does not 
influence the likelihood of subsequent discussions with GPs regardless of whether or 
not the hospital  provided HRT.  
 
4.2.3 Do different socio-economic groups use different information sources in 
hospital?  
It may be supposed that women from different backgrounds access information from 
different sources; however, this did not appear to be the case in the present study. 
  
There is no association between the SIMD score of the patient and whether the doctor, 
nurse or HRT pamphlet is the main source of information about HRT. If the SIMD 
scores are split into two groups at band 4, the most deprived being groups 1-4 and the 
least deprived being groups 5-10, then the doctor is mentioned as a source by 28.2% 
of the most deprived women compared with 38.7% of the least deprived women. 
However, this is not a statistically significant result ( p .096), and therefore it cannot 
be said that women from less deprived backgrounds are able to discuss this aspect of 
their care more confidently with their doctor. There is no difference in the numbers of 
women citing the nurse, or HRT pamphlet as a source of information when patients 
are classified by SIMD scores. It may be argued that nurses give the same information 
to all patients, or provide leaflets in lieu of personal advice; so variations by social 
class might be expected to be less evident. If the SIMD scores are more equally 
divided at 5, with the most deprived women in groups 1-5, and the least deprived in 
groups 6-10, then there is still no statistical association demonstrated. 
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 There is no association between SIMD and whether or not the doctor is cited as a 
source of information; likewise there is no association between SIMD and whether of 
not the nurse or HRT pamphlet is cited. This would further confirm that the 
information sources used by the women in this study are not associated with SIMD. 
 
4.2.4 Is socio-economic status associated with the duration of therapy? And is 
there any association between prescription charges and HRT use?  
Are wealthier women more likely to use HRT for a longer time than women from less 
affluent backgrounds? And do prescription charges, or the eligibility for exemption 
certificates, affect HRT use by the women in this study? 
   
Some association between socio-economic group and the timing of stopping treatment 
is seen. When the women are grouped by SIMD groups 1-5 and 6-10, the least 
deprived women appear to take HRT for longer, when all stopping times are 
considered. Overall there is only a close to significant result (p .061) found here. This 
effect is amplified if the timing of cessation of treatment is divided into two groups: 
„up to 7 years‟ and „beyond 7 years‟. Table 4.9 shows that 77.5% of the most deprived 
women cease treatment within 7 years compared with 42.5% of the least deprived 
women. More than double the number (57.5%) of the least deprived women take HRT 
for more than 7 years, compared to only 22.5% of the most deprived. This is 
statistically significant. 
 
If the timing of the cessation of treatment is divided into two different groups, „up to 5 
years‟ and „more than 5 years‟, and if the respondents classified by SIMD5 the same 
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effect is seen, with more of the least deprived women taking treatment for longer 
(Table 4.10). Women from different backgrounds give the same reasons for stopping 
treatment.  
 
Table 4.9 Women who stop HRT after up to 7 years of use, or after more than 7 years 
use, classified by their socio-economic group, SIMD 1-5 or SIMD 6-10. 
 
 
When stopped 
 
Most Deprived 
(SIMD 1-5) 
n              % 
Least Deprived 
(SIMD 6-10) 
n            % 
Total 
 
n      % 
Stopped up to 7 
years 
 
 
31       (77.5 ) 
 
17      (42.5)  
 
 
48     (60.0)  
Stopped beyond 7 
years 
 
 
9         (22.5 ) 
 
 23      (57.5)  
 
32      (40.0) 
Total 
 
40       (100)  40        (100)  80       (100)  
-square 10.208 
p < .001  
 
 
 
Table 4.10 Women who stop HRT after up to 5 years of use, or after more than 5 
years use, classified by their socio-economic group, SIMD 1-5 or SIMD 6-10.  
 
 
When stopped 
 
Most Deprived 
(SIMD 1-5) 
n             % 
Least Deprived 
(SIMD 6-10) 
 n          % 
Total 
 
n       % 
Stopped up to 5 
years 
 
 
23        (57.5)  
 
14       (35.0)  
 
37     (46.2) 
Stopped beyond 5 
years 
 
 
17         (42.5)  
 
 
26        (65.0)  
 
43      (53.8)  
 
Total 
 
 
40         (100) 
 
40        (100) 
 
80       (100)  
 
- square 3.701 
p < .05 
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It may be thought that prescription charges have an influence on the length of time a 
woman decides to continue with treatment, and that socio-economic group would 
reflect this aspect. Nearly 80% of the women answering said that they did pay for 
their HRT prescription. 
 
When grouped by SIMD 5 (least deprived 6-10), 23.7% of the most deprived women 
and 17.9% of the least deprived women did not pay for their prescriptions. When this 
is cross-tabulated with the stopping times of „up to‟ and „more than‟ 5 years, no 
association is seen. Of those who do not pay for their medication, those who stop 
taking HRT at up to 5 years and those stopping at over 5 years do so in equal number. 
If those who stop after a longer period of time, 7 years or more, are compared to those 
who stop before this there is still no association with prescription charges. When 
asked if free prescriptions would make them more likely to take HRT, 75.4% of 
women said that it would not.  
 
When asked if they discussed with their doctors their decision to stop, 65% said that 
they had done so. If the women are grouped by SIMD, there is no association between 
socio-economic group and the likelihood of this consultation taking place. This is true 
irrespective of whether SIMD 4 (least deprived SIMD 5-10) or SIMD5 (least deprived 
SIMD 6-10) is used to categorise the study population. 
 
 
 
 
 152 
4.2.5 Do women from different socio-economic groups view the “risks versus 
benefits” of HRT therapy differently?  
When the achieved study population was asked whether the benefits of HRT outweigh 
the side effects for them personally, 142 women (74.7%) answered in the affirmative. 
There is no statistical evidence that socio-economic group is associated with this 
response. The women were also asked to consider the benefits of HRT and rank, in 
order of importance, the prevention of menopausal symptoms, osteoporosis 
prevention and possible cardiovascular protection. 
 
Table 4.11 shows that the relief of menopausal symptoms was ranked as most 
important by 31.5% of respondents, and a further 36% ranked this as of medium 
importance. The prevention of osteoporosis was thought to be most important for 
26.3% of women, and a further 47.5% ranked this as of medium importance. Possible 
cardiovascular protection was thought to be most important for 15.6% of respondents, 
with a further 37.4% ranking this as of medium importance. (Some women did not 
clearly rank this question, as some gave joint importance to two or more choices; 
hence the intermediate classification of 1.5 and 2.5 in tables 4.11, 4.12 and 4.13.) 
 
If the indication of joint importance of symptoms is considered, and the intermediate 
scores of 1.5 added to score 1, and 2.5 added to score 2, then the relief of menopausal 
symptoms appears to be most important to 38.2% of women. The prevention of 
osteoporosis is most important to 33% of women, and cardiovascular protection most 
important to 20.1%. 
 
 
 
 153 
 
Table 4.11 Importance ranking by achieved sample of the benefits of HRT.  
 
 
Importance ranking Menopause 
symptoms 
n            % 
Osteoporosis 
protection 
n             % 
Heartdisease 
prevention 
n           % 
1.Most important 
 
% of Total 
 
1.5 
% of Total 
 
2.Medium 
importance 
 
% of Total 
 
2.5 
% of Total 
 
3. Least important 
 
% of Total 
 
 
 
56        (31.5)  
 
 
12       (6.7)  
 
 
 
 
64       (36.0)  
 
 
4           (1.7)   
 
 
 
43       (24.1)  
 
 
 
 
 47        (26.3)  
 
 
12         (6.7)  
 
 
 
 
85 (47.5) 
 
  
7            (3.9)  
 
 
 
28          (15.6)  
 
 
 
 
28       (15.6)  
 
 
8          (4.5)  
 
 
 
 
67        (37.4)  
 
 
10         (5.6)  
 
 
 
66        (36.9)  
 
 
Total % 179       (100)  179         (100)  179     (100)  
 
 
 
When SIMD scores are cross-tabulated with these ranked answers, we see some 
difference in the responses between women from different socio-economic groups.  
If the respondents are divided by SIMD5, where the most deprived women are in 
groups 1-5 and the least deprived in groups 6-10, then there is a close-to significant 
difference in how the two groups rank the importance of the relief of menopausal 
symptoms. Table 4.12 shows a higher number of the least deprived women (35.1%), 
compared to 28.7% of the most deprived women rank relief of menopausal symptoms 
as most important (p .053). No statistical difference is seen in the way these two 
groups of women rank the importance of osteoporosis protection. 
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Table 4.12 Importance ranking of the relief of menopausal symptoms by deprivation 
score.  
 
Importance of 
menopause 
symptoms  
Most Deprived 
SIMD (1-5) 
n        %  
Least Deprived 
SIMD (6-10) 
n         % 
Total  
 
n          %  
1.Most 
important 
 
 
1.5 
 
 
2.Medium 
importance 
 
2.5 
 
 
3.Least 
important 
 
 
 
29 (28.7)  
 
 
10       (9.9)  
 
 
31     (30.7)  
 
  
3       (3.0)   
 
 
 
28       (27.7)  
 
 
 
27      (35.1) 
 
 
2        (2.6)   
 
 
33      (42.9) 
 
 
0         ( 0) 
 
 
 
15       (19.5)  
 
 56     (31.5)  
 
 
12       (6.7)  
 
 
64     ( 36.0)  
 
 
3        (1.7)  
 
 
 
43      (24.2)  
Total  
 
 
 101     (100)  
 
77       (100) 
 
178   (100)  
-square 9.331 
p = 0.053 
 
When the importance of cardiovascular protection is considered, there is a difference 
between the two groups of women. Of those most deprived, 20.6% ranked 
cardiovascular protection as most important, 33.3% as of medium importance, and 
31.4% as of least importance. Those women who are least deprived appear to view the 
benefits differently. Only 9.1% consider cardiovascular protection as of most 
importance, 42.9% as of medium importance and 44.1% as of least importance. This 
is statistically significant (Table 4.13). This possibly may be explained by the 
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differences in perceived risk of a cardiovascular event, a possibility which will be 
considered in the discussion chapter to follow.  
  
Table 4.13 The importance ranking of heart disease prevention by the achieved 
sample. 
 
 
Importance of 
Heart Disease 
Most Deprived 
(1-5) 
n              % 
Least Deprived 
(6-10) 
n                % 
Total 
 
n           % 
 
1.Most important 
 
 
1.5 
 
 
2.Medium 
importance 
 
 
2.5 
 
 
3.Least important 
 
 
 
21         (20.6)  
 
 
8             (7.8)  
 
 
 
34           (33.3)  
 
 
7             (6.9)  
 
 
32            (31.4)  
 
 
7             (9.1)  
 
 
0              (0) 
 
 
 
33           (42.9)  
 
 
3              (3.9)  
 
 
34          (44.1)  
 
 
28       (15.6)  
 
 
8         (4.5)  
 
 
 
67        (37.4)  
 
 
10       (5.6)  
 
 
66       (36.9)  
 
Total 
 
 
 
102      (100) 
 
 
77          (100)  
 
 
179     (100)  
-square 13.446 
p < .01 
 
In conclusion, it may be said that there is a trend for women from less deprived 
backgrounds to be older at the time of hysterectomy than those from more deprived 
backgrounds. Although this is not evident in the achieved sample, the difference is 
statistically significant in the target sample. All women, regardless of background 
have the same discussions with their doctors, use the same information sources, and 
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have HRT offered to them. Women from less deprived backgrounds use HRT for 
longer and prescription charges do not influence the timing of discontinuance. The 
same reasons are given for discontinuance regardless of socio-economic group. There 
is some difference between socio-economic groups as to how risk-benefit is 
perceived.  
   
4.3 Does the geographic location of the hospital in which the women were treated 
affect HRT use? 
Are all women treated in the same way when comparing the two hospitals in the 
study? Obviously this question cannot be answered in simple terms, as there are many 
facets which need consideration. In each unit, different consultants and nursing teams 
care for patients, possibly in different ways. We now consider four differences, which 
might be apparent between the two units, in terms of what information the patient 
received, who gave it, and the timing of HRT prescription. We will also explore any 
individual or collective differences between consultants, as well as any possible 
gender differences. 
     
4.3.1 Are there any differences between the two hospital units, in the information 
regarding HRT, given to patients? 
It might be expected that there would be differences between the pre-operative 
consultations taking place in the different hospitals. This is considered because 
different consultants, who may differ in their information–giving in terms of detail 
and ease of understanding from the patient perspective, conduct the consultations.    
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One of the first questions in the questionnaire asked was: “was HRT was mentioned 
to you before you had the operation?” Table 4.14 shows that nearly three–quarters of 
the women who returned their questionnaires remember that HRT was a topic in their 
pre-operative discussion. 
   
 Table 4.14 Frequency of pre-operative discussion about HRT. 
 
 
 Frequency Percent 
Valid   No 
            Yes 
            Total 
Missing 
system 
Total         
55 
129 
184 
 
6 
190 
28.9 
67.9 
96.8 
 
3.2 
100 
 
 
When the 129 women who responded in the affirmative are differentiated by the 
hospital in which the operation took place, 75 cases were in treated in HB and 109 in 
HA. Cross tabulation shows HB with 72% of their patients being told about HRT 
prior to operation in comparison with 68.8% of patients in HA. This is not statistically 
significant. 
 
So there is no difference between the two hospitals with respect to patient recollection 
of their pre-operative discussions about HRT. 
 
Likewise, when considering information sources prior to surgery, there is no 
difference seen between units. Question 3 asked “who mentioned HRT before the 
operation?” 7.4% of women could not remember, 44.9% said that the hospital doctor 
had mentioned it, and only 16.9 % responded that their GP had counselled them. 
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However, 30.9% said that both the GP and the hospital doctor had discussed it with 
them. When this is examined in terms of unit attended, there is no difference between 
HA and HB. Although it would seem that HB GPs have a slightly higher proportion 
(21.8%) of their patients recalling a discussion prior to surgery compared with 13.6% 
for their HA counterparts, this difference is reduced if the number of women recalling 
GP input together with hospital doctor input is added together. 
  
The questionnaire also asks whether or not symptoms of the menopause were 
mentioned and specifically if the benefits and side-effects associated with taking HRT 
were discussed (questions 4 and 5). When considering whether symptoms and 
benefits were mentioned, 66.7% of women recalled being told about the relief of 
menopausal symptoms (Table 4.15). 62.9% of women remember being told about 
osteoporosis prevention, (Table 4.16). 25.3% say they recall a discussion on 
cardiovascular protection (Table 4.17). Only 17.7% say that no benefits were 
mentioned.  
 
When the units are compared, HA significantly tells more women about the 
symptoms of the menopause than does HB. Nearly three-quarters (73.6%) of HA 
patients recall the conversation, compared with 56.6% of HB patients (Table 4.15). 
This difference is seen again when considering whether osteoporosis prevention is 
mentioned (Table 4.16), and also if beneficial effects on the cardiovascular system are 
discussed (Table 4.17). The number of women being told about the possible beneficial 
effect of HRT on heart disease is much smaller than the numbers told of other 
benefits. This is presumably because that claim was disputed in the literature, and is 
now not thought to be of benefit.  The number of women who state that they were not 
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told of any benefits of HRT is 11.8% of HA patients, and 26.3% of HB patients; this 
is also significant (Table 4.18). 
 
There seems to be a difference then, between the two hospitals, in the amount of 
information being given to women regarding the benefits of HRT. HA provides 
information about the benefits of HRT to more women. The accuracy of data 
produced by recall however needs careful consideration.  
 
 
Table 4.15 Frequency of recalled discussion about menopausal symptoms by location 
of treatment. 
 
  HB 
n          % 
HA 
n           % 
Total 
n           % 
Menopausal 
symptoms 
mentioned 
 
Not mentioned 
 
 
Yes, 
mentioned 
 
 
33     (43.4)  
 
 
43      (56.6)  
 
29      (26.4)  
 
 
81       (73.6)  
 
62     (33.3)  
 
 
124     (66.7)  
Total 
 
 
 
 
 
76       (100)  
 
 
110     (100)  
 
186    (100) 
-square 5.885 
p < .05 
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Table 4.16 Frequency of recalled discussion about osteoporosis by location of 
treatment. 
  
 
  HB 
n            % 
HA 
n           % 
Total 
n       % 
Osteoporosis 
mentioned 
 
Not mentioned 
 
 
Yes, 
mentioned 
 
 
38       (50.0)  
 
 
38       (50.0)  
 
31       (28.2)  
 
 
79        (71.8) 
 
69     (37.1)  
 
 
117   (62.9)  
Total 
 
 
  
76       (100)  
 
110     (100)  
 
186      (100)  
-square 9.169 
p < .01 
 
 
 
 
Table 4.17 Frequency of recalled discussion about heart disease by location of 
treatment. 
 
 
  HB 
n           % 
HA 
n          % 
Total 
n         % 
Prevents heart 
disease 
 
Not mentioned 
 
 
Yes, 
mentioned 
 
 
63      (82.9)   
 
 
13       (17.1)  
 
76     (69.1)  
 
 
34    (30.9)  
 
139    (74.7)  
 
 
47      (25.3)  
Total 
 
 
  
76      (100)  
 
110   (100)  
 
186    (100)  
-square 4.535 
p < .05 
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Table 4.18 Frequency of no benefits of HRT being recalled by location of treatment. 
 
 
 
  HB 
n        % 
HA 
n          % 
Total 
n          % 
No benefits 
mentioned 
 
Benefits were  
mentioned 
 
 
Benefits were  
not mentioned 
 
 
56     (73.7)  
 
 
 
20      (26.3)  
 
97     (88.2)  
 
 
 
13      (11.8)  
 
153     (82.3)  
 
 
 
33      (17.7)  
Total 
 
 
  
76     (100)  
 
110    (100)  
 
186  (100) 
-square 6.473 
p < .05 
 
 
Associated risks and side-effects of any medicine need careful consideration when a 
patient and her doctor are discussing long- term prescription. A total of 181 women 
answered the question about side-effects (9 cases were missing). It would seem that 
discussing risks is not done as effectively as discussing benefits. Table 4.19 shows 
65.2% of all patients responded that no side effects of HRT were discussed with them. 
 
Table 4.19 Frequency of side-effects not being discussed by location of treatment. 
 
  HB 
n          % 
HA 
n           % 
Total 
n          % 
Side effects 
mentioned  
or 
NOT 
mentioned. 
 
 Side effects 
mentioned  
 
Side effects 
not mentioned 
 
 
20      (27.8)  
 
 
52       (72.2)  
 
43      (39.4) 
 
 
66       (60.6)  
 
63      (34.8)  
 
 
118   (65.2)  
Total 
 
 
  
72     (100)  
 
109     (100)  
 
181   (100) 
-square 2.603 
p = 0.114 
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Specifically, when asked if an increased risk of breast cancer was discussed, 69.1% of 
all patients answered negatively (Table 4.20). Meanwhile, Table 4.21 shows that 
87.8% of all patients do not recall being told about increased risk of blood clots 
(DVT). 
 
 
Table 4.20 Frequency of cancer risk being discussed by location of treatment. 
 
  HB 
n          % 
HA 
n            % 
Total 
n           % 
Cancer side-
effect 
mentioned 
 
Not mentioned 
 
 
Yes, 
mentioned 
 
 
53      (73.6)  
 
 
19       (26.4)  
 
72     (66.1)  
 
 
37      (33.9)  
 
125    (69.1) 
 
 
56       (30.9)  
Total 
 
 
  
72       (100)  
 
109      (100) 
 
181    (100) 
-square 1.159 
p = 0.326 
 
 
 
Table 4.21 Frequency of DVT risk being discussed by location of treatment 
 
  HB HA Total 
DVT risk 
discussed 
Not discussed 
n 
% within unit 
 
Yes, discussed  
n 
% within unit 
 
65 
90.3 
 
 
7 
9.7 
 
94 
86.2 
 
 
15 
13.8 
 
159 
87.8 
 
 
22 
12.2 
Total n  
% within unit 
72 
100 
109 
100 
181 
100 
-square .663 
p = 0.491 
 
It is clear that there is no difference between the individual units when discussing the 
possible side effects of HRT.  
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There is also no statistical difference seen between HB patients and HA patients in 
terms of where their information comes from - whether nurse, doctor or HRT 
pamphlet, (Tables 4.22, 4.23 and 4.24.) The nurses in HA are cited as a source of 
information more often than nurses in HB, but not significantly. 
 
Table 4.22 Frequency of nurse cited as information source by location of treatment 
 
 
  Nurse not 
mentioned as 
source 
n           % 
Nurse 
mentioned as 
source 
n          % 
Total 
 
 
N           % 
UNIT  
HB 
 
 
HA 
 
 
45        (63.4)  
 
 
53         (54.6)  
 
26       (36.6)  
 
 
44       (45.4)  
 
71       (100)  
 
 
97       (100)  
Total 
 
 98          (58.3) 70      (41.7) 168     (100) 
-square 1.289 
p = 0.272 
 
 
 
Table 4.23 Frequency of doctor cited as information source by location of treatment. 
 
  Doctor not 
mentioned as 
source 
n          % 
Doctor 
mentioned as 
source 
n            % 
Total 
 
 
n            % 
UNIT  
HB 
 
HA 
 
 
49       (69.0)  
 
66        (68.0)  
 
22       (31.0) 
 
31       (32.0) 
 
71       (100)  
 
97       (100)  
Total 
 
 
  
115      (68.5) 
 
53        (31.5)  
 
168     (100)  
-square .018  
p = 1.000 
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Table 4.24 Frequency of pamphlet cited as information source by location of 
treatment. 
 
 
 
  Pamphlet not 
mentioned as 
source  
n            % 
Pamphlet 
mentioned as 
source 
n           % 
Total 
 
 
n      % 
UNIT  
HB 
 
 
HA 
 
 
 
44        (62.0)  
 
 
62        (63.9)  
 
27      (38.0)  
 
 
35      (36.1)  
 
71     (100)  
 
 
97      (100)  
Total 
 
 
  
106       (63.1)  
 
62       (36.9)  
 
168    (100)  
-square .067 
p = 0.872 
 
 
 
 
4.3.2 Does the unit attended for treatment affect the uptake of HRT? 
Moving on from the pre-operative consultation, the next two questions were designed 
to ascertain how many women leave hospital with a prescription for HRT. 187 women 
answered the question “were you offered HRT in hospital before you went home?” 
89.3% said that they were, and 10.7% said that they were not. 
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Table 4.25 Frequency of HRT offered in hospital by location of treatment. 
 
 
  HB 
n         % 
HA 
n          % 
Total 
n         % 
HRT offered in 
hospital 
 
Not offered 
 
 
Yes, offered 
 
 
7       (9.5)  
 
 
67     (90.5) 
 
13      (11.5) 
 
 
100      (88.5)  
 
20    (10.7)  
 
 
167    (89.3)  
Total 
 
 
  
74      (100)  
 
113     (100)  
 
187   (100)  
-square .196 
p = 0.810 
 
 
It would be usual practice to commence HRT in the early post- operative phase, 
providing no contraindications to such therapy had been found at the time of surgery. 
This is reflected in the figures above (Table 4.25). 
 
Only 167 women answered the question as to whether they accepted that offer of 
HRT in hospital. This is because 20 cases had previously said that they had not been 
offered HRT and therefore the question was not applicable to them. 98.2% of 167 
women accepted the offer of HRT (Table 4.26). 
 
Table 4.26 Overall frequency of HRT acceptance whilst in hospital.  
 
Accept HRT in hospital?
3 1.6 1.8 1.8
164 86.3 98.2 100.0
167 87.9 100.0
20 10.5
3 1.6
23 12.1
190 100.0
No
Yes
Total
Valid
N/A
System
Total
Missing
Total
Frequency Percent Valid Percent
Cumulative
Percent
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HA and HB have similar percentages of women offered HRT whilst in hospital (Table 
4.25), and of those who accept that offer (Table 4.27). Therefore it can be said that 
although women perhaps do not have an exhaustive explanation of the risk-benefit 
ratio of HRT prescription given by their Gynaecologist, the vast majority are content 
to commence therapy after their hysterectomy. 
 
 
 
 
 
Table 4.27 Frequency of HRT acceptance whilst in hospital by location of treatment. 
 
  HB 
n            %  
HA 
n           % 
Total 
n      % 
Accept HRT in 
hospital 
 
No  
 
 
Yes 
 
 
2         (3.0)  
 
 
65       (97.0)  
 
1         (1.0)  
 
 
99        (99.0)  
 
3      (1.8)  
 
 
164   (98.2)  
Total 
 
 
  
67      (100)  
 
100      (100)  
 
167   (100)  
-square .896 
p = 0.565 
 
 
Of the 163 women who responded to question 8, which asks about further discussion 
with the GP, 74.8% discussed HRT with their GP when their hospital prescription 
required renewing. Patients are encouraged to do this. The first form of medication 
may not be the most suitable, and another preparation may be more appropriate, or 
there may be transient side-effects, which will settle with perseverance. There is no 
association between which unit the operation took place in, and whether or not these 
women were more or less likely to speak to their GP (Table 4.28). 
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Table 4.28 Frequency of subsequent GP HRT discussions by location of treatment, if 
hospital had provided HRT.  
 
 
 
 
  FDRI  
n         % 
SRI 
n       % 
Total 
 n        % 
Discuss with 
GP if hospital 
provided 
 
No 
 
 
Yes 
 
 
18     (27.7)  
 
 
47      (72.3)  
 
23     (23.5)  
 
 
75     (76.5)  
 
41    (25.2)  
 
 
122    (74.8)  
Total 
 
 
  
65      (100)  
 
98     (100)  
 
163   (100)  
-square .370 
p = 0.583 
 
 
 
Twenty-four women did not have HRT prescribed in hospital. Nearly all these women 
discussed HRT with their GP after discharge from hospital (Table 4.29). All but one 
of them subsequently had it prescribed by their GP (Table 4.30). Where the operation 
took place has no effect on this, and GP‟s referring to HA, are just as likely to discuss 
HRT, and prescribe it for these women, as their HB counterparts (Table 4.29 and 
Table 4.30). 
 
 
 
 
 
 168 
Table 4.29 Frequency of subsequent GP HRT discussions by location of treatment, if 
hospital had not provided HRT 
 
  HB 
n         % 
HA 
n         % 
Total 
 n          % 
Discuss with 
GP if hospital 
did not provide 
 
No 
 
 
Yes  
 
 
 
2       (20.0)  
 
 
8       (80.0)  
 
 
 
0        (0.0)  
 
 
14       (100)  
 
2        (8.3)  
 
 
22       (91.7)  
Total   
10    (100)  
 
14     (100)  
 
24     (100)  
-square 3.055 
p = 0.163 
 
Table 4.30 Frequency of GP prescribed HRT by location of treatment.  
 
 
  HB 
n        %   
HA 
n          % 
Total 
n         % 
GP prescribed 
if hospital did 
not prescribe 
 
No 
 
 
Yes 
 
 
0       (0)          
 
 
10     (100)  
 
1         (7.1)  
 
 
13       (92.9)  
 
1        (4.2)  
 
 
23      (95.8)  
 
Total   
10      (100)  
 
14      (100)  
 
24      (100)  
-square .745 
p = 1.0 
 
 
As would be expected then, the majority of women in the study left hospital with a 
prescription for HRT. Those women who did not subsequently consulted their GP, 
who then prescribed it for almost all of them. This may be explained in that on 
occasion it is necessary to wait for definitive histology results before prescribing 
HRT.  Once these are known, and HRT can be safely prescribed, the patient may 
already be at home and in the care of her GP. 
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4.3.3 Does the individual consultant in charge of care affect HRT use? 
It may be assumed that different consultant Gynaecologists have different views when 
deciding at what age a hysterectomy is the treatment suitable for their patient. The age 
of the patient will affect HRT use. From the data collected, it appears that the average 
age at operation does vary between consultants. 
 
Using data from the achieved sample, two consultants appear to operate on slightly 
younger women. Consultant H operates on women with an average age of 42.58 years 
and Consultant D on women with an average age of 42.44years. Other consultants 
operate on women at an average age of between 43.00 years and 46.80 years (Table 
4.31).  
Table 4.31 Mean patient age at time of operation by consultant. 
 
Consultant Mean Age n Std.Deviation 
A 
B 
C 
D 
E 
F 
G 
H 
I 
J 
Other 
45.05 
43.35 
46.8 
42.44 
46.67 
43.00 
45.71 
42.58 
43.64 
43.92 
44.21 
43.92 
20 
20 
5 
16 
12 
4 
21 
52 
14 
12 
14 
190 
4.019 
4.522 
2.280 
3.076 
3.774 
4.320 
3.481 
5.203 
4.088 
3.579 
5.409 
4.484 
 
 
 
Table 4.32 illustrates that consultant H operates at a significantly younger age than do 
his colleagues. 
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Table 4.32 Mean age at time of operation of patients treated by consultant H, 
compared to patients treated by other consultants. 
 
  n Mean age Std. Deviation 
Age of patient 
at operation 
 
 
Consultant H 
 
All others 
52 
 
138 
42.58 
 
44.42 
5.203 
 
4.088 
t-value -2.564 
p < .05  
 
 
When consultant H and consultant D are compared (together) against their colleagues, 
the difference becomes even more significant (p< .001). The mean age of their 
patients at operation is 42.54 years compared to the mean age of their colleagues‟ 
patients is 44.68 years (Table 4.33). 
 
Table 4.33 Mean age at time of operation of patients treated by consultants H and D 
combined, compared to patients treated by other consultants. 
 
 
  n Mean Std. Deviation 
Age of patient 
at operation 
Consultants H 
and D 
 
All others 
68 
 
 
122 
42.54 
 
 
44.68 
4.768 
 
 
4.143 
t-value -3.226 
p < .001 
 
When the target population (n=306) is examined in Table 34, the same trend is seen, 
suggesting that this is a real phenomenon, not just an artefact of the achieved sample. 
Consultant‟s D and H together operated on 127 women with an average age of 42.67 
years, which is significantly younger than the women treated by the other consultants. 
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Table 4.34 Mean age at time of operation of patients in the target sample treated by 
consultants H and D combined, compared to patients treated by other consultants. 
 
 
  n Mean Std Deviation 
Age of patient 
at operation 
Consultants H 
and D 
 
All others 
127 
 
 
179 
42.67 
 
 
44.08 
4.590 
 
 
4.672 
t-value -2.618 
p < .01 
 
 
It is of note that one of these consultants worked in HA and the other in HB; thus both 
hospitals had one consultant operating on slightly younger women. It is also 
interesting that this finding appears to be linked personally with these two consultants, 
and is not based on their gender. 
 
Looking again at the target population (n = 284, because 22 procedures were 
performed by locum consultants whose gender is not known), it was found that male 
consultants operate on women with an average age of 43.49 years. Their female 
colleagues operate at an average age of 43.6 years, a difference that is not statistically 
significant. The average age of patients undergoing hysterectomy who returned their 
questionnaires is slightly older. For those in the care of male consultants the mean is 
43.57 years, and for those in the care of female consultant gynaecologists the mean is 
44.77 years. This is also not a statistically significant difference. So it is the individual 
consultant gynaecologist, rather than the gender of the gynaecologist, that appears to 
be associated with the age of the patient at time of operation. 
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 The source of any information given to patients will probably have an effect on how 
well that information is understood and remembered. It is still probably true to say 
that many patients are happy to comply with treatment, purely on the basis that it is 
what is recommended by their doctor. There has been much discussion in the press 
concerning the safety of HRT in recent years. This has made women more aware of 
the possible side–effects of treatment and the new advice given to women in terms of 
how long treatment should continue. The women in this study were treated before the 
results of the American Women‟s Health Initiative were published in the national 
press, and therefore their responses may not reflect the impact of these findings.  
 
When asked “who” or “what” was the major source of information regarding the 
taking of HRT, 182 women responded. 30.8% of women said that the doctor was their 
main source of information in hospital, whilst 31.9% chose the nurse and 28% the 
HRT pamphlet. Combinations of doctor-plus-pamphlet and nurse-plus-pamphlet 
account for the remaining 9.3% of cases. It has to be said, at this point, that although 
respondents were asked to choose just one source, the answers obtained often 
included more than one choice. The data has been analysed accordingly. If a 
respondent had indicated that the source of information was both the doctor and a 
pamphlet, then the answer was included in both categories.  
   
When the doctor, nurse and HRT pamphlet input are considered in terms of a 
collective approach, then the figures change slightly. Looking at whether the doctor is 
mentioned as a source of information, either alone or in conjunction with the other 
sources, then 34.6% of women respond in the affirmative (Table 4.35). 39% of 
women recall the nurses, either alone or with other sources, as the supplier of 
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information (Table 4.36) and 36.8% remember an HRT pamphlet (Table 4.37). It is 
clear, then, that nurses are an important source of information, and that information 
pamphlets are useful. 
 
When individual consultants are considered in relation to which sources of 
information their patients cite, some individual differences emerge. The number of 
patients recalling the doctor as a source of HRT information ranges from just 9.1% to 
60%. Only 9.1% of Consultant E‟s patients mention the doctor as a source (Table 
4.35), but 90.9% of these same patients say that they obtained information from an 
HRT pamphlet (Table 4.37). Consultant C mentions HRT to 60% (Table 4.35) of 
patients and none of these patients cite a pamphlet as a source of information. 
However, 40% mention the nurse as a source (Table 4.36). Twenty-five percent of 
consultant F‟s patients mention the doctor as a source, 50% mention the nurse, and 
25% the HRT pamphlet. Consultant G‟s patients recall the nurse as the main source of 
information  (61.9%), while 19% mention the doctor and 28.6% the pamphlet. 
Likewise 63.6% of patients under the care of consultant J also mention the nurse. The 
women in the care of consultant H obtain information from all three sources in 
roughly the same proportions, doctor 38%, nurse 38% and HRT pamphlet 36%. The 
use of the HRT pamphlet as a source of information is shown to be significantly 
different by consultant (Table 4.37), whereas whether or not the doctor or the nurse is 
mentioned displays individual differences but no statistical difference. So some 
consultants use pamphlets more than others to relay information to their patients, 
again displaying differences of an individual nature. 
 
 
 174 
Table 4.35 Frequency of doctor cited as source of HRT information by consultant 
providing care. 
 
 
Consultant Doctor not cited 
n              % 
Doctor  cited 
n                % 
Total 
n            % 
  
 A                    
 
 B                    
     
 C 
 
 D      
  
 E                 
     
 F                    
     
 G                   
 
 H                   
 
 I  
                    
 J                   
   
 Other            
     
 
14        (73.7)  
 
12        (66.7)  
 
2         (40.0)  
 
9          (60.0)  
 
10        (90.9)  
 
3           (75.0)  
 
17         (81.0)  
 
31         (62.0)  
 
9            (64.3)  
 
8           (72.7)  
 
4            (28.6)  
 
5              (26.3)  
 
6              (33.3)  
 
3              (60.0)  
 
6             (40.0)  
 
1              (9.1)  
 
1             (25.0)  
 
4             (19.0)  
 
19            (38.0)  
 
5              (35.7)  
 
3              (27.3)  
 
10            (71.4)  
 
19        (100)  
 
18        (100)  
 
5          (100)  
 
15        (100)  
 
11        (100)  
 
4           (100)  
 
21         (100)  
 
50         (100)  
 
14         (100)  
 
11         (100)  
 
14         (100)  
Total 
 
119        (65.4)  63            (34.6)  182       (100)  
 -square 16.691 
p = 0.081 
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Table 4.36 Frequency of nurse cited as source of HRT information by consultant 
providing care.  
 
 
Consultant Nurse not cited 
n              % 
Nurse cited 
n                % 
Total 
n           % 
 
A                  
          
B 
    
C                    
     
D                    
 
E                    
     
F                    
 
G                   
 
H                   
     
I                     
     
J                     
 
Other            
     
 
10          (52.6)  
 
12          (66.7)  
 
3            (60.0)  
 
11          (73.3)  
 
8            (72.7)  
 
2            (50.0)  
 
8            (38.1)  
 
31          (62.0)  
 
9             (64.3)  
 
4             (36.4)  
 
13           (92.9)  
 
9              (47.4)  
 
6               (33.3)  
 
2               (40.0)  
 
4               (26.7)  
 
3               (27.3)  
 
2               (50.0)  
 
13             (61.9)  
 
19             (38.0)  
 
5                (35.7)  
 
7                (63.6)  
 
1                 (7.1)  
 
 
19         (100)  
 
18         (100)  
 
5           (100)  
 
15         (100)  
 
11         (100)  
 
4           (100)  
 
21         (100)  
 
50        (100)  
 
14        (100)  
 
11        (100)  
 
14        (100)  
Total              
    % within consult 
 
111         (61.0)  
 
71             (39.0)  
 
182      (100)  
 -square 16.096 
p = 0.097 
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Table 4.37 Frequency of pamphlet cited as source of HRT information by consultant 
providing care. 
 
 
Consultant Pamphlet not cited 
n              % 
Pamphlet cited 
n               % 
Total 
n              % 
 
A                    
                 
B                    
        
C                    
 
D                    
 
E                    
     
F                    
     
G                   
     
H                   
     
I                     
 
J  
                    
Other            
     
 
14          (73.7)  
 
11          (61.1) 
 
5            (100)  
 
10          (66.7)  
 
1             (9.1)    
 
3            (75.0)  
 
15          (71.4)  
 
32          (64.0)  
 
8            (57.1)  
 
7           (63.6)  
 
9           (64.3)  
 
 
26.3% (5) 
 
38.9% (7) 
 
0.0% (0) 
 
33.3% (5) 
 
90.0% (10) 
 
25.0% (1) 
 
28.6% (6) 
 
36.0% (18) 
 
42.9% (6) 
 
36.4% (4) 
 
35.7% (5) 
 
 
19         (100) 
 
18         (100)  
 
5           (100)  
 
15         (100)  
 
11         (100) 
 
4           (100)  
 
21         (100)  
 
50         (100)  
 
14         (100)  
 
11         (100)  
 
14         (100)  
 
 
Total              
     
 
115        (63.2)  
 
36.8% (67) 
 
182     (100)  
 -square 18.859 
p < . 05 
 
If the individual consultants are considered in terms of whether their patients recall 
being told about HRT prior to surgery, individual differences are seen. There is a 
range of between 60.0% and 100% of patients confirming that pre-operative 
discussions about HRT took place. Some consultants seem to be most effective in 
giving this information, with an overall total of 70.1% of all patients recalling these 
discussions. However there is no statistical evidence to suggest that some consultants 
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are better than others at delivering information, or that their patients are better than 
others at recalling such information are. Likewise, there is no statistical difference 
between individual consultants in the length of time their patients expect HRT 
treatment to last. 
 
It would seem, then, that there are some differences in how different consultants relay 
information to their patients - or at least how it is recalled by their patients - but that 
whatever strategies are used they are equally effective.  
 
4.3.4 Does the gender of the consultant in charge of care influence HRT use? 
If the consultants are divided by gender, it is seen that male consultants operated on 
125 patients whilst the female consultants operated on 45 patients. 14 cases were lost 
for statistical analysis, as locum consultants whose gender could not be determined 
had performed the operations. There is no association between the gender of 
consultant and whether or not they discussed HRT prior to surgery. 66.4% of male 
consultants and 75.6% of female consultants have this conversation with their patients 
but the difference is not significant. Therefore, neither the different consultants nor 
the gender of the consultant affects whether or not HRT is mentioned prior to surgery. 
As stated previously gender is not implicated in the slightly earlier age at which two 
consultants operate. 
 
There is also no association between the gender of the consultant seen in hospital and 
whether or not the patient recalls who, out of a choice of hospital doctor, GP or both, 
provided a pre-operative discussion about HRT (there is no data collected on the 
gender of the G.P consulted). 
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When the gender of the individual consultant is considered, it is seen that there is no 
association with whether or not the patient is told about symptoms of the menopause 
or about osteoporosis prevention. Likewise, the gender of the individual consultant 
seen is not associated with whether or nor cancer risk is discussed or if DVT risk is 
mentioned. The figurers for no side effects being mentioned are identical for both 
male and female consultants at 65.9%. 
  
If, as reported by Hall and Roter (1988), the recall of information by patients is 
associated with female physicians, then the gender of the consultant may affect the 
way that information is given to patients. This does not appear to be the case in the 
present study. Of the 168 valid responses (14 cases removed as gender of consultant 
not known) 32.5% of women in the care of male consultants and 28.9% of women in 
the care of female consultants, cited the doctor as a source of HRT information. The 
number of women citing the nurse as a source of information is equally close, with 
41.5% of the male consultants‟ patients and 42.2% of the female consultants‟ patients 
responding in this way. It appears that the female consultants use an HRT pamphlet 
more often than their male colleagues. Nearly forty- seven percent ( 46.7%) of women 
in the care of a female consultant mentioned an HRT pamphlet as a source compared 
with 33.3% of those women cared for by a male consultant. This however is not 
statistically significant. 
 
The gender of the hospital consultant is not associated with whether or not a woman is 
offered HRT whilst in hospital, or whether the offer is accepted. Nor is it associated 
with the length of time women expected to take HRT for. Likewise, the patients of 
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female consultants are no more likely than those of male consultants, to discuss HRT 
with their GP when their prescription needed renewal. Of the small number of women 
who did not have HRT commenced in hospital (n =24), most, as previously 
mentioned, had it prescribed by their GP. This prescribing is not influenced by the 
gender of the consultant in charge of their hospital patient care.  There is no 
association between the gender of consultant and whether or not this particular group 
of women speak to their GPs.  
 
 We have examined the data collected in this study, in terms of “ outside influences” 
on women‟s HRT decisions. That is to say how the individual consultant or unit 
attended might affect patient choice. We now consider the possible inherent 
differences in the women in the study in terms of age and previous HRT experience. 
 
 4.4 How do inherent differences in the study population, in terms of patient age 
and prior use of HRT, affect HRT use after hysterectomy? 
 4.4.1 Age at time of operation 
The mean age at the time of operation is 43.92 years, the youngest woman being 28 
years old and the eldest woman 51 years old (the upper age limit for the study). 
It can be seen in figure 3 below, that the age of operation increases gradually, peaking 
at age 45, then declining to 51 years. This would be expected, as surgeons would be 
reluctant to perform this operation in younger women without very specific reason. 
Most women will have completed their families by their 40s and be entering the 
perimenopausal phase of their lives by their late 40s. It would be reasonable to 
suggest that women in their mid-to-late 40s who experienced menorrhagia would be 
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suitable for hysterectomy, and would therefore choose this option with the support of 
their Gynaecologist. 
 
 Figure 4.3 Frequency distribution of patient age at time of operation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There is little difference between the mean ages at operation between the two units. 
The average age at operation in HA cases 43.65 years, and in HB cases 44.32 years. 
This is not significant.  
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The age of the patient is not associated with the source of their information. No age 
differences are found, in the use of doctor, nurse or HRT pamphlet.  
 
Part of the discussion surrounding HRT prescription is the length of time the patient 
should expect to take the preparation for. 183 women answered the relevant question. 
The majority of women, 112 cases, expected to take HRT for more than 7 years 
(Table 4.38). This is linked to the age of the women at the time of their operation and, 
as expected, the younger women expected to take HRT for a longer time (Table 4.39). 
 
 
Table 4.38 Expected duration of HRT use 
 
How long 
expect to take 
HRT  
 
Frequency Percent Valid percent 
Less than 1 yr 
1-5 years 
5-7 years 
More than 7 yr 
Total 
Missing 
Total 
5 
35 
31 
112 
183 
7 
190 
2.6 
18.4 
16.3 
58.9 
96.3 
3.7 
100.0 
2.7 
19.1 
16.9 
61.2 
100.0 
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Table 4.39 Increasing expected duration of HRT use and decreasing mean age of 
women at time of operation. 
  
 
How long expect to 
take HRT 
Mean age at 
operation 
n Std.Deviation 
Less than 1 yr 
1-5 yrs 
5-7yrs 
More than 7 yrs 
Total 
46.60 
45.17 
44.97 
42.95 
43.81 
5 
35 
31 
112 
183 
2.702 
3.374 
4.363 
4.717 
4.500 
 
 
If the women are divided into two groups, those who expect to take HRT for up to 7 
years (mean age 45.18), and those who expect to take for more than 7 years (mean age 
42.95), a statistical difference in the mean age is found. In both groups, the taking of 
HRT for the expected time would take the patient up to around the natural age of 
menopause at 51 years (Table 4.40). 
 
Table 4.40 Mean age of women taking HRT for up to 7 years and for more than 7 
years. 
 
 
How long expect to 
take HRT 
n Mean age at 
operation 
Std.Deviation 
Up to 7 years 
More than 7 years 
71 
112 
45.18 
42.95 
3.777 
4.717 
t-value 3.368 
p < .001 
 
There is no evidence that women having their operations in the later 1990s/2000 
expected to take HRT for a shorter duration, which would be a predicted result as 
these women were treated prior to the publication of the Women‟s Health Initiative 
study. 
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It may be expected that, if a woman had taken HRT prior to her operation, this may 
influence her response when asked how long she expected to take it for. Table 4.41 
shows that women who take HRT prior to surgery are significantly older than women 
who do not. 
 
 
Table 4.41 Mean age at time of operation of women who have taken HRT prior to 
surgery and those who have not.  
 
 
Age at operation n Mean age at 
operation 
Std.Deviation 
 
Taken HRT before 
operation 
 
Not taken HRT 
before operation 
 
 
31 
 
 
157 
 
46.13 
 
 
43.50 
 
3.649 
 
 
4.533 
t-value 3.035 
p <. 01 
 
One would assume that, as older women, the pre-operative users should expect to take 
HRT for a shorter time. This, however, does not seem to be the case. The data shows 
that the majority (67.9%) of those women who had taken HRT before their operation 
still expect to take it for more than 7 years. This is not statistically significant because 
59.7% of women who had not taken HRT prior to surgery also expected to take HRT 
for more than 7 years, (Table 4.42). 
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Table 4.42 Cross tabulation of expected duration of HRT use of up to, or beyond 7 
years and prior use of HRT.  
 
 
Expected duration 
of HRT use 
Not taken HRT 
before operation 
n               %  
Taken HRT before 
operation 
n                % 
Total 
 
n             % 
 
Up to 7 years 
 
More than 7 years 
 
 
 
62           (40.3)  
 
92           (59.7)  
 
 
 
9               (32.1)  
19             (67.9)  
 
71         (39.0)  
 
111       (61.0)  
Total 
 
 
154           (100)  
 
28              (100)  
 
182       (100)  
 -square .656  
p = 0.529 
 
 
The purpose of question 12 in the questionnaire was to determine for how long after 
their operation the women expected to take HRT. It is possible that this question was 
not sufficiently clearly specified, and therefore difficult to interpret. It is also possible 
that, at the time of this study, women were actually expecting to take post-operative 
HRT for a longer duration than is now currently recommended, regardless of their 
age.    
 
4.4.2 Prior use of HRT and duration of therapy 
Most women have not taken HRT prior to their operation (83.1%). Of those 16.9% 
who have taken HRT before, most are over 45 years old. Only 8.4% of women aged 
up to 44 years had taken HRT before, while 23.6% of women aged 45 years and older 
had done so. Table 4.43 again demonstrates a relationship between increasing age and 
pre-operative HRT use, which is expected. 
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Table 4.43 Cross tabulation of age band up to 44yrs and over 45 yrs with prior use of 
HRT.   
 
 
Age band at 
operation 
Not taken HRT 
before operation 
n              % 
Taken HRT before 
operation 
n              % 
Total 
 
n              % 
 
Up to 44 years 
 
45 years plus  
 
 
76           (91.6) 
 
81           (76.4)  
 
7             (8.4)  
 
25           (23.6) 
 
 83     (100) 
 
106    (100) 
Total 
 
 
157          (83.1)  
 
 
32           (16.9) 
 
 
189     (100) 
 -square 7.598 
p < .01 
 
There is little association between prior HRT use and women‟s expected duration of 
use. Of those aged under 45 years who had not taken HRT before, 72.4% expected to 
take HRT for more than 7 years, while only 47.4% of the over 45 year-olds did. 
Similarly 83.3% of the younger women who had taken HRT prior to surgery expected 
to take HRT for more than 7 years. This confirms that younger women expect to take 
therapy for longer. However, 63.6% of those women who had taken HRT prior to 
surgery and were over 45 years old also expected to take HRT for over 7 years (Table 
4.44), perhaps reflecting the longer use of HRT recommended by doctors at the time 
of these operations. 
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Table 4.44 Cross tabulation of age band, and pre-operative HRT use with 
 expected duration of post-operative HRT. 
 
  
Taken HRT 
before 
Expect to 
take < 1 yr 
n         % 
Expect to 
take 1-5 yrs 
n          % 
Expect to 
take 5-7 yrs 
n         % 
Expect to 
take > 7 yrs 
n          % 
Total 
 
n         % 
 No  
 
Up to 44 
 
 
45 plus 
 
 
 
1        (1.3)  
 
 
2        (2.6)  
 
 
 
10     (13.2)  
 
 
21      (26.9)  
 
 
10    (13.2)  
 
 
18    (23.1)  
 
 
 
55     (72.4)  
 
 
37     (47.4)  
 
 
76    (100) 
 
 
78     (100)  
Total 
 
 
3       (1.9)  
 
31      (20.1)  
 
28    (18.2)  
 
92     (59.7)  
 
154   (100)  
Yes 
 
Up to 44 
 
 
45 plus 
 
 
 
 
0        (0)  
 
 
2        (9.1)  
 
 
1       (16.7)  
 
 
3       (13.6)  
 
 
0        (0)  
 
 
3       (13.6)  
 
 
 
5     (83.3)  
 
 
14    (63.6) 
 
 
6       (100)  
 
 
22      (100)  
Total  
 
 
2       (7.1)  
 
4      (14.3)  
 
3      (10.7) 
 
19    (67.9)  
 
28     (100)  
 
HRT before No  -square 10.020  p < .05 
HRT before Yes  -square 1.663  p = 0 .645 
The findings above perhaps give evidence of a flawed question, compounded by the 
small case numbers in the study. It is impossible to know whether the older pre-
operative users actually did expect to take HRT well into their fifties, or whether they 
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have added their preoperative treatment time into their calculated expectation of 
therapy duration. Today, it would be expected that the older women would anticipate 
a shorter time of HRT therapy after their operation; but this is not seen in this study. 
 
In general, most of the women in this study expect to take HRT for more than 7 years, 
which may be a reflection of the advice they received at the time of their surgery. As 
previously mentioned, neither the individual consultant who cares for them nor the 
gender of that consultant, influences this.  
  
Of the 32 women who had taken HRT before their operation, only 30 disclosed the 
length of time they had taken it for. The time taken ranges from 2 to144 months. 
86.7% of women had taken it for 45 months or less. The ages of the 4 women who 
had taken HRT for 5 years or longer ranged from 45 to 50 years old. The woman who 
said she had used HRT for 144 months prior to surgery was 48 years old at the time of 
operation, which means she was 36 years old at the time of commencement of 
therapy. This is unusual, in that she must have taken HRT for some twelve years pre-
operatively, and then had a hysterectomy for menorrhagia. This may perhaps indicate 
a coding problem with the diagnosis code which defined inclusion in the study or, 
more likely, that there has been some ambiguous interpretation of the question. 
  
When asked if they were still taking HRT, 107 women  (56.3%) said that they were. 
These numbers are obviously from the returned sample and not just the women who 
had taken HRT prior to surgery. The length of time taken ranges from 18 to 192 
months. The woman who reports 192 months of therapy is the same woman who 
reported 144 months of therapy pre-operatively. Over three-quarters (77.6%) of 
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women had taken therapy for up to 10 years. This is probably a reflection on the 
timing of this investigation. 
 
When the source of the prescription is analysed, it is seen that the hospital prescribed 
medication is taken for an average of 88.46 months, whilst the GP-prescribed HRT 
averages 101.55 months. This is not a significant difference, and the numbers of GP- 
prescribed first prescriptions is small (n = 11). Although it would seem that primary 
care medication is taken for longer duration this can be explained: it is the primary 
care prescriber who manages the patient once she is no longer under the care of the 
hospital consultant. 
 
4.4.3 Does taking HRT prior to operation affect the recollection of HRT 
discussions at time of hysterectomy?  
It might be supposed that, had a woman taken HRT before her surgery, she would 
recall the earlier consultation concerning this prescription more fully than the 
discussions in hospital post-operatively. The discussions with women who have 
previously taken HRT concern the difference in preparation required after 
oophorectomy, rather than detailing of risks and benefits. The side-effects of 
treatment should have been detailed in previous consultations. Of the 20 women who 
said that they were not offered HRT while in hospital only 6 (30%) had taken HRT 
prior to their surgery. HRT taking prior to surgery does not negatively influence the 
offer of HRT post-operatively (Table 4.45). There must be some other explanation for 
why these women do not recall the offer or were not offered HRT whilst in hospital. 
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Table 4.45 Cross tabulation of pre-operative HRT use and recalled offer of post-
operative HRT. 
 
 
  Not taken 
before surgery 
Taken before 
surgery 
Total 
HRT offered in 
hospital 
No 
n 
% within HRT 
offered in 
hospital 
 
%within Taken 
HRT before op 
 
Yes  
n 
% within HRT 
offered in 
hospital 
 
%within Taken 
HRT before op 
 
14 
(70.0) 
 
 
 
(9.0) 
 
 
 
142 
 
(85.5) 
 
 
 
(91.0) 
 
6 
(30.0) 
 
 
 
(20.0) 
 
 
 
24 
 
(14.5) 
 
 
 
(80.0) 
 
20 
(100) 
 
 
 
(10.8) 
 
 
 
166 
 
(100) 
 
 
 
(89.2) 
Total n 
% within HRT 
offered in 
hospital 
 
% within 
Taken HRT 
before op 
156 
(83.9) 
 
 
 
(100) 
30 
(16.1) 
 
 
 
(100) 
186 
(100) 
 
 
 
(100) 
-square 3.187 
p = 0.102 
 
Of the 30 women who had used pre-operative HRT and revealed the source of their 
information about HRT, the doctor is cited as a source by 43.3% of them. The nurse 
by 33.3%, and an HRT pamphlet by 36.7%. The women who had not taken HRT prior 
to their operation surprisingly mention the doctor as a source in fewer numbers. Only 
33.1% cite the doctor as a source, 40.4% mention the nurse, and 36.4% an HRT 
pamphlet, (Tables 4.46, 4.47 and 4.48). 
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Table 4.46 Cross tabulation of pre-operative HRT use, with the doctor cited as a 
source of HRT information. 
 
Taken HRT before 
operation 
Doctor not 
mentioned 
Doctor mentioned 
as source 
Total 
No 
n 
% within taken 
before operation 
 
Yes 
n 
% within taken 
before operation 
 
101 
(66.9) 
 
 
 
17 
(56.7) 
 
50 
(33.1) 
 
 
 
13 
(43.3) 
 
151 
(100) 
 
 
 
30 
(100) 
Total 
n 
% within taken 
before operation 
 
118 
(65.2) 
 
63 
(34.8) 
 
181 
(100) 
-square 1.152 
p =0.300 
 
Table 4.47 Cross tabulation of pre-operative HRT use, with the nurse cited as a source 
of HRT information. 
 
Taken HRT before 
operation 
Nurse not 
mentioned 
Nurse mentioned as 
source 
Total 
No 
n 
% within taken 
before operation 
 
Yes 
n 
% within taken 
before operation 
 
90 
(59.6) 
 
 
 
20 
(66.7) 
 
61 
(40.4) 
 
 
 
10 
(33.3) 
 
151 
(100) 
 
 
 
30 
(100) 
Total 
n 
% within taken 
before operation 
 
110 
(60.8) 
 
71 
(39.2) 
 
181 
(100) 
-square .524 
p = 0.543 
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Table 4.48 Cross tabulation of pre-operative HRT use, with pamphlet cited as a 
source of HRT information. 
 
 
Taken HRT before 
operation 
Pamphlet not 
mentioned 
Pamphlet 
mentioned as 
source 
Total 
No 
n 
% within taken 
before operation 
 
Yes 
n 
% within taken 
before operation 
 
96 
(63.6) 
 
 
 
19 
(63.3) 
 
55 
(36.4) 
 
 
 
11 
(36.7) 
 
151 
(100) 
 
 
 
30 
(100) 
Total 
n 
% within taken 
before operation 
 
115 
(63.5) 
 
66 
(36.5) 
 
181 
(100) 
-square .001 
p  = 1.000 
Although these differences are not significant, they are interesting. It might be 
expected that women receiving HRT for the first time would have longer and more 
memorable discussions with their hospital doctor, but this does not seem to be the 
case. They do, however mention the nurse in higher numbers. It may be supposed that 
those women who had taken HRT prior to their operation would have a clearer 
understanding of the principles of HRT, having discussed this with their GP at the 
time of prescription. This may mean that they need less information, and that the 
nurse cannot give the information they need - such as preparation changes - 
adequately. Although the study questionnaire specifically asks about the source of 
information in hospital, it may be that women who take HRT prior to operation 
remember a doctor as the source, and perhaps have less recollection of where these 
discussions took place. It is clear that HRT literature is used equally by both groups of 
women.   
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In the following and final section, we will consider what the study can tell us about 
the information women receive (according to their own reports), about HRT, and the 
timing of discontinuance, together with the reasons they give for stopping treatment.  
 
4.5 Is patient information satisfactory? 
If we accept that satisfactory information received by the patient, and the confidence 
women have in the source of such information, are paramount in their decision 
making process, then it is encouraging to see that the majority of women (98.2%) 
accept HRT when it is offered in hospital (Table 4.26). However, when asked if they 
had sufficient information before leaving hospital to make their decision, only 61.1% 
of women said that they had. Of the women who chose not to accept the offer of HRT 
(only three cases), two said that they had sufficient information (Table 4.49). That 
there were so few of these women makes it difficult to draw a conclusion here; but it 
might be said that, overall, the level of satisfactory information- giving needs to be 
improved. 
Of the women who said that they did not have sufficient information, 37.4% still 
accepted HRT (61 cases). 
 
This means that over one third of hospital patients accepted a prescription for HRT 
without feeling that they had sufficient information to make such a decision. 
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Table 4.49 Cross tabulation of HRT offered in hospital with sufficient information 
given. 
 
INHOSP * Before home from hospital, enough info Crosstabulation
1 2 3
33.3% 66.7% 100.0%
61 102 163
37.4% 62.6% 100.0%
10 9 19
52.6% 47.4% 100.0%
72 113 185
38.9% 61.1% 100.0%
Count
% within INHOSP
Count
% within INHOSP
Count
% within INHOSP
Count
% within INHOSP
Offered, but not accepted
Offered and accepted
Not offered
INHOSP
Total
No Yes
Before home from
hospital, enough info
Total
 
-square 1.696 
p = 0 .428 
 
Of the women for whom the hospital did not prescribe HRT (n=24), 91.7% discussed 
HRT with their GPs, who prescribed for all but one case. Slightly more than half 
(54.5%) of these women felt that they did not have sufficient information given to 
them in hospital. Again, the numbers are small, and no statistical significance can be 
attributed. 
 
When benefits of treatment are considered it would be expected that, if the perceived 
benefits outweighed the side–effects of such treatment then therapy would continue 
for a longer period of time. Of the 180 cases that answered both questions 16 and 21, 
103 were still taking HRT and 77 were not. 98.6% of those who were still taking 
thought that the benefits of treatment outweighed the side – effects, fewer than 2% did 
not agree. More than half (53.25%) of those who had stopped therapy also agreed that 
benefits outweighed side -effects. This could be explained by the fact that some of the 
women in this study might have been advised to cease therapy for reasons other than 
side –effects, such as lengthy duration of treatment. However, those women who 
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continue to take HRT are of the opinion that the benefits of treatment offset the side–
effects (Table 4.50). 
 
Table 4.50 Cross tabulation of benefits of HRT use with continued or discontinued 
use. 
 
 
Still taking HRT? No Benefits do not 
outweigh side-
effects 
n                % 
Yes Benefits do 
outweigh side-
effects 
n               % 
     Total 
 
 
n               % 
 No 
 
Yes 
 
36           (46.8) 
 
2             (1.95) 
 
41 (53.2) 
 
101           (98.05) 
 
77 (100) 
 
103           (100) 
 
Total 
 
38           (21.1) 142            (78.9) 180            (100) 
-square 53.126 
p .000   
 
 
When asked if, before they left hospital, they had sufficient information regarding 
HRT, 110 out of 180 (61.1%) patients said that they did. Of those women who 
mentioned the doctor as a source, 77.8% say that they had sufficient information, 
(Table 4.51), whereas only 60.6% of women who mention the nurse as a source say 
that they had sufficient information (Table 4.52). The statistical analysis shows that a 
significant number of the women who had enough information cited the doctor as a 
source; but the nurse input is not significant. When HRT pamphlets are considered 
(Table 4.53), 52.3% of those women who had enough information mentioned the 
pamphlet as a source. This is a disappointing result from a nursing perspective. 
Nurses see health education, information giving and patient choice as an integral part 
of their role. However, in this study there is no real evidence that this is occurring in 
relation to HRT prescription. 
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Table 4.51 Cross tabulation of sufficient information given and doctor cited as a 
source of HRT information. 
 
Before home from 
hospital, enough 
information? 
Doctor not cited as 
source 
n               % 
Doctor cited as 
source 
n                 % 
      Total 
 
n               % 
 
No  
 
 
Yes 
 
 
56           (47.9)  
 
61           (52.1)  
 
14             (22.2)  
 
49             (77.8)  
 
70          (38.9)  
 
110         (61.1) 
Total 
  
 
117         (100)  
 
63             (100)  
 
180         (100)  
-square 11.329 
p < .001 
 
 
Table 4.52 Cross tabulation of sufficient information given and nurse cited as source 
of HRT information. 
 
 
Before home from 
hospital, enough 
information? 
Nurse not cited as 
source 
n                 % 
Nurse cited as 
source 
n                 % 
      Total 
 
n                  % 
 
No  
 
 
Yes 
 
 
 
42             (38.5)  
 
 
67             (61.5) 
 
28             (39.4)  
 
 
43             (60.6)  
 
70             (38.9)  
 
110           (61.1) 
Total 
  
 
109           (100)  
 
71            (100)  
 
180           (100)  
 
-square .015 
p = 1.000 
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Table 4.53 Cross tabulation of sufficient information given and pamphlet cited as 
source of HRT information.  
 
 
 
Before home from 
hospital, enough 
information? 
Pamphlet not cited 
as source 
n                  % 
Pamphlet cited as 
source 
n                  % 
      Total 
 
n                % 
 
No  
 
Yes 
 
 
39              (33.9)  
 
76               (66.1)  
 
31             (47.7)  
 
34             (52.3)  
 
 
70          (38.9)  
 
110         (61.1)  
Total 
  
 
115           (100)  
 
65              (100)  
 
180         (100)  
-square 3.318 
p = 0.081 
 
 
4.6.When do women stop HRT therapy? 
When those women who had stopped taking HRT are examined, it transpires that 80 
women stopped at periods of between two months and more than 10 years after 
starting it. The most (n = 31) stopped after taking treatment for between 7 and 10 
years.  Nine women ceased treatment within one year of starting, and 37 women had 
stopped within 5 years. Over half the women (43) women took HRT for more than 5 
years, and one woman for more than 10 years (Table 4.54). 
 
If, then, we consider that 38.8% of those women who had stopped therapy, did so at 
between 7 and 10 years of HRT use, this is a slightly longer duration of treatment than 
is currently recommended. This might be thought to be related to the age of the 
patient at the time of operation. However, if the mean age is calculated for those 
women ceasing therapy at the intervals given on the questionnaire, there is no 
association between age and when therapy is ceased. The mean age of women taking 
HRT for up to 3 years is 44.0years, and for those taking it for more than 3 years it is 
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45.16 years. It would be expected that the older the patient is at the time of 
hysterectomy then the shorter the duration of post-operative HRT therapy. However, 
this is not statistically demonstrated in the present study, possibly owing to the small 
number of cases stopping in the early post-operative period. 
 
 
Table 4.54 Duration of HRT use with stopping times.  
If stopped, when
2 1.1 2.5 2.5
3 1.6 3.8 6.3
4 2.1 5.0 11.3
8 4.2 10.0 21.3
7 3.7 8.8 30.0
13 6.8 16.3 46.3
11 5.8 13.8 60.0
31 16.3 38.8 98.8
1 .5 1.3 100.0
80 42.1 100.0
108 56.8
2 1.1
110 57.9
190 100.0
Less than 3 months
3-6 months
6 months to a year
1-2 years
2-3 years
3-5 years
5-7 years
7-10 years
more than 10
Total
Valid
n/a
System
Total
Missing
Total
Frequency Percent Valid Percent
Cumulative
Percent
 
 
 
 
4.7 Why do women stop HRT therapy? 
The main reasons for stopping were examined, and over a quarter (26.6%) said that 
the main reason was the advice of the doctor. Side–effects of treatment led to 
discontinuance in 21.5% of women, and 13.9% of women thought that they had taken 
it for long enough. When the advice of the doctor, the patient‟s feeling that they had 
taken it for long enough, and side effects are combined then discontinuance is 
explained for 72.2% of women. As previously indicated, there is no association 
between socio-economic group and the reasons given for discontinuance.   
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If the respondents are classified by whether they stopped therapy at up to, or after, 5 
years, then a difference is seen in the reasons given for stopping. In those women who 
stopped therapy at any time up to 5 years, the most common reason given for their 
discontinuance was side-effects (36.1%), and not liking the idea of hormones in a 
further 11.1%. In those women who stopped after 5 years, the most common reason 
was the advice of their doctor (35.7%); a further 23.8% said that they felt that they 
had taken treatment for long enough. Only 9.5% of the later discontinuers cited side-
effects as their reason. This is significant in statistical terms (Table 4.55). This can be 
explained in one or both of two ways. First, those women troubled by the side-effects 
of treatment would be expected to stop therapy before those who were unaffected. 
Second, doctors would be more likely to recommend ceasing treatment once patients 
had taken HRT for a longer period of time. 
 
If there was some further reason for stopping therapy out with the given choices on 
the questionnaire, women were asked to state that reason. Most (68.4%) gave no 
further reason. The additional reasons, when given, were varied, including the 
development of breast lumps (2.5%), diagnosed with breast cancer (1.3%), breast 
tenderness (1.3%), migraine headaches (1.3%), worries about cancer and DVT risk 
(1.3%) and the effect of the media (3.8%).  
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Table 4.55 Main reasons for stopping HRT at up to 5 yrs and after 5 yrs use.  
  
Main reason for 
stopping (% within 
when stop) 
Stopped up to 5 
years 
n                  % 
Stopped after 5 
years 
n                     % 
        Total 
 
n                % 
 
Doctor‟s advice 
 
Didn‟t need 
 
Taken long enough 
 
Side effects 
 
Didn‟t help 
 
Didn‟t like 
hormones  
 
No symptoms 
 
Advice + taken 
long enough 
 
Advice+ side 
effects 
 
Side-effects + 
taken long enough  
 
Side effects + 
didn‟t help 
 
Side effects + 
didn‟t like 
hormones 
 
Didn‟t help+ didn‟t 
like hormones 
 
Didn‟t help+ cost 
 
 
 
6                   (16.7)   
 
1                     (2.8)  
 
1                     (2.8)  
 
13                 (36.1)  
 
1                     (2.8)  
 
4                   (11.1)  
 
 
1                     (2.8)  
 
0                        (0)  
 
 
2                     (5.6)  
 
 
1                     (2.8)  
 
 
3                     (8.3)  
 
 
1                     (2.8)  
 
 
 
1                     (2.8)  
 
 
1                     (2.8)  
 
 
 
15                (35.7)  
 
2                    (4.8)  
 
10                (23.8)  
 
4                    (9.5)  
 
2                    (4.8)  
 
0                        (0)  
 
 
3                     (7.1)  
 
2                      (4.8)  
 
 
3                      (7.1)   
 
 
0                         (0)  
 
 
1                      (2.4)  
 
 
0                         (0) 
 
 
 
0                         (0) 
 
 
0                         (0) 
 
21               (26.9)  
 
3                   (3.8)  
 
11               (14.1)  
 
17               (21.8)  
 
3                   (3.8)  
 
4                   (5.1)  
 
 
4                    (5.1) 
 
2                    (2.6)  
 
 
5                    (6.4)  
 
 
1                    (1.3)  
 
 
4                    (5.1)  
 
 
1                    (1.3)  
 
 
 
1                     (1.3)  
 
 
1                     (1.3) 
 Total 
 
 
 
36                  (100) 
 
 
42                   (100)  
 
 
78                (100)  
-square 28.560 
p < .01 
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Although there were no questions specific to media influence, it was anticipated that 
media influence would have featured in the responses to Question 19, which asked 
respondents to state their main reason for stopping HRT. In the event, however, it was 
not cited frequently. When asked to state any further reasons for stopping HRT 3.8% 
of responders quoted media influence. This was the largest “other” reason. The media 
is cited by 6.4% of all the women who stop HRT as having some effect on their 
decision to cease therapy. 
 
Those women who had cited side effects as a main reason for stopping HRT were 
asked to specify what those side-effects were, from five choices specified alternatives. 
The side–effects most commonly cited were weight gain (13.8%), worries about 
increased breast cancer risk (10.3%), and headaches (3.4%). Many women had 
indicated more than one side-effect; weight gain is cited by 60.2% of respondents, 
headaches by 44.5% and worries about breast cancer by 30.8%. Weight gain is cited 
as a side-effect in 85% of women who stop therapy at up to 5 years, and by only 50% 
of those who continue therapy beyond 5 years (Table 4.56). Headache is cited by 65% 
of those who discontinue therapy before 5 years, and by only 25% of those who 
continue beyond 5 years (Table 4.57). 
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Table 4.56 Cross tabulation of Weight gain cited as a reason to stop HRT with timing 
of discontinuance at up to or beyond 5 years.  
 
Weight gain Stopped up to 5 yrs 
 
n                % 
Stopped after more 
than 5 yrs 
n                  % 
       Total 
 
n                % 
 
Weight gain not 
cited 
 
 
Weight gain cited 
  
 
 
3               (15.0)  
 
 
17            (85.0)  
 
 
4              (50.0)  
 
 
4              (50.0) 
 
 
7              (25.0)  
 
 
21            (75.0)  
Total  
 
 
20              (100)  
 
 
8                (100) 
 
 
28              (100) 
-square 3.733 
p = 0.077 
 
 
Table 4.57 Cross tabulation of Headache cited as a reason to stop HRT, with timing of 
discontinuance at up to or beyond 5 years.  
 
 
Headache Stopped up to 5 yrs 
 
n                 % 
Stopped after more 
than 5 yrs 
n                  % 
        Total 
 
n                 % 
 
Headache not cited 
 
 
Headache cited 
  
 
7              (35.0)  
 
 
13            (65.0)  
 
 
6               (75.0)  
 
 
2                (25.0)  
 
13            (46.4)  
 
 
15            (53.6)  
Total  
 
 
20            (100)  
 
8                (100)  
 
28            (100)  
-square 3.676 
p = 0.067 
 
 
Breast tenderness is cited by 35% of early discontinuers, and by only 12.5% of later 
discontinuers. More early discontinuers (25%) than late discontinuers (12.5%) cite 
DVT risk as a reason for stopping HRT. Although none of these results is statistically 
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significant, a trend is seen which, had the study numbers been larger, may have 
produced a significant result. 
   
When cancer risk is examined, the reverse pattern emerges, in that 62.5% of women 
taking HRT for more than 5 years cite increased cancer risk as a reason for 
discontinuing treatment. Only 35% of early discontinuers mention this as a reason to 
stop (Table 4.58). 
 
Table 4.58 Cross tabulation of cancer risk cited as reason to stop HRT, with timing of 
discontinuance at up to or beyond 5 years.  
 
 
Cancer risk Stopped up to 5 yrs 
 
n                % 
Stopped after more 
than 5 yrs 
n                 % 
     Total 
 
n                 % 
 
Cancer risk not 
cited 
 
 
Cancer risk cited 
 
 
 
13            (65.0)  
 
 
7              (35.0)  
 
 
 
 
 
3            (37.5)  
 
 
5             (62.5)  
 
 
16           (57.1)  
 
 
12            (42.9) 
Total  
 
 
20             (100)  
 
8            (100)   
 
28            (100)  
-square 1.765  
p = 0.183 
 
 
 
Again although not statistically significant it is an interesting result that may have 
been more evident with a larger study sample, or with greater numbers of early 
discontinuers.  
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These results will now be discussed in further detail and in comparison with 
previously published material in the final chapter.  
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Chapter five 
 Discussion 
The original aim of this study was to determine if women undergoing hysterectomy 
with bilateral oophorectomy have patterns of HRT use, which are specific to them 
when compared to HRT users in general. Many of the published studies in this area 
have considered menopausal women as a homogenous category, and have not 
evaluated women with surgical menopause as a distinct group, to be investigated 
separately. 
 
This chapter will discuss the findings detailed in the previous chapter in terms of the 
differences, if any, found between the women in this study and previously published 
literature on HRT use by women in general.  
  
To begin, some observations regarding the age of the study subjects are made before 
the findings of this study are discussed under three main headings. The prevalence 
and duration of HRT use found in women with surgical menopause will be considered 
first, followed by the socio-economic factors associated with that use. Finally any 
effects of the location of treatment will be discussed, before general conclusions from 
the study are drawn. 
 
The women in this study are older in general than women in some previous American 
based studies. Brett and Maddens (1997) quote a mean reported age at menopause of 
45.9 years age in their American population of both naturally and surgically 
menopausal women, and of 40.1 years for those who had bilateral oophorectomy. The 
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women in their study who had experienced natural menopause did so at a mean age of 
47.5 years. In the U.K. Maresh at al (2002), found a median age at hysterectomy was 
45 years, but do not quote a mean age for concomitant bilateral oophorectomy, nor do 
they limit their population by clinical indication for surgery.   The mean age in the 
achieved sample of surgically menopausal women in this region of Scotland is 43.9 
years. In the target sample the mean age is slightly younger at 43.5 years. So the Forth 
Valley women are older on average than some surgically menopausal (with BSO) 
women, but younger on average than Brett and Madden‟s general menopausal 
population. This older age at surgery, (and therefore of menopause), may be linked to 
the original reason for that surgery. All the women in this study had surgery for 
menorrhagia, and as such would be treated after less radical alternative therapies had 
been exhausted, rather than as urgent cases requiring immediate surgery for possible 
malignancies.  Lewis et al (2000), states that the peak rate for hysterectomy in the U.S 
is between 40-44 years, but that the peak rate of concomitant bilateral oophorectomy 
is later, at 45-54 years. These figures relate to operations carried out for a variety of 
indications, rather than solely benign menorrhagia with an upper patient age limit of 
65 years. The mean age at operation therefore will be older due to this age limit, with 
oophorectomy more likely with increasing age. The women in this study were no 
older than 51 years at the time of hysterectomy so the mean age at operation is 
predictably younger than Lewis found, and yet older than the women described by 
Brett and Maddens.         
The main findings from this study are now discussed. 
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5.1 The prevalence and duration of HRT use in women with hysterectomy and 
bilateral oophorectomy.  
Women with surgical menopause are more likely to take HRT, and to take it for a 
longer time, than HRT users in general. When they stop therapy, they cite some of the 
same reasons as other users but are more likely to stop on the advice of their doctor. 
      
Finley at al (2001) quote a prevalence rate for HRT use of 40% in their American peri 
and post-menopausal women aged between 50 and 70 years old, and a further 17% of 
the women in their study have used HRT in the past. However they along with other 
authors, suggest that surgical menopause greatly increases the likelihood of taking 
HRT when compared to natural menopause. In another American study, Brett and 
Maddens (1997) found that 71% of surgically menopausal women took HRT.    
 
Maclaren and Woods  (2001) found that 56% of women with surgical menopause 
were taking HRT compared with 39% of peri-menopausal or naturally menopausal 
American mid-life women .The age range of women in their study is 40-65 years, and 
this will explain the lower rate, as many of the older women would have discontinued 
use by the time of their survey. If the women who had started therapy but 
discontinued it are added to those still taking HRT, then a figure close to 75% is 
obtained. This study does not determine oophorectomy status, so it may well be that 
the remaining 25% (approximately) of women did not have their ovaries removed and 
therefore did not require post-operative HRT. In the United Kingdom Griffiths and 
Convery (1995) find similar rates of HRT use in women with hysterectomy and 
bilateral oophorectomy. Of the women in their general practice in Stockton -on –Tees 
that were under 52 years old and had had a hysterectomy with bilateral oophorectomy, 
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71% were taking HRT and a further 8.4% had taken it in the past. Only 50.6% of their 
women had commenced therapy immediately after surgery. They report 20.6% of 
women had never taken HRT, a finding which  may be explained by the specific 
reason for surgery. If the operations had been carried out for reasons other than 
benign menorrhagia, then HRT may not have been appropriate. 
 
Almost all women (98.2%) in the region studied who have hysterectomy with 
bilateral oophorectomy at less than 51 years of age start HRT in the early 
postoperative period. This figure is higher than quoted by the authors mentioned. This 
high rate is associated with the benign indication for surgery and the young age of the 
patient. Only 9 women stopped therapy within a year of starting treatment. 
 
Women in this study have taken HRT for a longer time than is currently 
recommended. The duration of use for this population would confirm earlier findings 
that hysterectomy with oophorectomy is associated with long-term HRT use. 
       
The current advice to women taking HRT after hysterectomy with bilateral 
oophorectomy for benign indications is to continue therapy for five years or until the 
age of natural menopause, and then discuss with a doctor- but probably stop at that 
point. Many of the women in this study had taken HRT for longer than this, with more 
than half of those who had eventually stopped reporting that they had used therapy for 
more than five years. Hope and Rees (1995) found 51% of their lapsed users stopped 
HRT much earlier, after less than a year; and Den- Tonkelaar (2000) found, in a 
mixed population of past and present HRT users, that 74.4% of past users aged 30-75 
had stopped HRT within 2 years. Maclaren and Woods (2001) quote a median of five 
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years‟ use in women aged 40-65 years, with 25% taking HRT for 10 years or more. In 
all these studies, many of the women had not had a surgical menopause, which may 
account for the higher rate of early discontinuance.  
 
Hysterectomy is associated with longer duration of HRT use (Brett and Maddens 
1997, Den- Tonkelaar 2000), which would explain why most of the women in the 
current study expect to take HRT for more than seven years. At the time of 
questioning, the majority of these Scottish women were still taking HRT, and the 
duration of use varied from eighteen months to sixteen years, (if HRT use prior to 
surgery, characteristic of some women, is included). Of these women, 77.6% had used 
treatment for up to ten years. In this study, there were 80 women who had stopped 
therapy and 38.8% of them had used HRT for between seven and ten years. Women 
who stopped treatment within one year of commencing totalled just 11.25% of all 
those who stopped, and account for only 5.4% of those who started HRT in hospital. 
     
The expected duration of treatment is linked to the age of the patient. Overall, younger 
women anticipate longer treatment, as they are oestrogen deficient for a longer time 
compared to older women. It is interesting, then, to find that there is no evidence to 
suggest that those women who had taken HRT prior to surgery expect to take HRT for 
a shorter time post-operatively, although they are statistically older than those women 
who have not taken pre-operative HRT. This suggests that the decision to take HRT 
after hysterectomy, and the ultimate duration of use, is unaffected by prior use of 
hormones. Post -surgery HRT is a different form of treatment with the change from 
combined therapy to oestrogen- only therapy. Perhaps women consider pre- and post 
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hysterectomy HRT, as separate entities, and do not worry about the additional length 
of time in oestrogen treatment of the two put together. (Alternatively, as previously 
mentioned, this result may be the product of a flawed question).  
 
Likewise, in this study, patient age is apparently not a factor in the actual timing of 
HRT discontinuance. This is also not expected, and may be linked to the small 
number of early discontinuers. At the time the women in this study were treated, the 
recommended duration of HRT treatment had no clear limit. A woman aged 48 years 
at operation for instance may have expected to continue treatment indefinitely, so her 
expectations may have been indistinguishable from those of a much younger woman 
who would also anticipate long-term use.   
       
Hysterectomised women stop HRT for largely the same reasons as women with an 
intact uterus. In this study, the most common reasons for stopping HRT were either on 
the advice of the doctor (26.6 %) or the side-effects attributed to treatment (21.5%). 
These figures are higher than those found in other studies for rates of discontinuance 
on medical advice, but lower than those found for side- effects. Discontinuance on 
medical advice has been found to account for 22% of women by Maclaren and Woods 
(2001), 22.9% by Newton at al (1997), and in18.8% of study subjects by Den-
Tonkelaar and Oddens (2000). Side- effects of treatment account for 31.8% of 
discontinuance, according to Den-Tonkelaar and Oddens, for 26.6% according to 
Newton et al (1997), and for 42% in the Maclaren study. 
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Considering medical advice first, it is interesting to note that a greater number of the 
women in this study consulted with their doctor (prior to stopping treatment) than was 
the case in previous studies of HRT users in general. Hope and Rees (1995) found that 
38% of women did not consult their doctor before stopping treatment, while Newton 
et al (1997) found that many more women (53.8%) stopped without medical advice. 
Only 35% of the Scottish women studied ceased treatment on their own. This figure is 
not, perhaps as low as might be expected, given that the original prescription for 
treatment was received at the time of hospitalisation, as a medical recommendation 
rather than a treatment option. It is perhaps more likely that these women feel the 
need to discuss stopping treatment, and the possible consequences of ceasing 
treatment more keenly than women experiencing natural menopause. It is also 
possible that consultations about HRT with surgically menopausal women are more 
straightforward than consultations with women who are naturally menopausal. For 
younger surgically menopausal women HRT is truly a “replacement” treatment for 
prematurely lost oestrogen, whereas it can be viewed as “additional” oestrogen 
support for a failing natural supply in women without hysterectomy and bilateral 
oophorectomy. Women with intact uteri need also to consider the potential side 
effects of combined HRT and the potential for bleeding problems. With this in mind, 
there may be less ambiguous information given to women after hysterectomy and 
bilateral oophorectomy, and they, in turn, find consultations more satisfactory. Bond 
and Bywaters (1999) highlight the dissatisfaction of some peri-menopausal/ naturally 
menopausal women regarding HRT discussions with their doctors, but exclude 
surgically menopausal women from their study as they recognise that women with 
hysterectomy and bilateral oophorectomy have fewer grounds to refuse HRT.  
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Women who are early discontinuers of therapy give reasons for stopping which are 
different from those of women who discontinue therapy later. Buist et al (1999) 
suggest that long- term HRT use may be closely related to women‟s beliefs about 
therapy and the interaction they have with their doctors.  Women stopping within five 
years cite side- effects and not liking the idea of hormones as the main reasons for 
stopping, whereas women stopping later do so on medical advice and because they 
feel they have taken it for long enough. Only 9.5% of late discontinuers cite side- 
effects as a reason to stop. This would be expected. If side-effects were a problem 
they would probably appear early in treatment; and, if not resolved they might prove 
intolerable in the short term. Once treatment were established with no experience of 
side-effects, therapy would be more likely to continue until advised to stop on medical 
grounds. Concerns about taking hormones has been shown to be linked to never using 
HRT, (Mansfield and Voda1994), and to account for its discontinuance in about 15% 
of users (Den Tonkelaar and Oddens 2000). It is cited by 11.1% of women who 
ceased therapy before five years in this study. 
  
If side-effects are considered, then many of the reasons given for discontinuing 
therapy in these women are the same as those found in previous studies of women 
regardless of hysterectomy status. Side-effects related to menstrual bleeding, which 
feature as reasons to discontinue treatment in women with natural menopause, will 
not be discussed as surgically menopausal women are not troubled by these 
symptoms. Weight-gain, headache and worries about breast cancer are the side-effects 
that concern these surgically menopausal women.  
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Weight- gain was the most commonly cited side- effect in this study, with 13.8% of 
women who had ceased treatment stating that this specific side effect was the reason 
for their decision. Many more women (60.2%) indicated that weight gain was partly 
responsible, together with other side effects, for their discontinuance. Hope and Rees 
(1995) found that 21% of current HRT users and 27% of lapsed users knew that 
weight gain was a possible side effect of treatment, but they do not claim that weight 
gain alone statistically makes women more likely to stop therapy.  Den-Tonkelaar and 
Oddens (2000) found that weight gain was implicated in HRT discontinuance for 
30.7% of their subjects, but also cites an endocrine study which shows that HRT does 
not in fact increase body weight when compared to placebo (Espeland et al 1997). 
 
According to Den-Tonkelaar and Oddens (2000), headache accounts for 5.7% of 
women stopping HRT; and according to Newton et al (1997) it functions as a reason 
to change HRT regimens in 4.1% of women. In the current study it is given as a 
reason by 3.4% of those women stopping treatment. It is however mentioned as being 
partly responsible for stopping, together with other side effects by 44.5% of these 
women. 
 
Concerns about increased risk of breast cancer affect 10.3% of the women in this 
study, and are given as a primary side- effect leading to discontinuance. Together with 
other side effects, these worries influence the decisions of 30.8% of women. Newton 
et al (1997) found “fear of cancer” was the reason to quit treatment in 15.4% of their 
past users, but do not specify which particular cancer. Long-term risks such as cancer 
are quoted by Hope et al (1998) to account for discontinuance in 18% of the women 
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in their study, with 70% of these discontinuers specifically mentioning breast cancer 
risk. Fear of breast or endometrial cancer, is the reason for stopping HRT in 10% of 
mid-life women according to Maclaren and Woods (2001.) 
  
So it would appear that, in women with surgical menopause, the side-effects/ worries 
that prompt them to stop taking treatment are the same as those that trouble HRT 
users in general. The impact of any one individual side- effect on discontinuance is 
relatively small, but when women are troubled by more than one side effect then 
stopping therapy is explained in higher numbers of women. 
 
As Hope and Rees (1995), found that current users of HRT were more able to tolerate 
side-effects than were lapsed users, it was anticipated that this study might show that 
there are differences in the reasons women give for stopping therapy at different 
times. This has proved not to be the case. There are however some trends that may 
have been more evident in a larger study. Women who discontinue treatment within 
five years report their reasons as weight gain, headache, breast tenderness and worries 
about DVT in greater numbers than those women whom take HRT for more than five 
years. Those women who take HRT for more than five years, cite breast cancer 
worries as their reason for stopping in greater number than earlier discontinuers. 
These differences are however not statistically significant.      
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5.2 Socio-economic factors associated with HRT use in women with hysterectomy 
and bilateral oophorectomy. 
Socio-economic group may be associated with the timing of hysterectomy, but in 
contrast to findings from menopausal women in general, it is not associated with the 
degree of uptake or the likelihood of continuation of therapy in women with surgical 
menopause. There is some evidence to suggest that women from different socio-
economic backgrounds perceive the risks and benefits of HRT use differently. 
 
It is suggested by the Scottish Government findings of 2007, in the second chapter of 
their publication “Growing up in Scotland. A study following the lives of Scotland‟s 
children”, that younger mothers tend to be from less affluent areas. If then, by 
comparison, less deprived women delay having their children until they are older, this 
could affect their decisions when considering the timing of hysterectomy. Settnes and 
Jorgensen (1996) found that, in Denmark, less educated women were more likely than 
educated women to have a premenopausal hysterectomy, and Cooper et al (2008) 
found similar trends when studying women in Britain and Australia.  It is not possible, 
on the basis of this study, to say that Scottish women from lower socio-economic 
groups are more likely to have hysterectomy at a younger age, because the socio-
economic distribution of the achieved sample does not accurately reflect the socio-
economic structure of the regional population generally. (This is particularly apparent 
in the most deprived category SIMD 1 which is under-represented: see Figure 2 in 
chapter 4). It is, however, possible to say that if women from higher socio-economic 
groups are less likely to have hysterectomy at an earlier age, then the women from 
more affluent backgrounds who do have surgery are likely to be older when that 
surgery takes place, and this is what is found in the study.  
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 In the target sample there is a difference of 1.5 years in the mean age at hysterectomy 
between women in SIMD groups 1-5 (most deprived) (42.9 years) and 6-10 (least 
deprived) (44.4) years.  
  
 It is also important to recognise that these more affluent women, who had their 
operations when they were older also returned their questionnaires in greater numbers 
so are disproportionately represented in the achieved sample. 
              
Socio-economic group is not associated with access to HRT treatment, nor the    
likelihood of uptake in women with surgical menopause, but women from less 
deprived backgrounds tend to use HRT for longer. Women use the same information 
sources regardless of socio-economic status. 
        
 It has been suggested that socio-economic group strongly affects the likelihood of 
HRT use (Finley et al 2001), but evidence from this study would suggest that these 
trends are not so evident in women with surgical menopause.  Finley et al (2001) 
found that wealthier peri- and post-menopausal women were three times more likely 
to use HRT than were poorer women in the USA. This is not seen in the surgically 
menopausal women of this Scottish study. Finley‟s findings may be linked to the ease 
of access patients have to advice regarding HRT. Consultations with GPs about 
preventative medicine are known to take place less frequently if the patient belongs to 
a lower social class (Goddard and Smith, 2001), so perhaps the wealthier women in 
Finley‟s study were consulting their physicians in greater numbers, and with greater 
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adherence, than the poorer women. This is particularly likely in view of the 
differences in health care funding between the USA and Scotland.  
 
All the women in this study should have had the opportunity to discuss the use of 
HRT with health professionals as part of their hysterectomy care. They will have had 
the discussion “brought to them” rather than having to seek out advice on menopausal 
symptoms from their GP. There is no evidence that these discussions differ according 
to the socio-economic group to which the patient belongs, suggesting that the advice 
given to this group of women does not vary in content, and equity of care is implied. 
The recommendation of a health professional has been positively linked to HRT use 
(Finley et al 2001), and it is likely that these recommendations are just as effective in 
surgically menopausal women. In any case, HRT use following hysterectomy and 
bilateral oophorectomy for a woman under 51 years of age is less controversial than 
for peri or postmenopausal women with intact uterus. So it may be easier for all 
women, regardless of socio-economic group, to accept therapy after surgery. 
 
There is evidence to suggest that, in this region of Scotland, socio-economic group 
does have some effect on the duration of HRT use, with women from less deprived 
backgrounds using HRT for a longer time. This would confirm findings from a large 
Swedish study (Persson et al 1997), and one from four general practices in the 
England, (Den Tonkelaar and Oddens 2000), both of which examined the 
characteristics associated with long-term (over 6 years) HRT use in women with both 
natural and surgical menopause. Den Tonkelaar‟s findings are consistent with the 
Persson study but are not statistically significant. These authors state that high 
educational level is associated with long-term use, and Den Tonkelaar and Oddens 
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(2000) suggest that women of greater intelligence may “ have been more aware of the 
risks of osteoporosis and were probably more likely to comply with their own 
decisions”(Den Tonkelaar and Oddens 2000 p 511), so implying that these women 
“make up their own minds”.   
         
If women from higher socio-economic groups take HRT for longer, and are more 
likely to consult their GP about preventative medicine, it might be expected that they 
also consult their GP in greater numbers when deciding to cease treatment. Thirty–
five percent of the women in this study did not discuss their decision with their 
doctor, a rate that is similar to that reported in some studies of the general menopausal 
population (38% in Hope and Rees 1995), but lower than the rate found in other 
studies (53.8% in Newton et al 1997).  These papers did not examine possible 
associations between socio-economic statuses, but there is no evidence in the current 
study that it affects the likelihood of consultation. 
 
The women in the current study, regardless of their socio-economic group, use the 
same sources to inform them about HRT. So, if it is not the source of the information 
that influences the uptake or duration of therapy, possibly it is the interpretation of 
such information that makes a difference. This is implied by Den-Tonkellar‟s (2000) 
suggestion that better educated women may have a greater understanding of the 
treatment, which in turn may lead to longer-term use.    
 
      Women from different socio-economic backgrounds view the risks and benefits of 
HRT differently. Most women (74.7%) from the current study believed that the risks 
associated with HRT were outweighed by the benefits; and this finding is unrelated to 
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socio-economic status. There are, however, some differences associated with socio-
economic group when the importance of these benefits is considered. More women 
from the lower socio-economic groups consider that cardiovascular protection is the 
most important benefit of HRT. There is, however, no difference between women 
from different backgrounds in how important they rate osteoporosis protection; and, 
although more women from less deprived backgrounds rate the relief of menopausal 
symptoms as of primary importance, this is not statistically significant. So women 
from deprived areas agree with women from more affluent areas about the importance 
of symptom relief and osteoporosis protection, but they are more likely to believe that 
cardiovascular protection is also important. 
 
The primary benefits of HRT have always been the relief of menopausal symptoms 
and osteoporosis protection, although cardiovascular protection was also thought to be 
a possible benefit at the time these Scottish women were taking HRT. There may be a 
possible explanation for the difference found in how cardiovascular protection was 
rated, either in the timing of the survey, or more significantly in the way different 
socio-economic groups perceive personal risk. In terms of survey timing, it is possible 
that women from the more affluent socio-economic groups were more aware of the 
findings of the Women‟s Health Initiative, and knew that this benefit had been largely 
discredited at the time they were asked to complete the questions. This might explain 
why only 9.1% ranked cardiovascular protection as their most important benefit. It 
does not explain why 42.9% ranked it as of medium importance. In terms of perceived 
personal risk, it may be that lower socio-economic groups feel at greater risk of a 
cardiovascular event, and therefore rate possible cardiovascular protection of HRT 
more highly. It is well known that coronary heart disease is more prevalent in lower 
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socio-economic groups, and low control beliefs are thought to contribute to these 
higher rates (Bosma et al 2004). 
 
A perceived lack of control, together with a perceived susceptibility to any health 
threat, is central to many models that try to explain health-related behaviours. The 
health belief model (Becker et al 1977) emphasises personal susceptibility, while 
Leventhal‟s common sense model places great importance on lay beliefs when trying 
to predict health decisions. If an individual believes that they are at risk of developing 
cardiovascular disease through familial traits, or as a consequence of life-style, then it 
would not be surprising if they rated the prevention of such disease more highly than 
somebody who considered themselves at lower inherent risk. The belief that that HRT 
may protect against heart disease, as well as relieving menopausal symptoms, and 
preventing osteoporosis, may have led some women to think that out of these three 
benefits, that cardiovascular disease is the most serious affliction and therefore the 
most important condition to prevent. At any rate, women from different backgrounds 
all take postoperative HRT, but their beliefs in the benefits of such treatment differ. 
 
It is unfortunate that, when the questionnaire was devised, no question specific to the 
risks of treatment was included, as this would, with hindsight, have been interesting. 
As it is, it is not possible to say how these women would rank the importance of their 
risk of breast cancer or DVT.   
          
When considering the possible effect of prescription charges, it is interesting to see 
that there is little difference in the numbers of women who are in receipt of free 
prescriptions when comparing the least and the most deprived groups. The assumption 
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would be that more deprived women are more likely to have free prescriptions; but, 
although more women from the most deprived backgrounds do not pay for 
medication, their number is not statistically greater than for less deprived women. One 
possible explanation for this may be the SIMD classification of the study population. 
SIMD is not designed to classify individuals but rather the area in which they live. It 
is entirely possible for women who are not income-deprived to live in an area of 
higher deprivation. In the recent publication of SIMD (Scottish Government 2009) it 
is stated that 64% of income-deprived people live outside the most deprived areas. 
Whatever their background, as designated by SIMD, most women say that free 
prescriptions would not make them more likely to take HRT. Since these women were 
surveyed, prescription charges in Scotland have been abolished.      
    
5.3 The impact of the location of treatment on HRT use in women with 
hysterectomy and bilateral oophorectomy. 
There is no evidence, in this study, to suggest that the two hospitals diverge in their 
practice in such a way as to impact on patterns of HRT use. However there is 
evidence that information given to patients could be improved. 
 
 There are differences between hospitals in the information given to patients 
concerning the benefits of HRT, but the hospital attended for treatment has no 
association with the subsequent use of HRT after hysterectomy. The medical staff in 
both hospitals discuss HRT with their patients prior to surgery, and women report no 
significantly different information sources contingent on where they are treated. 
Discussions related to the relief of menopausal symptoms, and osteoporosis protection 
is recalled by two thirds of all the women in the study. 
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 A greater number of women seen by medical staff at hospital A recall discussions 
about the benefits of taking HRT when compared to those women attending 
consultations at hospital B. So hospital A appears to be more effective than hospital B 
at informing women of the benefits of treatment. Although there is a statistical 
difference in the data here, its reliability is possibly questionable as it is dependent on 
patient recollection. It is possible that benefits are remembered and risks forgotten. 
Further concerns over reliability of recall are evident when the risks of treatment are 
considered. 
 
Apparently, the potential risks of treatment with HRT are not always discussed with 
patients, with 65.2% of women saying that side-effects were not referred to. This is 
hard to believe and needs to be explored further. The study subjects were asked to 
recall a conversation, which took place (in some cases) a considerable length of time 
before the survey, and which is consequently liable to be inaccurately recalled. It is 
entirely possible that, in a consultation with her doctor, a woman opting for elective 
hysterectomy with bilateral oophorectomy, will focus on the benefits of the operation 
rather than on possible post-operative side-effects. Similarly, the doctor when 
discussing the need for HRT will focus on the relief of premature menopause rather 
than the small likelihood of the patient experiencing any serious side-effects of 
treatment. The overall risk-versus-benefit balance in these consultations will favour 
HRT prescription, and this may explain why women do not remember being informed 
of the risks of treatment. There is no difference between the two hospitals in the 
information given to patients about risks of treatment. 
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If the patients attending hospital A receive better information about the benefits of 
treatment then it might be expected that they are more likely to take HRT post-
operatively. This is not the case. Both hospitals offer HRT to a high percentage of 
their patients, and those patients have almost the same uptake level, at 99% of hospital 
A patients and 97% of hospital B patients. 
     
The fact that there appears to be no significant difference in the timing of HRT 
prescription, and that similar numbers of women leave both hospitals with that 
prescription, would indicate that both units adopt similar practice. In this respect, at 
least, there does not appear to be a “postcode lottery”, perhaps because the same 
health authority governs both hospitals.  
 
There may be no significant differences between the two hospitals in their 
management of women undergoing hysterectomy, but there is evidence of differences 
in the timing of treatment, dependent on which consultant is seen. There are two 
consultants who operate on significantly younger women. One of these doctors works 
in HA, the other in HB. Had they both worked in the same hospital, some statistical 
difference between the hospitals might have been seen. As it is, there is no significant 
difference in patient age at operation by hospital. One of these two consultants also 
performed more than a quarter of all cases, a fact which supports the observation of 
Gupta & Manyonda (2006) that hysterectomy rates for benign disease vary between 
consultants in the same hospital. These differences appear to be idiosyncratic, and not 
based on gender. 
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Patient satisfaction with medical consultations has been shown to be linked to the 
communication style of the doctor (Hall et al 1994), and differences in 
communication style are found according to gender (Hall et al 1994 cited Roter at al 
1999). The patients of female physicians are associated with higher rates of adherence 
to treatment than the patients of male physicians (Hall, Roter & Katz 1988 cited Roter 
et al 1999). This study does not support the claim that a physician‟s gender is 
associated with the uptake or continued use of HRT by their patients. The gender of 
the consultant has no effect on the timing of hysterectomy, or the content of pre-
operative discussions about HRT. Nor does it determine whether HRT is offered in 
hospital, or whether this offer is accepted. In this respect the surgically menopausal 
women in this study are no different than midlife women in general. Maclaren and 
Woods (2001) found no statistical association between physician gender and HRT 
use, although in their study, HRT use was more likely in women who saw male 
doctors. Some authors have found that women prefer to see female doctors 
(Schmittdiel and Selby et al 1999), but patient preference for physician gender was 
not explored in the current study. It may well be that women prefer female 
gynaecologists, but there is no evidence from this study to suggest that the care from 
male gynaecologists is any different than that provided by their female colleagues. 
This would concur with the suggestion by Christen et al (2008) that patient 
satisfaction and adherence to treatment is influenced by the communication style of 
the doctor and not by the gender of that doctor alone.    
  
On the basis of this study, it could be argued that patient information about HRT 
needs to be improved in this NHS trust. Although 98.2% of the women in this study 
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accept HRT when it is offered to them in hospital, not all of them thought that they 
had sufficient information to make the decision to start long-term medication. Of 
those who accept treatment, 62.6% consider themselves well enough informed. 
Equally, of the three women who did not accept HRT in hospital, two said that they 
had sufficient information for their purposes. However, over one third (37.4%) of the 
women said that they did not have enough information. So women appear to take 
treatment whilst acknowledging they have too little information on which to base their 
decision. 
 
In this study, not having enough information did not deter women from taking HRT 
when it is offered to them. Women in the immediate post-operative stage were 
apparently prepared to commence treatment on the advice of the doctor, even though 
they now believe that they needed more information. Of the women who said that 
they did have sufficient information, most mention the doctor as a source of that 
information, perhaps confirming that patients are more likely to remember what 
doctors say. Nurses are certainly mentioned as an information source; however, they 
are not remembered by more of the women who believe they had sufficient 
information when compared to the women who believed they did not have enough 
information. It could therefore be said that doctors do a better job than nurses do in 
giving information to these women. As previously discussed, physician 
recommendation is known to be associated with HRT uptake generally (Finley 2001). 
The fact that women remember the doctor as the source of their HRT information may 
be further evidence to support this, with these surgically menopausal women not 
differing from HRT users in general in this respect.  
 
 225 
Those women who continue to take HRT in this study are, as expected, of the opinion 
that the benefits of taking treatment outweigh the possible risks. This confirms the 
findings of Den –Tonkelaar and Oddens (2000) in past or present HRT users in 
general. Over half of the women, who had stopped therapy also thought that benefits 
outweighed risk, which suggests that the long-term user is content with therapy but 
ceases treatment on medical advice. 
  
5.4 OVERALL CONCLUSION  
In all probability, the decision to take HRT after hysterectomy with oophorectomy is a 
relatively easy one, compared to the decision that must be taken by naturally peri-
menopausal or menopausal women. After surgery, women face “ instant menopause” 
and are therefore advised to take HRT to prevent menopausal symptoms and to 
protect their bones against osteoporosis. The relative risks of treatment, including 
breast cancer and venous thrombosis, in these comparatively young women, are small 
as HRT is considered to replace a prematurely lost oestrogen supply rather than 
supplement or extend that supply after a natural menopause. These risks are perhaps 
offset by the fact that women with premature menopause are at higher risk of 
osteoporosis than women experiencing menopause naturally.  There are no concerns 
for the surgically menopausal woman in terms of the return of menstrual bleeding, or 
the risk of endometrial cancer, as they have no uterus. Bleeding and concerns about 
cancer risks are known to be reasons for stopping treatment in HRT users in the 
general. For women who do not like the idea of exogenous hormones, HRT after 
surgery may be considered acceptable due to its compensatory role. Naturally 
menopausal women who dislike hormones may think treatment unnatural and or 
unnecessary, but for surgically menopausal women any concerns about taking 
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“unnatural” exogenous hormones may be outweighed by the argument that HRT in 
these circumstances is not “extra” but “replacement”. If there are fewer issues 
surrounding treatment then discussions between medical staff and patients are easier 
and outcomes more predictable. This is certainly consistent with the findings in the 
present study. 
 
Following hysterectomy with oophorectomy, nearly all women in this study take HRT 
on the advice of their doctors. This is expected and is consistent with previous 
findings that treatment is associated with hysterectomy and oophorectomy (Den- 
Tonkelaar and Oddens 2000).  HRT is offered and accepted by women regardless of 
their social background, and irrespective of the medical professional consulted. The 
association between HRT use and higher social status found in studies of generalised 
HRT users, (Persson et al 1997, Finley et al 2001, and Maclaren and Woods 2001), is 
not evident in these surgically menopausal women. Many of the women in this study 
have taken HRT for a longer time than is found in the general HRT- using population, 
and this may be in part due to prescribing advice at the time. They stop treatment for 
many of the same reasons as women with natural menopause do, but are more likely 
to consult their doctor prior to stopping. They cite side-effects of treatment less often 
than general users and weight gain is the most common complaint associated with 
discontinuance. Weight gain is also reported as an undesirable side–effect by HRT 
users in general (Den- Tonkelaar and Oddens 2000). All women tend to use the same 
information sources, yet there are some differences, associated with socio-economic 
status, in how the information about risks and benefits is perceived; cardiovascular 
protection was rated more highly by women from more deprived backgrounds. Over 
one third of women said that they had insufficient information prior to starting HRT. 
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It is this last observation that has some interest in terms of any clinical applications 
resulting from this study. 
 
If the discussion about post-operative HRT is straightforward, why do some women 
say that they did not have enough information? Although they start treatment, the fact 
that they consider themselves not adequately informed raises questions about the 
effectiveness of these discussions. Is it because there are fewer side-effects to discuss, 
and the argument for treatment stronger in cases of surgical menopause that impacts 
in these discussions? If the consultation focus is that of replacement of a prematurely 
lost natural hormone rather than the addition of hormones to relieve menopausal 
symptoms, then perhaps doctors do not put the same emphasis on the side-effects 
because they are fewer and less serious.  A naturally menopausal or peri-menopausal 
woman can choose HRT to relieve menopausal symptoms; a surgically menopausal 
woman is positively encouraged to take HRT. 
 
The consultations, then, are essentially different for the two groups of women. 
From the patient‟s perspective, the recollection of what information has actually been 
given is perhaps less than full. Discussions about HRT take place at a time when 
major surgery is being contemplated or has just been performed, and it would be 
understandable if recollections were not completely accurate. It is important to know 
that, regardless of whether adequate information was given, these women say that 
they were not sufficiently informed. Nurses were cited in this study as a source of 
information, but not as a particularly memorable or effective one. One possible reason 
for this may be that nurses are subject to time constraints, and do not have time in an 
acute setting for lengthy discussions. Alternatively, they might not have been 
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confident in their own understanding of HRT and might therefore have felt unable to 
answer questions knowledgably. 
 
This latter possibility is particularly relevant to the present study because of the 
emerging controversy and changing recommendations (with respect to HRT use) at 
the time some of these women were treated. 
 
It is clear from this study, that when making their decisions about HRT, these women 
were content to follow the advice of their doctors, but they wanted more information. 
It is essential that the information given to them is accurate and up to date. Part of the 
problem for these, and indeed other, HRT users has been how to interpret the research 
findings, as they emerged. It may be supposed that it was difficult for women taking 
HRT, at the time, to understand how they might be affected personally. There is 
something to be learned from the career of HRT, which has implications for medical 
and nursing practice. 
 
McKinlay (1981) says that “no government should support through public funding for 
general public use any service, procedure or technology, the effectiveness of which 
has not been, or cannot be demonstrated” (p 402). As discussed earlier, the 
effectiveness needs to be established by experimental studies, for example RCTs. If   
“doctors and nurses are the gatekeepers of innovation” (Wright 2005 p1096), then 
there is a duty to ensure that only treatments with proven efficacy are promoted. 
 
One proposal is that the pharmaceutical industry should continue to be obliged to 
make very clear statements of efficacy and clinical indications for use when new 
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medicines are licensed for the market. Claims of secondary benefits, such as (in the 
case of HRT) CHD prevention, should not be made until proven. Early release of any 
data obtained showing possible detrimental effects of treatment should also be 
publicised more readily. This, however, is probably unrealistic, given the financial 
investment made by the pharmaceutical industry in the development of new 
medicines, and the need for accurate data collection. It can be argued that, if all new 
innovations were not marketed until long-term data were available, then it may be 
impossible to collect data from large-scale studies, and it could take decades to prove 
a treatment to be both effective and safe. This clearly would stifle innovation and 
progress in medicine. The media also have a responsibility to report accurate 
information and, as previously discussed, the power of sensationalism is clearly 
evident in the general press.  
 
All nurses should have an understanding of how new drugs are tested in clinical trials, 
and most importantly, an awareness of the power of the pharmaceutical industry and 
the influence of the media. As Wright (2005) advises, medicine prescribing by doctors 
and nurses should not be influenced by the media or the pharmaceutical industry but 
by empirical evidence.  
 
The Royal College of Nursing, as the largest professional union for nurses in the UK, 
representing some 400,000 members, “promotes excellence in practice and shapes 
health policies” (RCN website 2011). It aims to lobby government to develop and 
implement policies that improve patient care. The RCN has a number of priorities 
when considering the maintenance and development of services provided by both the 
NHS and the private sector.  These include maintaining staffing levels, protecting 
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time for the training of nurses as part of professional development, protecting the 
nation‟s health by providing public health information, investing in specialist nurses, 
and sustaining health care investment. All these influence the effectiveness of nurses‟ 
clinical role in regard to helping women with their HRT decisions. Maintaining 
staffing levels permits time to spend on proper discussion with patients to 
individualise their care. Formal training, networking and private study allow the nurse 
to be confident and informed in practice, thus able to impart up-to-date, individualised 
care. Using the consultation time for a holistic assessment of the patient allows for 
other health information to be given, and provides an opportunity to engage in health 
screening. 
 
The RCN National Menopause Nurse Group was formed as a sub group of the RCN 
Women‟s Health Forum in 2003. The objectives of this group were to develop the 
clinical role of nurses working in menopausal health, promote education on 
menopause related issues to all nurses, and to encourage a multidisciplinary approach 
to menopause care. To ensure safe and effective practice, the group developed a 
national competency framework. Published as “An integrated career and competence 
framework for nurse and health care support workers working in the field of 
menopause” (RCN Competences: 2009), it is designed for use by nurses working 
within menopause services, and elsewhere. It is recognised that nurses working in 
menopause health work in many different settings, in both primary and secondary 
care, and that their roles vary according to their setting. The framework is useful to all 
nurses involved in women‟s health, but specifically ensures competency in those 
nurses involved in menopause care at a more specialist level.   
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Specialist menopause nurses, with this extended training, have a role in helping 
women with more difficult HRT decisions. The women in this study might have had 
their information needs met if the discussion about HRT had been undertaken by a 
specialist nurse, at a time when the women themselves were less pressured by 
decisions to be made regarding major surgery, or in the immediate post-operative 
period. These discussions could instead perhaps, take place as an extended part of the 
pre-operative assessment. This assessment takes place after the decision to have 
surgery has been made, yet before the operative procedure has taken place. Then, 
allowing for some time for reflection, a follow up discussion prior to discharge on the 
ward, or at the post-operative visit in clinic could be made. Alternatively, information 
evenings for women waiting for hysterectomy could be held by suitably qualified 
nurses, as happens in some of the major teaching hospitals, for example Birmingham 
Women‟s NHS Foundation Trust.  The information would best be given without time 
constraint and supported by literature to take home. Other women contemplating HRT 
also need to be given quality information, tailored to their individual need, by a 
competent practitioner, in order to make their decision.  
 
There is a role here for written, hysterectomy-specific information in leaflet form for 
women to read and keep following their operation. In the NHS Trust where this study 
was conducted, written HRT information is given to patients in this form but the 
leaflet used contains broad-based information for women regardless of the origins of 
their menopause, be they peri-menopausal, naturally menopausal, or surgically 
menopausal. If this information was specific to women undergoing hysterectomy with 
bilateral oophorectomy, and if the risks and benefits were stated with particular 
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reference to this group of women, then their information needs may be better met, and 
the information in question more consistently retained.  
 
In recent times, the role of the specialist nurse has been under threat as posts have 
been left unfilled due to budget cuts. A recent article in the Sunday Observer, entitled 
“Diabetics are put at risk as NHS cuts specialist nursing posts”, written by health 
correspondent Denis Campbell, reported a doubling of unfilled diabetic specialist 
nurse posts within the UK in the last year (Campbell 2011 p 8). The RCN‟s Frontline 
First campaign, designed to protect services, predict that at present there are more 
than 1500 nursing and midwifery posts under threat in Scotland (rcn.org.uk 2011). 
Quality of care can only be maintained by adequate staffing levels, and the protection 
of specialist nurse posts is of great importance. All areas of health care are affected by 
investment in their service. Women‟s health is no exception; if funding is not to be 
increased, it needs protecting at the current level, and the nursing profession needs to 
lobby for such protection. 
 
 
 
 
 
 
 
 
 
 
 233 
Chapter six Limitations 
6.1 The limitations of this study 
The final chapter will acknowledge and discuss a number of the study‟s limitations, 
which will be considered under the following three headings,     
Research study design 
Data source 
The researcher 
 
6.1.1 Research design 
Three questions, relating to the design of the study, need to be addressed. 
1. Can the findings of this study be generalised to a wider population? 
2. Are the findings affected by unpredicted exogenous influences? 
3. Do issues around recollection influence responses?  
  
6.1.1.1 Can the findings of this study be generalised to a wider population? 
This is a very modest study of patients treated in two general hospitals. These 
hospitals, approximately 8 miles apart, serve a relatively small area in central 
Scotland. The target number of possible participants was 306 women, of whom only 
190 returned questionnaires that were useable. So the study draws on the opinions of a 
small, and conceivably biased, sample of women in a small geographical area. 
Consequently, it could be criticised for being too small and local to support 
generalisations. Although the socio-economic status of the respondents is roughly 
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comparable to the population of the region as a whole, there are two SIMD 
classifications in particular, which are not representative of the population as a whole. 
The most deprived group (SIMD 1) is significantly under-represented and so the 
opinions of the poorest women are not known, and the opinions of SIMD 5 women 
are over-represented. As HRT use is known to be associated with higher socio-
economic group in HRT users in general, the lack of data collected from women with 
lower socio-economic status may have contributed to the high rate of uptake and the 
long duration of treatment found in this study. The small size of the sample is also 
implicated in the findings related to the age of the patient at the time of operation. In 
the target sample women from more deprived backgrounds (SIMD 1-5) are 
significantly younger when they have surgery compared to women from less deprived 
backgrounds. This statistical association between age and time of hysterectomy is not 
found in the achieved sample. The mean age of the achieved sample is significantly 
older than that of the women who did not respond to the questionnaire. The advice 
given to a patient regarding the duration of HRT use after surgery varies depending on 
patient age; and, as the achieved sample does not accurately represent the younger 
woman, the findings regarding duration of treatment cannot be generalised to the 
population as a whole. 
   
6.1.1.2 Are the findings affected by unpredicted exogenous influences? 
There may also be some question as to the relevance- in 2010- of data that refers to 
events which happened some years ago, as medical treatments change and indications 
for drug therapy vary in the light of continued research. Some of the findings may be 
relevant to this particular group of women, and to other women who were treated 
within the same time frame; but because of changes in HRT use, they cannot be 
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generalised to a wider population of women having hysterectomies now. This point 
applies primarily to the duration of therapy because the women in this study took 
HRT for a longer time than is currently recommended. Some women in their late 40‟s 
having hysterectomies today may not start HRT immediately after surgery, but rather 
wait to see if they are affected by menopausal symptoms. If they do start, they will 
probably expect to take it until they were 50, and then reassess.   
 
Robson (2001, p 70) discusses the validity of research findings, using Cook and 
Campbell‟s (1979) list of possible threats to such validity. They note that various 
external influences can affect research findings. One of these influences is historical 
context. This may particularly affect this study, as there was a great deal of discussion 
about HRT use in both the medical and general press just as the questionnaires were 
being sent out to participants. Publicity if this kind may have prompted the study 
subjects to re-examine their reasons for taking HRT, or it may have informed them of 
risks and benefits of which they had been previously unaware. It is impossible to be 
sure that these press reports affected survey responses but it is certainly a distinct 
possibility.  
 
6.1.1.3 Do issues around recollection influence responses?  
 This is a retrospective study, over a 10-year period, involving women who had 
surgery between January 1992 and December 2001. Consequently, some of the study 
participants had undergone their surgery some considerable time before they were 
asked to participate. This will inevitably result in some problems with the recollection 
of past events and, in general, the reliability of the respondents‟ memories is 
obviously open to question. It is difficult for anyone to be certain where knowledge 
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originates from and this is particularly true when it is accrued over time and the topic 
is the subject of publicity in the press. Not only did the study ask women to remember 
events in the past, it asked questions about a medication that had received significant 
media attention. For this reason, it is difficult to be sure that the responses made 
reflect accurate memories, and that they have not been reconstructed on the basis of 
more recent information. 
    
The problem of obtaining reliable information applies to this study for other reasons 
too. The data was obtained using a postal questionnaire, and there are corresponding 
concerns regarding the accuracy of responses. It is recognised that problems exist in 
even the best designed questionnaires because they are completed quickly, and not 
always truthfully. In addition, the women in this study were questioned by someone 
associated with the medical team who had cared for them in the past, possibly 
influencing the responses given. If, as Robson (2001 p128) suggests, people 
sometimes respond “in a way that shows them in a good light”, then they may not 
reveal their true feelings to those who treated them. It is likely that sampling a group 
of patients with whom the researcher had no previous connection would have 
produced more robust data. 
 
6.1.2 Data source 
The relatively small number of patients in this study is due, in part, to difficulties 
experienced in the accessing of patient records. If this task had been easier and 
quicker to achieve, then study numbers may have been increased. 
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The researcher checked case notes individually, to determine eligibility, and 37 
possible subjects were lost to the study because their case notes were incomplete, 
untraceable, destroyed or incorrectly coded. The incorrectly coded records are of 
particular interest, and may be partially implicated in the apparent drop in the 1996 
figure for hysterectomy as a treatment for menorrhagia. If notes are incorrectly coded, 
then the recorded rate of hysterectomy with bilateral oophorectomy will be inaccurate. 
Moreover, it is reasonable to assume that if notes are incorrectly coded for one 
operation then other operations may be similarly miscoded. To ensure that all possible 
participants were identified would have required the researcher to check all 
hysterectomy notes, regardless of the clinical indication for surgery, over the 10-year 
period. Clearly this would have been a lengthy process. Time constraints also 
prevented exhaustive tracing of lost case notes. 
 
It is worth adding that the clinical indication for surgery in this study is exclusively 
menorrhagia. Study numbers could also have been increased if the indication had 
been widened to include other benign conditions. 
 
The design of the questionnaire is central to the quality of the data obtained. Once the 
responses were returned, it was clear that the questions were not all without 
ambiguity. For example, Question 12 would have been clearer if it had specified that 
it was asking about taking post-operative HRT. Further, more substantive data on the 
reasons for stopping treatment may have been elicited by a more exhaustive and 
specific list of reasons, or by allowing the respondent to complete the question in her 
own words. These difficulties in interpretation were not evident in the pilot, perhaps 
due to where the pilot was conducted. 
 238 
 
Face- to- face interviews with study subjects who agreed to such questioning would 
have produced the most detailed data about the reasons women stopped treatment. 
The decision not to proceed with this part of the study was again the result of time 
considerations, as discussed at the end of Chapter Three under “Ethical and legal 
considerations”.    
        
6.1.3 The researcher 
Robson (2001) states that the “ trustworthiness of the data depends to a considerable 
extent on the technical proficiency of those running the survey”(p125). This was the 
first time the researcher had undertaken a research study. Many of the limitations of 
this study are therefore linked to inexperience, and much has been learned with the 
benefit of hindsight. 
 
For example, the study could have been improved if the researcher had broadened the 
subject base in terms of the clinical indication for surgery. The primary reason that 
this was not done was to keep the subject population as uniform as possible, and to 
exclude any condition making post-operative HRT less straightforward. 
 
The questionnaire could have been improved in terms of format, with clearer 
instructions to the respondents. The ambiguities in the questionnaire may have been 
highlighted had the pilot study been performed using subjects from another hospital or 
indeed from a different clinical area within gynaecology.  
 
 239 
Owing to personal circumstances, this study has taken some considerable time to 
complete. This has had a negative effect in terms of the relevance of the study. HRT is 
viewed somewhat differently today, when compared to the 1990s, so the data obtained 
here is perhaps less relevant than it might have been if the study had been completed 
quickly, and without the concerns raised by the WHI study. The impact of the WHI 
study, along with media influences on HRT use, was not explored in any depth, and 
this is regrettable. The reason for this is that the questionnaire was designed prior to 
these reports being published, and ethical approval already granted. Further ethical 
approval would have been necessary if additional questions had been added, so 
delaying the commencement of the study. 
 
Nevertheless, this study has given the researcher an appreciation of the difficulties of 
conducting research, and the subsequent management and interpretation of data. It has 
given an interesting insight into practice at her place of work, extended her knowledge 
of the issues surrounding HRT prescription in general, and those relevant to HRT 
following hysterectomy with bilateral oophorectomy in particular.   
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APPENDICES                                                                                                                                     
 
Appendix 3.1 Questionnaire                                                                                                                                      
 
 
 
COMPLIANCE WITH HORMONE REPLACEMENT THERAPY AFTER 
ELECTIVE HYSTERECTOMY AND THE REASONS WOMEN GIVE FOR 
CONTINUANCE OR DISCONTINUANCE. 
 
 
QUESTIONNAIRE 
 
This questionnaire is designed to find out how many women take hormone 
replacement therapy (HRT) after having a hysterectomy, and for how long they take 
it. It does not matter which type of HRT you take, tablet, patch or implant. 
 
It also includes questions about the information you were given and the reasons you 
have for taking it or not taking it. 
 
Finally, it asks some details about yourself, and also if you might be prepared to be 
interviewed by the researcher to explain your opinions further. 
 
THE FIRST QUESTIONS ARE ABOUT YOUR HYSTERECTOMY AND THE 
INFORMATION YOU WERE GIVEN BEFORE AND AFTER SURGERY.  
PLEASE ANSWER AS FAR AS YOU CAN RECALL.  
 
 
1.When did you have your operation?  Month…….. Year…… 
 
 
2. How old were you when you had your hysterectomy? 
……..Years. 
 
 
3.Was HRT mentioned to you before you had your hysterectomy? ( please tick) 
           Yes 
 
            No 
 
If yes, please tick one of the following answers          
 
a) Yes, by my family doctor  
b) Yes ,by the hospital doctor  
c) Yes ,by both family and hospital doctors 
d) Cannot remember  
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4.As far as you can recall were any of the following benefits of HRT mentioned? 
  ( please tick all that were mentioned) 
 
       a) Helps the symptoms of the menopause e.g. Hot flushes 
b) Helps prevent osteoporosis in later life 
 c) May help prevent heart disease. 
d) No benefits mentioned  
 
5.As far as you can recall were any of the following side effects of HRT mentioned?   
(please tick all that were mentioned) 
 
a) Increased risk of breast cancer. 
b) Increased risk of blood clots ( DVT) 
c) No side effects mentioned  
 
 
6.Were you offered HRT in hospital before you went home? ( please tick) 
 
a) Yes 
b) No  
 
If you answer yes to this question please answer the next 2 questions 
If you answer no to this question please go to question 8. 
 
7.Did you accept HRT when offered it in hospital? ( please tick) 
 
a) Yes  
b) No  
 
 
8.If the hospital did provide HRT, Did you discuss HRT with your family doctor 
when your prescription from hospital needed renewing?( please tick) 
 
a) Yes  
b) No  
 
 
9.If the hospital did not provide HRT, did you discuss HRT with your family doctor 
after you went home? ( please tick) 
 
a) Yes 
b) No  
 
 
10.If the hospital did not provide HRT did you have HRT prescribed for you by your 
family doctor after you went home? ( please tick) 
 
 
a)Yes  
b)No  
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11.What was the main source of the information you were given in hospital ?      
    (please tick one answer) 
 
 
a) Doctor  
 
b) Nurse  
 
c) HRT pamphlet 
 
12.How long did you think you would have to take HRT for? ( please tick) 
 
a) Less than 1 year? 
 
b) About 5 years? 
 
c) More than 5 years? 
 
d) More than 7 years? 
 
 
13.Before you went home from hospital did you feel you had sufficient information  
    about HRT to make your decision to take it or not take it? 
 
a) Yes 
b) No  
 
 
THE NEXT QUESTIONS ARE ABOUT TAKING HRT AND THE REASONS 
YOU MAY HAVE FOR EITHER CONTINUING TO TAKE IT OR FOR 
STOPPING TAKING IT. 
 
14. Had you taken HRT at any time before you had your operation? 
(please tick) 
a) Yes 
b) No  
 
15.If the answer is yes then how long did you take it for approximately?  
    ……..Years, ……….Months  
 
 
16.Are you still taking HRT? ( please tick) 
 
a) Yes  
b)  No  
 
 
If you have answered yes to this question then please go to question 21 
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17.If you have stopped taking HRT when did you stop? ( please tick one answer )  
 
a) Less than 3 months of starting it? 
 
b) Within 3 and 6 months of starting it? 
 
c) Within 6 months and one year of starting it? 
 
d) Within 1 and 2 years of starting it? 
 
e) Within 2 and 3 years of starting it? 
 
f) Within 3 and 5 years of starting it? 
 
g) Within 5 and 7 years of starting it? 
 
h) Within 7 and 10 years of starting it? 
 
18.When you stopped did you discuss your decision with your doctor beforehand?   
     
a) Yes  
b) No  
 
19.What was your main reason for stopping? (please tick one only) 
 
a) Doctors advice  
 
b) Didn‟t need it anymore 
 
c)  taken it for long enough 
 
d) Side effects 
 
e) Didn‟t help the symptoms 
 
f) Didn‟t like the idea of taking hormones 
 
g) Didn‟t have any symptoms of the menopause 
 
h) Cost of prescription  
 
 
If there is any other reason you stopped taking HRT could you detail it in the space 
provided. 
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20. If you answered “side-effects” to question 19,could you please indicate which 
side-effects influenced your decision.( please tick)  
 
  
a) Weight- gain 
b)  Headaches 
c)  breast tenderness 
d)  worries about increased breast cancer risk 
e) worries about DVT 
 
 
 
 
THE NEXT QUESTIONS EXPLORE YOUR OPINIONS ON THE EFFECTS 
OF HRT, AND THE CURRENT PRESCRIPTION CHARGES MADE. 
 
21.Do you believe that, for you the benefits of HRT outweigh the side 
    effects?(please tick) 
 
a) Yes 
b) No 
 
 
22.For you what do you consider the most important beneficial effects of HRT?   
    Please rate the following three effects in order of importance to you , where 
 
1= most important 
                                      2=medium importance. 
                                      3= least important.                    
                                                       
Prevents menopausal symptoms e.g. hot flushes  
          Vaginal dryness/ urinary problems 
           Irritability  
 
Helps prevent osteoporosis 
 
 
May help prevent heart disease  
 
 
 
23.Do you have to pay for your HRT prescription?( please tick) 
 
a) Yes 
b) No  
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24.Would free prescription make you more likely to take HRT?( please tick) 
   
a) Yes  
b) No 
 
THE FINAL QUESTIONS ARE ABOUT YOU AND ALSO TO FIND OUT IF 
YOU MAY BE WILLING TO MEET WITH THE RESEARCHER FOR 
INTERVIEW. 
 
25.What is your date of birth  
 
                       
26.What is your post code [first 3 characters] 
 
 
27.Do you suffer now or did you at any time in the past, from a medical condition, 
which the doctor said was a reason not to take HRT? 
  
         Yes 
 
          No 
       
28.If yes, what was / is that condition? 
 
 
 
Thank you very much for taking the time to complete this questionnaire. 
 
 
I am hoping to talk to a number of women about their experiences and opinions .If 
you would be prepared to meet with the researcher to discuss your answers in more 
detail please tick the box and enter your name address and telephone number in the 
space provided. Ticking the box does not mean the researcher will visit you without 
prior arrangement. 
 
 
 
 NAME; 
 
ADDRESS; 
 
TELEPHONE NUMBER; 
 
THANK YOU VERY MUCH FOR TAKING THE TIME TO COMPLETE THIS 
QUESTIONNAIRE. 
IT WOULD BE MOST HELPFUL IF YOU COULD RETURN IT TO ME BY 
……… 
 
A STAMPED ADDRESSED ENVELOPE IS ENCLOSED. 
 
 264 
Appendix 3.2            
HRT COMPLIANCE STUDY 
                                             FIONA BEST WARD  
 
 
                NAME                            …..…………………… 
               ADDRESS                       …..…………………… 
                                 …..…………………… 
                                 …..…………………… 
 
                D.O.B.                             ……………………….. 
 
                UNIT NUMBER            ……………………….. 
 
                 G.P.                                ……………………….. 
                                ……………………….. 
 
 
                              RESPONSIBLE CONSULTANT 
 
               
 
               1                                                                                              7    
               2                                                                                              8    
               3                                                                                              9    
               4                                                                                             10   
               5                                                                                             11   
               6                                                                                             12   
 
 
            DIAGNOSTIC CODE                         
 
 
 
          OPERATIONAL PROCEDURE CODE  
                                                               
 
            DID/DOES THIS PATIENT HAVE A HISTORY OF BREAST C.A. 
 
              YES                                                                   NO       
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Appendix 3.3 (a) Letter to all consultant gynaecologists at hospital A   
GynaecologyWard  
All Consultant Gynaecologists  
Hospital A 
 
 
Dear Consultant Gynaecologists 
 
Compliance with hormone replacement therapy after elective hysterectomy and the 
reasons women give for continuance or discontinuance 
ERC Study No: (789) 
 
I am writing to ask for your support in the above study.  The study is to be carried 
out by the author, Fiona Best Staff Nurse, as part of an MSc by Research.  The aim 
of the study is to answer the following related questions: 
 
1. How many women in the NHS trust who have undergone elective hysterectomy 
with bilateral oophorectomy for menorrhagia take HRT? 
2. When do they commence therapy? 
3. When do they stop therapy? 
4. Why do they stop? 
5. Are the reasons for early discontinuance different form those for late 
discontinuance? 
6.  Does socio-economic group influence HRT use in the region? 
 
Participants will be selected from in-patient records at hospital A and hospital B for 
the time period January 1992 to December 2001.  Subjects will be under 51 years of 
age at the time of operation and women who had undergone surgery for malignancy 
or who have a medical history of breast carcinoma will be excluded.  The study has 
been approved by the Ethical Committees of both Stirling University and the NHS 
Board (ERC Study Number 789) 
 
I ask firstly for your permission to check your patients‟ case notes to ensure that 
they do indeed fit the inclusion criteria and secondly for your permission to 
subsequently send selected patients a postal questionnaire to complete at home.  A 
copy of the questionnaire is appended.  I confirm that the General Practitioner of 
each subject will also be approached for their permission prior to any contact being 
made with patients.  If you wish any further details of the study please contact me at 
the above address 
Thank you very much for your assistance. 
Yours sincerely Fiona Best Staff Nurse 
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Appendix 3.3 (b) Letter to all consultant gynaecologists at hospital B 
 
Gynaecology ward  
 
All Consultant Gynaecologists  
Hospital B 
 
Dear Consultant Gynaecologists 
 
Compliance with hormone replacement therapy after elective hysterectomy and the 
reasons women give for continuance or discontinuance 
ERC Study No: (789) 
 
I am writing to ask for your support in the above study.  The study is to be carried 
out by the author, Fiona Best Staff Nurse, as part of an MSc by Research.  The aim 
of the study is to answer the following related questions: 
 
1. How many women in the NHS trust who have undergone elective hysterectomy 
with bilateral oophorectomy for menorrhagia take HRT? 
2. When do they commence therapy? 
3. When do they stop therapy? 
4. Why do they stop? 
5. Are the reasons for early discontinuance different form those for late 
discontinuance? 
6.  Does socio-economic group influence HRT use in the region? 
 
Participants will be selected from in-patient records at hospital A and hospital B for 
the time period January 1992 to December 2001.  Subjects will be under 51 years of 
age at the time of operation and women who had undergone surgery for malignancy 
or who have a medical history of breast carcinoma will be excluded.  The study has 
been approved by the Ethical Committees of both Stirling University and the NHS 
Board (ERC Study Number 789). 
 
I ask firstly for your permission to check your patients‟ case notes to ensure that 
they do indeed fit the inclusion criteria and secondly for your permission to 
subsequently send selected patients a postal questionnaire to complete at home.  A 
copy of the questionnaire is appended.  I confirm that the General Practitioner of 
each subject will also be approached for their permission prior to any contact being 
made with patients.  If you wish any further details of the study please contact me at 
the above address. 
 
Thank you very much for your assistance. 
Yours sincerely Fiona Best Staff Nurse 
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Appendix 3.4 Letter of introduction from consultant gynaecologist 
Department of Gynaecology  
The Gynaecology Office  Telephone No:  
 
Dear 
 
This letter relates to the hysterectomy operation you had some time ago. We are 
trying to find out how many women use HRT (hormone replacement therapy) after 
hysterectomy, and would very much like your help. 
 
Staff Nurse Fiona Best from the Gynaecology Department will contact you soon, by 
letter, to see if you are happy to help. If you agree, you will be given a short 
confidential questionnaire to fill in and return. 
 
If you like, we will tell you what we have found at the end of the study. 
 
If you do not wish to be contacted by Fiona, would you please telephone the above 
number and ask for your name to be removed from the list of possible participants. 
 
Thank you for reading this letter. 
 
Yours sincerely 
 
Consultant Gynaecologist/Obstetrician 
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Appendix 3.5 Letter to GP 
                                                                                                                     
 
  Gynaecology ward. 
 
Dear Dr 
I am writing to inform you of a research project I am undertaking concerning 
women who have undergone elective hysterectomy with bilateral oophorectomy for 
menorrhagia and their use of HRT.  It is a voluntary study involving the answering 
of a postal questionnaire.  The aim of the study will be to answer the following 
related questions: 
 
1. How many women in the NHS trust who have undergone elective hysterectomy 
with bilateral oophorectomy for menorrhagia take HRT? 
 
2. When do they commence therapy? 
 
3. When do they stop therapy? 
4. Why do they stop? 
 
5. Are the reasons for early discontinuance different from  those for late 
discontinuance? 
 
6.  Does socio-economic group influence HRT use in the region? 
 
Participants will be selected from in-patient records at hospital A and hospital B the 
time period January 1992 to December 2001.  Subjects will be under 51 years of age 
at the time of operation and women who had undergone surgery for malignancy or 
who have a medical history of breast carcinoma will be excluded.  The study is part 
of an MSc by Research and has been approved by the Ethical Committees of both 
Stirling University and the NHS Board (ERC Study Number 789) If you have any 
patients who have had this operation for menorrhagia and in your opinion should 
not be approached for participation in this study, would you please inform me at the 
above address ( before         ) so that I may exclude them from the study. 
Thank you very much for your assistance. 
Yours sincerely 
 
 
Fiona Best 
Staff Nurse 
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 Appendix 3.6 Covering letter to patient for questionnaire 
 
 
Dear  
 
Do women use hormone replacement therapy after hysterectomy?  How long 
do they take it for and why do they stop? 
 
I am writing to you to ask if you would consider completing the short questionnaire 
enclosed.  I am hoping to discover what women think about the use of Hormone 
Replacement Therapy (HRT), and if they use it. 
 
Before you decide if you can help me, it is important that you understand what is 
involved; so I have enclosed some information about the study, so that you will be 
able to understand what is involved. 
 
The study is entirely voluntary and your personal details will not be identifiable to 
anybody other than the researcher (that is, myself). Once your answers to the 
questionnaire have been received they will be confidential, and all collected answers 
will be destroyed at the end of the study.  
 
The questionnaire should take no more than 15 minutes to complete. 
 
While I realise that there is no direct benefit to yourself, if you take part in this 
study, I would be very grateful if you felt able to participate as I believe that the 
information you can give is of great value, and could be used by nurses when 
planning future gynaecology care.   I would be happy to send you a copy of the 
findings of the study, once it is complete. 
 
It would be most helpful if you could return the completed questionnaire by ………. 
 
If you choose not to take part in the study, please return the uncompleted 
questionnaire in the envelope provided in order to ensure that you are not contacted 
again. 
 
Thank you for taking the time to read this letter, and I look forward to hearing from 
you. 
  
Yours sincerely, 
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Appendix 3.7 Patient information sheet. 
 
 
Gynaecology  Department Address 
Gynaecology office telephone no; 
 
Study Title  
Do women use hormone replacement therapy after hysterectomy?  How long 
do they take it for and why do they stop? 
 
 
You are being invited to take part in a research study. Before you decide whether to 
take part, it is important for you to understand why the research is being done and 
what it will involve.  Please take time to read the following information carefully 
and discuss it with others if you wish. Ask me if there is anything that is not clear, 
or if you would like more information. Take time to decide whether or not you wish 
to take part. 
 
Thank you for reading this. 
As you will probably be aware, there is an increasing amount of information about 
Hormone Replacement Therapy (HRT).  The purpose of this study is to find out 
how many women take HRT after having a hysterectomy, with the removal of their 
ovaries; how long they take it for; and why and when they stop taking it.  The 
reason this is important is that we would like to improve the service we give to 
women in the region having this type of operation; and in order to do this, we need 
to understand fully what experiences such women have had in the past. 
 
You have been chosen as one of approximately 360 women who had this operation 
at some time between 1992 and 2001, at either hospital A or hospital B.The 
consultant in your case has given me permission to write to you. 
 
 
The study is entirely voluntary, and it is up to you to decide if you wish to take part.  
If you do decide to take part, you are still free to withdraw at any time and without 
giving a reason.  A decision not to take part will not affect the standard of care you 
will receive from any hospital at any time in the future. 
 
The study involves the completion of the enclosed questionnaire only, and this 
should take no longer than 15 minutes to complete. However, you may wish to 
consider being interviewed as well.  If you agree to this, you will be asked to sign a 
standard consent form agreeing to the interview, a copy of which you will be given 
to keep. Interviews will be arranged at a time and place convenient to you and may 
last approximately one hour.  The questions you will be asked will be about your 
opinions of HRT, and your experiences of it; the reasons you take it or the reasons 
you don‟t. The questionnaire has a box you can tick if this is something you would 
be prepared to consider.  
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In the event of an interview taking place, it will be possible for you to request 
access to a psychologist, should you feel that there are any unresolved issues arising 
out of your HRT treatment (this is standard interview practice).   
 
I realise there is no direct benefit to yourself in taking part in this study; however, 
women in the future may be able to benefit from the findings of this study. I should 
also emphasise that you will incur no expenses as a result of taking part in the study.  
 
All information that is collected about you during the course of the research will be 
kept strictly confidential.  Any information about you, which leaves the hospital, 
will have your name and address removed, so that you cannot be recognised from it. 
 
The results from this study will form the basis of an MSc thesis that may be 
published in the future.   No individual participant in the study will be identified. 
 
Fiona Best, a Staff Nurse in Gynaecology at hospital B is carrying out this research 
project.  The Ethics Committees of both the local Health Board and the University 
of Stirling have approved it. There is no collaboration with any pharmaceutical 
company. 
 
Should you wish to contact me for further information, I can be reached at the above 
address and telephone number. 
 
Please keep this sheet for your records if you decide to participate. 
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Appendix 3.8 Reminder letter 
 
Gynaecology Ward 
Telephone no. 
 
 
Dear 
 
Sometime ago I sent you a questionnaire and some information regarding a study I 
am conducting into women‟s use of HRT after hysterectomy. To date I do not 
appear to have received your reply. I now enclose a duplicate copy of the 
questionnaire in case the original was lost. I would be most grateful if you felt able 
to complete it, but if you do not wish to do so return the blank questionnaire to me 
and I will ensure that you are not contacted again. 
 
Thank you for reading this letter. 
 
Yours faithfully, 
 
Fiona Best, Staff Nurse.  
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Appendix 3.9 Consent to interview 
 
 
COMPLIANCE WITH HORMONE REPLACEMENT THERAPY AFTER ELECTIVE 
HYSTERECTOMY AND THE REASONS WOMEN GIVE FOR CONTINUANCE OR 
DISCONTINUANCE 
 
 
 
 
CONSENT TO INTERVIEW. 
 
I hereby consent to an interview, which may be tape recorded for research purposes. 
 
I understand that I am free to withdraw at any point in time, without giving any 
reason, and am under no obligation to answer any question put to me by the 
researcher.    I also understand that all my answers will be treated confidentially, 
and that any recordings will be destroyed at the end of the study. 
 
I confirm that I have been informed of the availability of a qualified counsellor if I 
should wish to use such a consultation. 
 
 
 
 
Signed ………………………………………………… 
 
Date …………………………………………………… 
 
 
 
